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Abstract 
Hepatitis C virus (HCV) is a positive-strand RNA virus present in 2-3% of the global population 
and commonly establishing a chronic infection, leading to long term diseases such as liver 
cirrhosis and hepatocellular carcinoma.  Recent advances have led to the development of a 
range of direct-acting anti-viral drugs (DAAs), some of which are already improving outcomes 
in the clinic.   It is clear however, that effective therapy for the treatment of HCV will most 
likely require a combination of DAAs to overcome the rapid onset of viral resistance. In this 
regard additional inhibitors of the virus lifecycle, which act through a novel molecular target, 
are required. 
The autoprotease activity encoded within the C-terminus of the non-structural 2 (NS2) protein 
is essential for processing of a precursor to the mature viral proteins, and as a consequence is 
also required for the onset of viral genome replication and the establishment of HCV infection. 
Despite representing an attractive target for anti-virals, no inhibitors of the NS2 autoprotease 
have been reported. 
In order to identify small molecule inhibitors of the NS2 autoprotease, two independent assays 
were optimised as a measure of NS2-mediated proteolysis. These assays were employed to 
demonstrate that inhibitors of the NS2 autoprotease were able to block HCV genome 
replication. The assays were subsequently used to identify a lead-like small molecule inhibitor 
by screening an in silico enriched library. This compound was further characterised in the 
context of NS2 activity in vitro and cell culture models of the virus lifecycle. The resultant series 
represent the first documented inhibitors capable of exerting an anti-viral effect by targeting 
the NS2 autoprotease. 
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1.1 Viral hepatitis 
The term hepatitis refers to the inflammation of the liver and is most commonly attributed to 
viral hepatitis, wherein the causative agent is one of the hepatitis A-E human viruses. Prior to 
the identification of hepatitis C virus (HCV) in 1989 (Choo et al., 1989), cases of viral hepatitis 
were primarily attributed to hepatitis A virus (HAV) or hepatitis B virus (HBV). It was later 
realised that the majority of cases of viral hepatitis were caused by an alternative pathogen 
unreactive to HAV and HBV diagnostic tests (Feinstone et al., 1975, Knodell et al., 1975). This 
pathogen, termed non-A, non-B hepatitis (NANBH) could be transmitted to chimpanzees 
intravenously and was initially proposed to compose several causative agents (Bradley et al., 
1983, Bradley et al., 1985). However, production of a complementary DNA library (cDNA) from 
the plasma of infected chimpanzees revealed a positive sense, single-stranded RNA molecule 
with a single ~3000 amino acid open reading frame (ORF) that showed significant homology to 
the non-structural (NS) proteins of Flaviviridae family members (Choo et al., 1989, Choo et al., 
1990). Thus development of NANBH was attributed to a single infectious agent termed 
hepatitis C virus (HCV). 
1.2 Hepatitis C virus 
1.2.1 HCV classification, epidemiology and genetic heterogeneity 
Hepatitis C virus is the prototype member of the Hepacivirus genus within the Flaviviridae 
family, which also comprises the genera Flavivirus, Pestivirus and Pegivirus (Figure 1.1A). 
Despite sequence homology and functional similarities between the non-structural proteins 
(Murray et al., 2008), HCV contains an altered genome organisation from that of members of 
the Flavivirus genus such as yellow fever virus (YFV), Dengue virus (DENV) and Japanese 
encephalitis virus (JEV). HCV is more closely related to the Pegivirus genus and the Pestivirus 
genus which typically infect mammals such as cattle and swine, as with the Pestivirus bovine 
viral diarrhoea virus (BVDV). Additional animal viruses are more closely related to HCV such as 
George Barker virus-B (GBV-B) which infects tamarin monkeys and more recently the non-
primate hepacivirus (NPHV), an equine virus, along with HCV-like and pegivirus-like viruses 
isolated from rodents (Burbelo et al., 2012, Kapoor et al., 2013). 
Within the Hepacivirus genus HCV can be divided into six distinct genotypes (and a recently 
postulated seventh genotype (Murphy et al., 2007)) which typically differ by 30-35% at the 
nucleotide level across the entire genome. These genotypes are further divided into numerous 
subtypes (a, b, c etc.), with genome sequence variation of 20-25%. While all the HCV 
Chapter 1 - Introduction 
 
3 
 
genotypes share significant similarities in aspects of their genome replication and ability to 
persistently infect the liver of their host, their distribution worldwide varies, as does their 
prevalence within the population of certain risk groups (Simmonds, 2004). 
The most prevalent HCV genotypes, namely genotype 1b, 1a and to a lesser extent 3a, are 
present worldwide, but account for the majority of infections in the Americas and Europe. 
Genotype 2 also has a worldwide distribution, albeit less overall prevalence, but is endemic to 
regions of West Africa. Central Africa and the Middle East are endemic for genotype 4, while 
much of East Asia is associated with genotypes 3 and 6 (Simmonds, 2004, WHO, 2009) (Figure 
1.1B). 
While certain genotypes are geographically constrained, they can also be associated with 
higher rates of infection within the population. An example of this is Egypt, where the 
overwhelming majority of infections are genotype 4 and up to 20% of the population are 
thought to be infected, compared to the global average of 3% (Frank et al., 2000). 
Despite high infection rates of some of the genotypes constrained to certain geographical 
locations, the majority of anti-viral strategies have attempted to target strains prevalent across 
the globe; primarily genotype 1 but also genotype 3 and to a lesser degree genotype 2. These 
strains make up a significant proportion of the 170-180 million people infected worldwide. 
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Figure 1.1: HCV epidemiology and distribution.  
A) Genera within the Flaviviridae family organised by amino acid sequence identity within the 
RNA dependent RNA polymerase, adapted from (Kapoor et al., 2011). B) Global prevalence of 
HCV as percentage of population infected and genotype distribution, adapted from (WHO, 
2009). 
Genotype 1
Genotype 2
Genotype 3
Genotype 4
Genotype 5
Genotype 6
>2.9% prevalence
2.0 - 2.9% prevalence
1.0 - 1.9% prevalence
<1% prevalence
No data
A
B
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1.2.3 HCV transmission 
HCV is a blood-borne pathogen. Prior to the introduction of donor screening in 1991 the major 
route of transmission was blood transfusions (Lauer and Walker, 2001). In developed nations 
blood transfusions are now routinely screened for indicators of liver disease; elevated serum 
alanine aminotransferase (ALT) and HCV antibodies. As such the majority of new infections are 
now due to intravenous drug-use, which is estimated to account for up to 80% of infections in 
some developed nations. The prevalence of infection in such countries has been reported as 
64-94% of long-term injectors (> 6 years), while it has also been reported that HCV is more 
permissive to transmission through this route than other blood-borne viruses (Shepard et al., 
2005). 
In developing nations, a larger proportion of infections can often be attributed to unsafe 
healthcare related practices such as therapeutic injections and blood transfusions. 
Other routes of transmission occur much more infrequently, with transmission due to 
occupation, such as with health care workers, and from religious or cultural practices including 
tattooing, body-piercing, circumcision and acupuncture. Perinatal transmission of HCV has 
been reported, but appears as low as 2.7-8.4%, while there is also a small risk of sexual 
transmission (Shepard et al., 2005). 
1.2.4 Disease progression 
 The majority of HCV infections will progress from an acute infection to a chronic infection, 
whereby virus persistence can be detected after 6 months either through detection of HCV 
RNA in the blood or increased levels of ALTs. 
70-80% of acute infections are asymptomatic and often undiagnosed, but where symptoms are 
observed they tend to present after 3-12 weeks, shortly after the typical peak in HCV RNA 
detected in the serum. Symptoms include weakness, jaundice, malaise and anorexia. Following 
the peak in serum HCV RNA of 105-107 IU/ml, only 15-25% of patients will clear the virus, 
wherein HCV RNA becomes undetectable and ALT levels normalise. The majority of cases (75-
85%) will progress to chronic infection, though several factors can influence this including 
ethnicity, gender and age at infection (Chen and Morgan, 2006). 
Disease progression from chronic infection involves development of liver fibrosis leading to 
cirrhosis. End stage liver cirrhosis and associated liver failure is a significant cause of mortality 
from HCV infection, as is the associated risk of developing hepatocellular carcinoma (HCC) 
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(Levrero, 2006). The risk of progressing through each disease state varies significantly both 
with risk factors and with time, but typically 10-20% of chronic infections will lead to cirrhosis 
over a period of 20 years (Chen and Morgan, 2006). This figure falls closer to 20% after 30 
years (Lauer and Walker, 2001). Additional risk factors, in combination with time, include 
gender, age at time of infection and comorbid conditions, but are most significantly influenced 
by co-infection with human immunodeficiency virus (HIV) or HBV and by excessive alcohol 
consumption (Figure 1.2). 
As with acute infection, the progression of a chronic infection to cirrhosis is usually 
asymptomatic, meaning many cases of HCV infection are not detected until the presentation 
of symptoms at end-stage cirrhosis or HCC. The development of HCC is almost exclusively 
linked to liver cirrhosis. Once the liver is cirrhotic the risk of developing HCC is 1-4% per year. 
The presentation of disease and development of cirrhosis also varies between the HCV 
genotypes. For example, while genotype 3 is associated with increased levels of spontaneous 
clearance at the acute phase, it also presents with faster progression of liver fibrosis, 
accompanied with liver steatosis. By contrast a higher proportion of genotype 4 infections 
progress to a chronic infection (Nunez and Soriano, 2005). 
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Figure 1.2: HCV disease progression.  
Natural progression of HCV infection towards disease states associated with highest mortality 
(darker boxes). Known environmental risk factors for the development of liver cirrhosis from an 
acute infection are shown in purple, adapted from (Chen and Morgan, 2006) and (Lauer and 
Walker, 2001). 
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1.3 Treatment of HCV 
Prior to recent advances in therapies, the standard of care (SOC) treatment for HCV infection 
was pegylated interferon-alpha (PEG-IFN) and ribavirin (RBV). The drive towards HCV anti-
virals has been principally due to the extensive problems with this therapy. 
The use of interferon (IFN) to treat viral hepatitis pre-dates the identification of HCV 
(Hoofnagle et al., 1986), with IFN monotherapy giving a sustained virological response (SVR), 
defined as the long-lasting absence of HCV RNA from the serum, in 5-20% of cases. SVR rates 
were improved to 40-50% with the addition of RBV, while the enhanced pharmacokinetics 
achieved by conjugating IFN to polyethylene glycol (PEG-IFN) further improved this to 54-63%. 
However, the success rate of achieving SVR varies greatly between HCV genotypes. While 
genotypes 2 and 3 respond well to PEG-IFN-RBV therapy, with SVR achieved in 75% of cases, 
the more prevalent genotype 1 infections are only successful in 40-50% of cases. Likelihood of 
achieving SVR often depends on treatment duration. Typical PEG-IFN-RBV treatment lasts 24 
weeks. This can be reduced to as low as 12 weeks for infections of genotypes 2 and 3, but 
often has to be extended for genotype 1 infections to 48 weeks or longer. When treatment is 
extended beyond 72 weeks patients frequently discontinue therapy before SVR is achieved, 
due mainly to the numerous serious side effects associated with IFN and RBV therapy which 
include haemolytic anaemia , fatigue, insomnia, depression, dermatitis, headaches, nausea, 
weight loss, diarrhoea, fever and muscle pain amongst others (Manns et al., 2006). 
The success of a PEG-IFN-RBV therapy can be gauged at 12-24 weeks, at which point if a 
decline in serum HCV RNA of greater than 2 log10 is not observed SVR will not be achieved and 
therapy is discontinued. This yields a large number of patients classed as ‘non-responders’ to 
IFN therapy. 
Patients who present with acute HCV infection can be treated with PEG-IFN alone, preventing 
the development of a chronic infection in 90% of cases. However, due to the aforementioned 
side effects of IFN treatment, treatment is often withheld until approximately 12 weeks to see 
if the patient spontaneously resolves the infection. While IFN therapy is fairly successful at 
clearing acute HCV infection, the asymptomatic nature of the majority of these cases means 
that they are usually not diagnosed. In fact many HCV infections are not diagnosed until late-
stage fibrosis or cirrhosis has developed, a relevant factor as the chances of achieving SVR with 
PEG-IFN-RBV therapy are further reduced in cases of liver cirrhosis or HCC (Lauer and Walker, 
2001). 
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Treatment of HCV was improved in 2012 with the approval of the first direct acting anti-virals 
(DAAs); Boceprevir (Merck) and Telaprevir (Janssen-Vertex). Both of these drugs target the 
virally encoded NS3/4A protease to directly block the virus lifecycle (Salam and Akimitsu, 
2013). To date these anti-virals are only licensed for genotype 1 infections in combination with 
PEG-IFN and RBV, with clinical trials suggesting these therapies can improve SVR rates to 55-
75% for Boceprevir triple therapy and 61-67% for Telaprevir triple therapy (Kanda et al., 2010). 
 
More recently second generation protease inhibitors have progressed through clinical trials, 
such as Simeprevir (Janssen Pharmaceuticals) and Faldaprevir (Boehringer-Ingelheim), as has a 
promising nucleoside analogue targeting the viral polymerase, Sofosbuvir (Gilead Sciences). 
Clinical trial data for these inhibitors are summarised below. 
The majority of trials are not yet of sufficient size to draw conclusions between genotype 1b 
and genotype 1a infections, but against treatment naive genotype 1 patients a 48 week course 
of the second generation protease inhibitor Faldeprevir in combination with PEG-IFN and RBV 
gave SVR in 73-92% of cases. It was noted that the chances of viral relapse after treatment 
were significantly higher if treatment duration was shorter. 
Simeprevir, also a second generation protease inhibitor, has also been trialled in combination 
with PEG-IFN and RBV for 12 weeks followed by an additional 24 weeks treatment with PEG-
IFN-RBV. Again SVR rates were improved in treatment naive genotype 1 populations to 80% 
SVR, but only 58% SVR was achieved in cases of cirrhosis (Barreiro et al., 2013, Miller et al., 
2014). 
The nucleoside analogue polymerase inhibitor Sofosbuvir has been trialled alongside PEG-IFN 
and RBV for 12 weeks followed by a 12 week course of RBV against a primarily treatment naive 
genotype 1 population, achieving 89% SVR. This was again reduced, to 80% SVR, when only 
cirrhotic patients were treated. 
Patients who are IFN non-responders have proved even more difficult to treat. Faldeprevir, 
PEG-IFN and RBV only achieved 21-35% SVR and even an extended 48 week treatment of 
Simeprevir and RBV only produced 59% SVR. However, as evidence that combinations of 
inhibitors may enhance treatment, an IFN-free therapy of Simeprevir, Sofosbuvir and RBV for 
up to 24 weeks gave 93% SVR against an IFN non-responder cohort. 
Chapter 1 - Introduction 
 
10 
 
Sofosbuvir has also been trialled against genotype 3 infections. In treatment naive patients the 
success of a course of Sofosbuvir and RBV depended on treatment duration (12 weeks; 61% 
SVR, 24 weeks; 94% SVR). Achievement of SVR was reduced in cases of cirrhosis (12 weeks; 
34% SVR) and IFN non-responders (12 weeks; 30%). 
Genotype 2 infections have traditionally been associated with higher SVR rates than infections 
of genotypes 1 and 3 using traditional PEG-IFN-RBV therapy. A trial of Sofosbuvir and RBV for 
12 weeks improved SVR rates to 97% (PEG-IFN-RBV control arm 78% SVR), but was again 
dramatically reduced, to 48% SVR, in cases of cirrhosis. While 12 week therapy gave 86% SVR 
against IFN non-responders, this could be improved to 94% SVR if treatment was extended to 
16 weeks (Barreiro et al., 2013, Miller et al., 2014).  
While some clinical trial data is available for infections with other HCV genotypes the cohorts 
tend to be smaller and the true degree of success of these inhibitors against genotypes 4-6 
remains to be seen. 
Despite the use of two inhibitors with different viral targets, protease and polymerase, the 
above clinical trial data presents similar results. These inhibitors as part of PEG-IFN-RBV based 
triple therapies achieve reasonably high SVR rates against treatment naïve patients, but are 
associated with less success in cases of cirrhosis and IFN non-responders. While the use of 
Sofosbuvir and Simeprevir together demonstrate that combining drug candidates may help 
improve SVR rates, all of these trials still involve the use of at least one of either PEG-IFN or 
RBV. Key future aims, in addition to improving SVR from therapies, are to negate the need for 
either PEG-IFN or RBV due to the adverse associated side effects, and to reduce the duration 
of treatment, as even in the absence of PEG-IFN and RBV several of the new drug molecules 
present with side effects. 
With regards to removing PEG-IFN and RBV, the current clinical data on combination therapies 
and the success of similar therapies for the treatment of other viruses, such as HIV (Pavlos and 
Phillips, 2012), suggest the answer to this is additional inhibitors of the HCV lifecycle. In this 
regard one other class of HCV DAA is being progressed, which target the NS5A protein through 
an as yet ill-defined mechanism of action. 
The most advanced of the NS5A inhibitors is Daclatasvir (Bristol Myers Squibb). A phase II trial 
of Daclatasvir, Sofosbuvir and RBV gave 100% SVR for genotype 1 infections and 91% SVR for 
genotypes 2 and 3. Similar results are reported for trials of the NS5A inhibitor Ledipasvir 
(Gilead) giving 100% SVR alongside Sofosbuvir and RBV. Yet a trial of Daclatasvir and 
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Asunaprevir (Bristol Myers Squibb), a second generation protease inhibitor, in genotype 1b IFN 
non-responders achieved SVR in only 64-91% of cases (Kohler et al., 2014), demonstrating that 
even as a double therapy these inhibitors are not always sufficient to clear the virus in 
infections which are more difficult to treat. 
The busy pipeline of HCV anti-virals offers great promise for a robust treatment with a high 
success rate of clearing the virus in an IFN and RBV free therapy. Many classes of DAA now 
achieve pan-genotypic activity but the ability to treat HCV infection is still greatly diminished in 
IFN non-responders and, significantly, in the large patient populations where infection is not 
diagnosed before the development of liver cirrhosis. The current evidence supports the use of 
combinations of DAAs to improve the chances of clearing the virus and reduce the risk of viral 
rebound in an IFN and RBV free setting. Additional DAAs would greatly improve the treatment 
options and the likelihood of successful combination therapy. While the list of HCV DAAs 
progressing through clinical trials is extensive, all of these drugs target one of the three current 
anti-viral targets; protease, polymerase or NS5A. Supplementation of combination therapies 
would benefit most from additional anti-viral agents with a novel molecular target or 
mechanism of action. The only viral protein possessing catalytic activity which is not currently 
being utilised for anti-viral development is NS2, representing an entirely novel field of 
therapeutic agents. 
Table 1.1 summarises the current drug development pipeline for HCV.  The precise mechanism 
of action of each class of inhibitor is described in more detail in Section 1.5. 
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Table 1.1: Key HCV anti-virals and current progress. 
Drug (Company) Target Current stage of 
development 
Telaprevir (Janssen - Vertex) 1st generation NS3/4A 
protease 
Approved 
Boceprevir (Merck) 1st generation NS3/4A 
protease 
Approved 
Simeprevir (Janssen) 2nd generation NS3/4A 
protease 
Phase III 
Faldeprevir (Boehringer-Ingelheim) 2nd generation NS3/4A 
protease 
Phase III 
Asunaprevir (Bristol Myers Squibb) 2nd generation NS3/4A 
protease 
Phase III 
Danoprevir (Genentech) 2nd generation NS3/4A 
protease 
Phase II 
Vaniprevir (Merck) 2nd generation NS3/4A 
protease 
Phase II 
Narloprevir (Merck) 2nd generation NS3/4A 
protease 
Phase II 
Sofosbuvir (Gilead) NS5B polymerase Phase III 
Mericitabine (Genetech) NS5B polymerase Phase III 
Daclatasvir (Bristol Myers Squibb) NS5A Phase III 
Ledipasvir (Gilead) NS5A Phase III 
ABT-267 (AbbVie) NS5A Phase III 
Alisporivir (Novartis) Cyclophilin A PPIase Phase III (on hold) 
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1.4 Molecular virology and lifecycle of HCV 
1.4.1 Genome organisation 
The HCV genome comprises a positive sense single stranded RNA molecule approximately 
9,600 nucleotides in length coding for a single open reading frame (ORF). The coding region is 
flanked by both a 5’ and a 3’ un-translated region (UTR) (Figure 1.3). The 5’ UTR is 341 
nucleotides in length and forms stable RNA secondary structures in the form of four stem 
loops, termed stem-loop (SL) I-IV. SLII, III and IV and a small section at the 5’ of the core ORF 
form an internal ribosome entry site (IRES) which binds directly to the 40s subunit of the 
ribosome to allow the initiation of translation in the absence of a 5’ cap (Hashem et al., 2013). 
The 5’ UTR also contains two tandem sites which bind to micro-RNA (miRNA) 122. The binding 
of miRNA-122 regulates replication and translation and helps to explain the tissue-specific 
tropism of HCV, as miRNA-122 is only present in liver hepatocytes (Shimakami et al., 2012). 
 
Figure 1.3: Genome organisation of HCV 
The 3’ UTR comprises a short variable region, a poly U/UC tract and a 3’ X-tail. The variable 
region displays low sequence conservation between genotypes but has high conservation 
between strains of the same genotype. Similarly, the length of the poly U/UC stretch varies 
between strains, unlike the 3’ X-tail which contains three highly conserved SLs important for 
the synthesis of negative sense RNA as a replication intermediate. 
The viral genome also encodes several cis-acting regulatory elements again important for 
regulation of replication and translation. SLs within the coding region of NS5B interact via both 
kissing loop and pseudoknot interactions to SLs within the 3’ UTR X-tail. It is likely the RNA 
genome contains multiple other secondary structure elements regulating aspects of the 
lifecycle. For example additional SLs have been identified in the core coding region, which play 
an as yet ill-defined role in replication (Vassilaki et al., 2008). 
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1.4.2 Virus particle composition 
Analysis of the HCV virion has been hampered by its heterogeneous nature. HCV particles from 
cell culture systems are typically 50-80 nm in diameter but have been observed between 40-
100 nm and more irregular in structure than other members of the Flaviviridae family 
(Catanese et al., 2013). The infectious HCV RNA circulating in the blood exists as a nucleocapsid 
particle encased in a host-derived membrane containing the viral envelope glycoproteins E1 
and E2. This virion is known to be associated with host lipoprotein-containing particles, most 
notably apolipoprotein B or E (ApoB / ApoE) in low density lipoprotein (LDL) or very low 
density lipoproteins (VLDL) particles. These lipid particles are naturally secreted from 
hepatocytes. As such infectious RNA particles can be referred to as lipoviroparticles (LVPs) 
(Nielsen et al., 2006, Vieyres and Pietschmann, 2013). The association of the virion with (V)LDL 
particles and extensive glycosylation of the viral envelope proteins most likely play important 
roles in preventing immune detection (Bartenschlager et al., 2011). 
 
1.4.3 Viral entry 
HCV entry is a complex multistage process. Current models suggest initial interaction with the 
hepatocyte is mediated by attachment molecules via the (V)LDL associated with the virion, 
such as heparin sulphate glycosaminoglycans (GAGs) and the low density lipoprotein receptor 
(LDL-R) (Nielsen et al., 2006, Zhu et al., 2014). Following this a specific binding event occurs 
between the virion glycoproteins, most notably E2, with numerous entry receptors. CD81 is 
the most fully characterised of these receptor interactions, with a large 89 residue 
extracellular loop binding E2 (Pileri et al., 1998, Tang and Grise, 2009) but considerable 
evidence implicates other receptors such as scavenger receptor-BI (SR-BI) (Scarselli et al., 
2002). Additional receptors identified as requirements for HCV entry include Claudin-1 (CLDN-
1) (Evans et al., 2007), CLDN-6, CLDN-9 (Meertens et al., 2008) and occludin (OCLN) (Ploss et 
al., 2009). These receptors are not accessible to sinusoidal blood as they are located at tight 
junctions, leading to the proposal of a two-stage mechanism whereby an initial specific 
interaction occurs between the virion and CD81/ SR-BI which mediate a translocation to the 
tight junction receptors to produce a co-receptor complex at the late stage of the entry 
process (Harris et al., 2008). Internalisation occurs by clathrin-mediated endocytosis 
(Blanchard et al., 2006), most likely still in complex with a co-receptor complex as CD81 and 
CLDN-1 co-endocytosis has been documented (Farquhar et al., 2012). The process of 
internalisation requires the co-receptor complex of CD81 and CLDN-1, whose interactions can 
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be modulated through epidermal growth factor receptor (EGFR) dependent signalling 
pathways. As such the receptor tyrosine kinase EGFR plays a role as an additional entry factor 
(Zhu et al., 2014). 
Following clathrin-mediated endocytosis, fusion of the viral and host membranes allows 
release of the viral nucleocapsid into the cytosol. While still a poorly understood process this is 
thought to require a conformational rearrangement of the viral envelope proteins in a pH 
dependent manner (Tscherne et al., 2006).  
An alternative route of infection of hepatocytes is from direct cell-to-cell transmission. Such 
events have been observed in cell culture models of infectious HCV and can occur in the 
presence of antibodies capable of neutralising cell-free HCV virions, providing a clear 
advantage for immune evasion. Cell-to-cell transmission appears to require an overlapping set 
of cellular receptors. While both CD81-dependent and CD81-independent routes have been 
observed, both routes required CLDN1 (Timpe et al., 2008).  
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Figure 1.4: HCV entry.  
A) Schematic of the HCV virion with key components labelled. Adapted from (Feneant et al., 
2014). B) Summary of current model of HCV entry. (1) Attachment molecules GAGs and LDLR 
facilitate initial association leading to specific interaction with entry receptors CD81 and SRB-1. 
(2) Co-receptor complex forms with tight-junction associated receptors CLDN1 and OCLN. (3) 
Co-receptor and virion internalised by clathrin mediated endocytosis. (4) Acidification of early 
endosomes instigates membrane fusion and genomic release. Adapted from (Zhu et al., 2014). 
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1.4.4 Polyprotein processing 
The released cytosolic genome is of a positive sense and thus acts directly as a mRNA. It is 
translated in a cap-independent manner through recruitment of the 40s ribosome subunit by 
the IRES and a kinetically slow conversion to an active 80s ribosome complex. Translation 
occurs at the rough endoplasmic reticulum (ER). Translation of the primary ORF produces a 
large polyprotein of approximately 3000 amino acids which is processed co- and post-
translationally to form the mature viral proteins.  
An additional ORF has been noted due to a +1/-2 ribosomal shift in the core coding region, 
producing a protein of roughly 160 residues termed Frameshift protein (F) or alternative 
reading frame protein (Xu et al., 2001). F protein is not required for the virus lifecycle in cell 
culture and is not conserved between genotypes, indicating a lack of function (Cristina et al., 
2005). While antibodies reactive to F have been isolated from HCV-infected patients any 
potential role for F remains unclear (Morice et al., 2009, Xu et al., 2001).  
The HCV ORF encodes 10 mature proteins; core, E1, E2, p7, NS2, NS3, NS4A, NS4B, NS5A and 
NS5B, which can be divided into two sections; the structural proteins involved in virion 
assembly and release and the non-structural proteins which primarily instigate genome 
replication. These regions can be alternatively characterised into three sections with different 
functions. The N-terminal third of the polyprotein (core-E2) encodes structural proteins which 
directly form the infectious particle alongside host membranes, lipoprotein particles and RNA 
genome. These structural proteins are followed by p7 and non-structural (NS) 2, which 
facilitate the processes of virus assembly and release. The C-terminal portion of the 
polyprotein encoding NS3-5B is sufficient for genome replication in cell culture (Lohmann et 
al., 1999). 
During translation the polyprotein is targeted to the ER by a signal sequence N-terminal of E1. 
Signal sequences are employed by numerous host proteins to instigate secretion by inserting 
proteins into the ER membrane, with the signal sequence subsequently removed by signal 
peptidase or signal peptide peptidase. These host cellular proteases perform the cleavage 
events required for the maturation of core, E1, E2, p7 and the mature N-terminus of NS2. 
Following insertion of the polyprotein into the ER lumen mediated by a signal peptide at the C-
terminus of core, host signal peptidase cleaves at the C-terminus of the signal peptide to 
liberate the authentic N-terminus of E1. Further signal peptidase activity processes the 
junctions at E1-E2, E2-p7 and p7-NS2. Core remains ER bound by its C-terminus (which acts as 
the signal peptide for E1) until an additional cleavage event by the signal peptide peptidase, 
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either at the N-terminus of or within the signal sequence, releases the mature core protein 
(Figure 1.5A). After separation from the membrane anchor core associates with lipid droplets 
(LDs) (McLauchlan et al., 2002). 
The signal peptidase and signal peptide peptidase cleavage events occur co-translationally or 
immediately post translation to leave mature core, membrane embedded E1 and E2 and 
transmembrane p7. The final membrane associated portion of polyprotein contains NS2-5B. 
The six non-structural proteins within this fragment are processed by virally encoded 
proteases.  Such a mechanism may allow a greater degree of control over production of the NS 
proteins that perform genome replication. Some of these proteins are postulated to dimerise 
or oligomerise for functional reasons and as such it has been proposed that the use of virally 
encoded proteases allows the regulation of the onset of replication until sufficient levels of 
viral proteins have accumulated, as with other RNA viruses which employ self-encoded 
proteases to regulate different stages of their lifecycle (Hellen et al., 1989). 
The first of the virally encoded proteases is an autoprotease activity encoded by the C-
terminus of NS2 but also requiring the NS3 N-terminus. Therefore the initial step of 
polyprotein processing and continuation of the virus lifecycle is wholly dependent on the 
function of the NS2 autoprotease, which cleaves at the NS2-NS3 junction to produce mature 
NS2 and the native N-terminus of NS3. The NS2 autoprotease is described in more detail in 
Section 1.8. The NS3 N-terminus encodes a second protease activity which initially cleaves 
itself at the NS3-NS4A boundary. NS4A acts as a co-factor for the NS3 protease to allow 
proteolysis at the NS4A-NS4B, NS4B-NS5A and NS5A-NS5B junctions (Figure 1.5A) to produce 
the last of the 10 mature viral proteins which can begin the process of genome replication, 
assembly of new virus particles and ultimately release of infectious virions. 
 
1.4.5 Genome replication 
The process of genome replication is performed by the NS5B RNA-dependent RNA-polymerase 
(RdRp), which synthesises positive sense RNA from a negative sense intermediate, but 
replication also requires NS3, NS4A, NS4B and NS5A. These proteins are tightly associated to 
each other and to ER membranes and concentrated in a remodelled lipid bilayer termed 
‘membranous web’ (Figure 1.5B). The remodelling of host membranes is a common 
characteristic of positive sense RNA viruses (Miller and Krijnse-Locker, 2008). In the case of 
HCV this remodelling is caused by NS4B, though NS5A has also been implicated via the host 
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factor phosphatidylinositol 4-kinase III α (PI4K-α) (Berger and Randall, 2009). ER-derived 
membrane is principally remodelled into single membrane vesicles (SMVs) or double 
membrane vesicles (DMVs) which house the viral non-structural proteins NS3-5B alongside 
positive and negative sense copies of the RNA genome. These membrane-encased 
concentrations of viral non-structural proteins are referred to as a ‘replication complex’ (RC) 
and are additionally thought to include numerous host factors (Berger and Randall, 2009). The 
formation of membranous web creates a favourable environment for the process of genome 
replication by allowing free exchange of nucleotide triphosphates (NTPs) for incorporation into 
newly synthesised RNA molecules, and release of freshly synthesised RNA into the cytosol, as 
well as facilitating concentration of the necessary components for replication. DMVs also 
provide several degrees of protection. Concentrating viral genomes within these DMVs is 
thought to aid protection from the host innate immune response, particularly RNA sensing 
mechanisms, while DMVs also provide a physical barrier to host proteases and nucleases (Gu 
and Rice, 2013). 
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Figure 1.5: HCV polyprotein processing and replication.  
A) Processing of the 10 HCV encoded proteins from the polyprotein. The mature N-termini of 
E1, E2, p7 and NS2 are produced by signal peptidase (black arrowheads). Mature core is 
produced following cleavage from the C-terminal signal sequence by signal peptide peptidase 
(white arrowhead). Processing at the NS2-NS3 boundary is performed by the NS2 autoprotease 
(green arrowhead). Proteolysis of the remaining non-structural proteins NS4A, NS4B, NS5A and 
NS5B is performed by the NS3 protease (red arrowheads). Figure adapted from (Lindenbach 
and Rice, 2005). B) Non-structural proteins form replication complexes in remodelled 
membranous structures termed ‘membranous web’. Figure adapted from (Miller and Krijnse-
Locker, 2008). 
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1.4.6 Virus assembly and release 
The process of assembly of progeny virus particles can be broadly divided into two events; the 
formation of an RNA-core nucleocapsid in an early stage and a late stage whereby this 
nucleocapsid is enveloped.  
The process by which RNA associates with mature, LD localised core in order to form a 
nucleocapsid is poorly understood. One current model hypothesises that viral RNA is delivered 
to the LDs allowing tight regulation between replication and assembly (Bartenschlager et al., 
2011). This function is believed to be performed by NS5A which is known to bind viral RNA 
(Foster et al., 2010a, Hwang et al., 2010) and has roles in both replication and release (Appel et 
al., 2008). Additionally NS5A co-localises with core at LDs in cell culture systems for virus 
propagation (Miyanari et al., 2007). 
An alternative model involves assembly of nucleocapsids at the ER, with core delivered from 
LDs to the ER membrane to interact with RNA-associated NS5A. This model may be more 
coherent with current understanding of the late stages of viral assembly and egress, which is 
tightly linked to the host VLDL pathway and involves the transfer of nucleocapsid from 
cytosolic LDs to luminal LDs (luLDs) (Bartenschlager et al., 2011). luLDs are produced at lipid-
rich microdomains within the ER and through fusion with apoE-pre-VLDL particles eventually 
form mature VLDLs. Thus nucleocapsid-containing luLDs will mature through this pathway to 
form LVPs before egress through the Golgi secretory pathway. 
Little is understood about the maturation of nucleocapsid loaded luLDs, particularly how the 
envelope glycoproteins E1 and E2 become associated with maturing LVPs. One potential 
mechanism can be drawn from the observation of NS2-mediated interactions with NS3, NS5A, 
p7 and the envelope glycoproteins at LDs (Jirasko et al., 2010, Popescu et al., 2011, Stapleford 
and Lindenbach, 2011). Hence NS2 may act as a link between glycoproteins and non-structural 
proteins involved in assembly. 
Release of infectious virus is acid sensitive and therefore requires oligomerisation of p7 to 
form a proton conducting ion channel which allows maturation of the virion without exposure 
to acidic conditions in intracellular compartments (Wozniak et al., 2010).  
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1.5 HCV encoded proteins 
1.5.1 Core 
While core is often described as a multifunctional protein, its principle role is as a key 
component of the nucleocapsid to protect the virus genome. Mature core is 21 kDa and can be 
divided into two domains. Domain 1, comprising the N-terminal ~117 residues, is hydrophilic 
and plays important roles in RNA binding and oligomerisation. The first 82 amino acids of this 
domain, an intrinsically disordered region, are sufficient to form nucleocapsid like particles in 
the presence of structured RNA in vitro (Fromentin et al., 2007). Domain 1 is thought to 
function as a dimer. Domain 2 by contrast is hydrophobic and responsible for core association 
with LDs or the ER. This domain comprises two amphipathic α-helices separated by a 
hydrophobic loop, with this helix-turn-helix conformation known to be required for LD 
localisation (Gawlik and Gallay, 2014). 
As a key component for the process of virus assembly, core interacts not only with genomic 
RNA but directly or indirectly with p7 and E1, NS5A, NS2 and NS3. In addition core has been 
shown to modulate a range of host processes; cell signalling, apoptosis and gene transcription 
(reviewed in (McLauchlan, 2000)). 
Core possesses the highest pan-genotype sequence conservation of all the HCV encoded 
proteins and as such has been postulated as a potential target for anti-virals. Small molecules 
which block core dimerisation appear to exert an anti-viral effect but remain in early pre-
clinical stages (Ni et al., 2011). 
1.5.2 E1 and E2 
E1 and E2 are the viral envelope glycoproteins which form an E1-E2 heterodimer. Both are 
type I trans-membrane glycoproteins which are present at the ER, with a short C-terminal 
trans-membrane domain (TMD) and an N-terminal ectodomain. E1 and E2 have complicated 
folding patterns requiring numerous host chaperones and are post-translationally modified by 
N-linked glycosylation. The number of glycosylation sites varies between genotypes but E1 can 
contain up to 5 glycans and E2 can have up to 11 sites of glycosylation (Vieyres et al., 2014). 
Glycosylation is important not only for correct folding of E1 and E2 but for the formation of E1-
E2 heterodimers, which are incorporated in the host membranes which envelope the 
nucleocapsid during assembly and egress (see Section 1.4.6). In line with this E2 co-localises 
with core at LDs (Counihan et al., 2011). Further to this the extensive glycosylation of the 
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envelope proteins, particularly E2, mask antigenic sites within the LVP to aid immune evasion 
(Helle et al., 2007). 
E2 contains three hypervariable regions (HVRs) which form the targets for HCV neutralising 
antibodies within the LVP. As such these regions are under a constant selective pressure and 
are very tolerant to modifications, an aspect further aiding the ability of HCV to evade the 
innate immune system and develop a persistent chronic infection (Vieyres et al., 2014). These 
HVRs, in particular HVR-1, mask important envelope epitopes such as those in E2 involved in 
CD81 binding (Bankwitz et al., 2010) and therefore regulate the binding event. Within the E1-
E2 heterodimer the E2 ectodomain interacts with CD81 (Pileri et al., 1998), SR-B1 (Scarselli et 
al., 2002) and CLDN-1 (Evans et al., 2007) while E1 binds LDLR (Mazumdar et al., 2011) to 
facilitate entry. 
The roles of E1-E2 in virus uncoating upon entry are ill-defined. Comparison to other 
Flaviviridae family members would predict one of these glycoproteins to acts as a class II 
fusion protein to mediate uncoating. Differing models suggest that either E1 or E2 may fulfil 
this function as a truncated class II fusion protein (Garry and Dash, 2003, Krey et al., 2010), 
though more recent evidence based on BVDV E2 homologs indicate a novel form of fusion 
protein (El Omari et al., 2013, Li et al., 2013). The fusion protein function of one or both of E1-
E2 appears to be modulated by a pH-dependent conformational change requiring interaction 
with CD81 (Sharma et al., 2011). 
1.5.3 p7 
p7 is a 63 amino acid hydrophobic protein which oligomerises to form hexameric or 
heptameric cation-selective ion channels (Griffin et al., 2003, Premkumar et al., 2004). Each 
monomer comprises two TMDs linked by a conserved cytosolic loop. The formation of 
oligomeric p7 ion channels allows proton conductance across the membranes of organelles 
such as secretory vesicles in the egress and release pathway which would otherwise be 
acidified. Thus p7 protects the maturing virion from exposure to acidic conditions (Wozniak et 
al., 2010). 
p7 plays additional roles in the early stages of virus assembly. Deletion of p7 from virus in cell 
culture blocks an early stage of assembly which occurs prior to formation of intracellular 
particles (Jones et al., 2007).  The signal peptidase mediated cleavage of E2-p7 and p7-NS2 
boundaries has been noted as inefficient, with suggestions that the ability to regulate the 
levels of mature forms of these proteins may be beneficial to the virus. p7 and its upstream 
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signal sequence (in E2) have been shown to facilitate correct localisation of NS2 adjacent to 
RCs in the ER which may be important for post-autoprotease roles of NS2 in virus assembly 
and release (Tedbury et al., 2011). Further to this p7 has been documented to play a role in re-
localisation of core from lipid droplets to putative assembly sites in the ER, potentially through 
a direct interaction of p7 with core which is modulated by interactions with NS2 (Boson et al., 
2011). The effects of p7 on both NS2 and core localisation are independent of a functional ion 
channel activity. 
The finding that amantadine, a viroporin inhibitor active against the Influenza M2 viroporin, 
blocks p7 ion channel activity has led to progression of p7 as an anti-viral target. Effects of 
adamantine in cell culture and in clinical trials have been modest, but the application of 
structural NMR techniques and a subsequent model of the p7 oligomeric channel have allowed 
the identification of improved inhibitors, a process facilitated by virtual high-throughput 
screening (vHTS) and rational design (Foster et al., 2014). 
1.5.4 Non-structural 2 
NS2, along with the other non-structural proteins as a NS2-5B polyprotein, is directed to and 
embedded into the ER membrane by its signal sequence within p7 prior to signal peptidase 
mediated processing of the p7-NS2 junction. However, expression of NS2 alone leads to 
localisation at organelle membranes (Yamaga and Ou, 2002). NS2 is 23 kDa and contains two 
domains. A 92 residue hydrophobic N-terminal trans-membrane domain spans the ER and 
orientates a 124 residue soluble C-terminal domain in the cytoplasm. This C-terminal domain 
encodes a cysteine protease which processes the NS2-NS3 boundary, termed the NS2 
autoprotease. Functions and current understanding of the C-terminal protease domain of NS2 
are discussed in Section 1.8. 
The NS2 N-terminal domain is thought to form three trans-membrane alpha helices, each of 
which has been independently observed in solvent by solution NMR (Jirasko et al., 2008, 
Jirasko et al., 2010). While the N-terminal TMD is clearly important for anchoring NS2 to ER 
membranes, the C-terminal catalytic domain has recently been shown to associate with 
membranes independently, and it is likely that a hydrophobic face of this soluble domain 
contributes an amphipathic membrane association (Lange et al., 2014). Membrane association 
of NS2 is essential in the virus lifecycle, at least as a requirement for the NS2 autoprotease 
activity (Lange et al., 2014), but functional membrane association does not appear to depend 
on the p7 encoded signal sequence, as demonstrated by viability of virus systems in cell 
culture where NS2 is genetically separated from p7 with an IRES (Jones et al., 2007). 
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NS2 plays additional roles in the virus lifecycle, most notably during assembly, following 
maturation from the NS2-5B polyprotein. Structural evidence suggests that mature NS2 is no 
longer active as a protease (Lorenz et al., 2006), hence effects on later stages of the lifecycle 
are thought to be mediated through protein-protein interactions. Numerous studies have 
documented NS2 interacting either directly or indirectly with the majority of virally encoded 
proteins. Confirmed interactions with p7 and the E1-E2 heterodimer (most likely through E2 
via a signal peptidase host factor complex (Suzuki et al., 2013)) appear to be mediated by the 
N-terminal TMD (Jirasko et al., 2010, Stapleford and Lindenbach, 2011). A validated interaction 
with NS3 also requires the NS2 N-terminal domain but this effect could be mediated through 
interactions with p7.  
Interestingly several groups have reported improved systems for culturing HCV through NS2-
based chimeras. Lindenbach et al. first reported a chimeric virus construct termed J6JFH, with 
the core-NS2 proteins derived from the J6CF isolate and NS3-5B from the JFH1 isolate (both 
genotype 2a; these isolates will be discussed in more detail in Section 1.7) (Lindenbach et al., 
2005).  Infectious titres were improved a further 100-1000-fold by fusing J6CF and JFH1 
genomes at a site within NS2 between the first and second N-terminal trans-membrane 
domains (designated Jc1) (Pietschmann et al., 2006). While all documented interactions with 
structural proteins occur through the N-terminus of NS2, the C-terminal catalytic domain (but 
not the catalytic activity) is required for virus assembly (Jones et al., 2007), suggesting the 
interactions formed through this domain also contribute to late stages of the virus lifecycle. As 
such NS2 has been postulated as a link between non-structural RC components and sites of 
virus assembly (Ma et al., 2011). 
NS2 has been isolated from high molecular weight complexes which also contain E1, E2 and 
NS3 (Stapleford and Lindenbach, 2011). The glycosylation pattern of the envelope proteins in 
these complexes suggest they have not yet trafficked to the Golgi, indicating an early stage of 
assembly. NS2 has been confirmed to play an early role in assembly, similar to and potentially 
linked to that of p7 (Jones et al., 2007). It would therefore appear likely that NS2 interactions 
with E2, p7 and NS3 could occur at LDs prior to egress to the Golgi. Substantial evidence is 
building for a role of NS3 in release (Ma et al., 2008, Shimakami et al., 2011). An interaction 
between NS3 and the NS2 C-terminal domain (or an indirect association of NS3 with NS2 via 
p7) may help explain how NS3 could be targeted to sites of assembly and why the catalytic 
domain of NS2 is required for virus release. In agreement with this genetically separating NS2 
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and NS3 with an IRES led to a reduction in NS2-NS3 association and a reduction in virus titre 
(Stapleford and Lindenbach, 2011). 
Investigations into NS2 interacting partners also suggested that NS2 is capable of 
multimerisation. Subsequently several groups have provided biochemical or structural 
evidence for the formation of NS2 homodimers (reviewed in Section 1.8.4). Perhaps the 
strongest evidence comes from a crystal structure of the post-cleaved NS2 catalytic domain 
which implicates the formation of the autoprotease active site with dimerisation (Lorenz et al., 
2006). Whether dimerisation is required for the numerous protein-protein interactions of NS2 
remains inconclusive. 
Optimisation of the HCV sub-genomic replicon (SGR), as described in Section 1.7, clearly 
demonstrated that NS2 is not required for genome replication (Lohmann et al., 1999), a finding 
further confirmed by mutagenesis in infectious virus (Jones et al., 2007). In fact the presence 
of NS2 in HCV SGRs is associated with impaired replication kinetics (Lohmann et al., 1999, 
Tedbury et al., 2011). The cause of this is unknown but could be due to slower kinetics of 
processing at the NS2-NS3 boundary, which is not required in SGRs comprising NS3-5B, or 
alternatively because of NS2 sequestering viral components at sites of assembly rather than 
replication through the aforementioned protein-protein interactions. 
Finally, NS2 has been implicated in the modulation of host signalling. Ectopic expression of NS2 
has been shown to affect transcription from a variety of promoters by causing ER stress (von 
dem Bussche et al., 2010), suggesting post-cleaved NS2 may modulate protein levels of the 
host cell via its N-terminus. In addition NS2, along with core, E2 and NS5A, has been shown to 
bind to components of the mitochondrial intrinsic apoptotic pathway and block apoptosis 
(Welbourn and Pause, 2006), an area that may be of future interest given the emerging 
evidence supporting direct oncogenic potential of HCV towards the development of HCC. How 
these functions, which were mostly observed through expression of NS2 alone, relate to the 
complete virus lifecycle remains unknown, but the reported short half-life of NS2 within 
hepatoma cells may aid regulation of these functions. Both NS2 and unprocessed NS2-3 (in the 
context of abolished autoprotease activity) are rapidly degraded, with NS2-3 precursors 
subject to ubiquitination on NS2 encoded lysine residues for targeting to the proteasome 
(Welbourn et al., 2009). For genotype 1a NS2, degradation has been linked to serine 168 in 
NS2 (Franck et al., 2005). This residue sits in a putative casein kinase II consensus sequence 
suggesting phosphorylation could regulate turnover, though these results have not been 
replicated for other genotypes. Mutation of NS2 serine 168 to alanine has been shown to alter 
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the co-localisation of NS2 and NS5A (Tedbury et al., 2011) and loss of particle assembly due to 
S168 mutation can be recovered by mutations within NS5A (Yi et al., 2009). While potentially 
regulating a NS2-NS5A interaction, the precise role of serine 168 in the virus lifecycle has yet to 
be determined. 
Several groups have also reported the observation of an anti-NS2 reactive 17 kDa species from 
virus lysates which is probably a truncation product, termed tNS2 (Boson et al., 2011, Jirasko et 
al., 2008, Jirasko et al., 2010). While studies on the protein-protein interactions of NS2 did 
observe tNS2, it was not isolated from the same p7-, E1-E2- and NS3-containing fractions 
assumed to be LDs or sites of assembly (Stapleford and Lindenbach, 2011). Whether tNS2 has 
any functional role is unknown, with some reports suggesting it may represent an aberrant 
initiation product as it appears upregulated in constructs with genetically separated p7 and 
NS2 (Ma et al., 2011). 
As summarised in Section 1.8.5 despite concerted efforts no small molecule inhibitors of the 
NS2 autoprotease have been identified. Other than recent reports that DNA aptamers 
targeting the N-terminus of NS2 block the virus lifecycle (Gao et al., 2014) NS2 has not been 
pursued as an anti-viral target. Given the number of essential roles NS2 contributes to the 
virus lifecycle it is an attractive target for novel therapeutic interventions. 
1.5.5 Non-structural 3 
NS3 is 70 kDa and can be divided into two domains, each with an enzyme activity. The N-
terminal 180 residues of NS3 forms a serine protease, while amino acids 181-631 function as 
an NTPase-dependent RNA helicase. 
The N-terminal serine protease functions as the second virally encoded protease for 
polyprotein processing. Following production of the mature NS3 N-terminus by the NS2-
encoded autoprotease activity, NS3, within the NS3-5B polyprotein, cleaves itself at the NS3-
NS4A boundary. This reaction occurs in cis in that it cannot be trans-complemented by 
addition of exogenous NS3 protease from an alternate polyprotein. The remaining proteolytic 
cleavages occur in a specific order. Once the NS3-NS4A junction is processed, NS4A remains 
associated with NS3 as an essential co-factor in a non-covalent complex. NS4A contributes 
both to the NS3 protein fold and to the complex’s membrane association. The NS3-4A 
protease can be complemented in trans and cleaves first the NS5A-NS5B boundary to release 
mature NS5B. The resulting NS4A-NS4B-NS5A polyprotein is next processed between NS4A 
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and NS4B, before the final proteolysis event occurs at the junction of NS4B-NS5A (reviewed in 
(Morikawa et al., 2011)). 
Reconstitution of the NS3-4A protease activity in vitro preceded the ability to replicate the HCV 
lifecycle in cell culture and allowed detailed investigation into the workings of NS3 
(Vishnuvardhan et al., 1997). The crystal structure of the NS3 protease domain has been solved 
to high resolution, revealing a chymotrypsin-like fold stabilised by the coordination of a zinc 
atom by C97, C99, C145 and H149 (Figure 1.6) (Penin et al., 2004, Romano et al., 2012). Two β-
barrel subdomains are formed, with a β-sheet from NS4A contributing to one. The catalytic 
triad; H57, D81 and S139, function as a classic serine protease, with the acidic residue 
stabilising a conformation of the histidine capable of deprotonating the catalytic serine and 
thus allowing nucleophilic attack of the carbon atom within the scissile bond (Figure 1.9C). 
Peptide substrates spanning P4-P2’ fit into the active site cavity and will be processed, but 
maximal efficiency is observed with peptides spanning P6-P4’ with the consensus sequence 
D/E-X-X-X-X-C/T | S/A-X-X-X where (|) indicates the scissile bond. An early observation in in 
vitro systems was that N-terminal products from the proteolysis of peptides were capable of 
inhibiting further proteolysis (Llinas-Brunet et al., 1998). This led to the development of 
peptide-based NS3 protease inhibitors which now include both linear tetrapeptide α-
ketoamides (Han et al., 2000) and second generation macrocyclic inhibitors such as Simeprevir 
(Rosenquist et al., 2014). The first NS3 protease inhibitors approved for use in the clinic, 
Telaprevir and Boceprevir, are both the former and bind covalently but reversibly to the NS3 
active site (Figure 1.6) (Flores et al., 2009). 
The NS3-4A protease plays additional roles in persistence of HCV within host cells by 
processing components of innate immunity. A proportion of NS3-4A traffics to mitochondrial 
membranes where it cleaves the mitochondrial antiviral signalling protein (MAVS), toll/IL-1 
receptor homology domain-containing  adaptor inducing IFN-β (TRIF) and T-cell protein 
tyrosine phosphatase (TC-PTP). These proteins act as signalling molecules from innate 
immunity sensors for viral RNA, such as the retinoic acid-inducible I (RIG-I) or toll-like receptor 
3 (TLR-3) signalling pathways. The adaptors cleaved by NS3-4A would otherwise induce IFN 
regulatory factor-3 to upregulate IFN stimulating genes (ISGs) and produce IFN-β, thus helping 
the host cell and neighbouring cells elicit an ‘anti-viral’ state (reviewed in (Morikawa et al., 
2011)). Thus inhibitors of the NS3-4A protease may also boost the innate immune response to 
viral infection, further enhancing the anti-viral effect. 
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The C-terminal NS3 helicase domain is part of the DExH/D-box family of helicases  which use 
ATP hydrolysis to drive the unwinding of double stranded or highly structured RNA (Kwong et 
al., 2005). Again, the enzyme activity can be reconstituted in vitro (Tai et al., 1996) and high 
resolution crystal structures are available (Appleby et al., 2011, Penin et al., 2004). The NS3 
helicase is essential for replication, presumably for the unwinding of RNA duplexes within RCs 
(Salam and Akimitsu, 2013). The beneficial reasons for encoding these two enzyme activities 
on one protein, which remains unprocessed, in order to coordinate replication are only 
recently starting to become apparent (Beran et al., 2009). 
Inhibitors of the NS3 helicase have been reported (Salam and Akimitsu, 2013) but challenges 
regarding selectivity over cellular helicases have hampered progression from pre-clinical 
development. 
 
 
Figure 1.6: NS3 protease – Telaprevir co-crystal structure.  
NS3-protease domain with catalytic residues highlighted with orange carbons. The catalytic 
serine forms a covalent interaction with the protease inhibitor Telaprevir (blue carbons). 
Additional polar contacts are shown. Structural zinc and co-ordinating residues are shown in 
red. Surface representation is shown with oxygen atoms in red and nitrogen atoms in blue. 
Image produced in Pymol using PDB 3SV6 (Romano et al., 2012). 
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1.5.6 Non-structural 4A 
NS4A is a 54 residue co-factor for the NS3 protease which directly contributes a β-sheet to a β-
barrel as part of the NS3 fold and serves to anchor NS3 to ER membranes. The first 21 amino 
acids form a trans-membrane α-helix. While the NS3 protease domain encodes an amphipathic 
helix for membrane association, through NS3-NS4A association the NS4A TMD is thought to 
ensure membrane localisation of the NS3 protein (Brass et al., 2008). Amino acids 21-32 form 
the β-strand contributing to the NS3 fold by interacting with the second β-barrel. The C-
terminal residues (amino acids 40-54) are thought to interact with additional HCV proteins and 
play essential functions both in replication and release (Phan et al., 2011). 
1.5.7 Non-structural 4B 
NS4B is a highly hydrophobic 27 kDa protein, the central portion of which forms four TMDs 
(Lundin et al., 2003), while additional amphipathic helices are present at the cytosolic N- and 
C-termini (Gouttenoire et al., 2009a, Gouttenoire et al., 2009b). The primary function of NS4B 
is the remodelling of host membranes so as to produce the membranous web upon which RCs 
form, a process thought to require NS4B oligomerisation (Egger et al., 2002, Paul et al., 2011). 
However, NS4B has also been documented to play roles in both replication and assembly, most 
likely through protein-protein interactions (Aligo et al., 2009, Han et al., 2013). 
Several groups have reported small molecule inhibitors of NS4B which prevent oligomerisation 
and show anti-viral effects in SGR systems (Dufner-Beattie et al., 2014, Einav et al., 2008, Rai 
and Deval, 2011). Compounds targeting NS4B remain at a pre-clinical stage. 
1.5.8 Non-structural 5A 
NS5A is a RNA-binding phosphoprotein with essential roles throughout the lifecycle. It consists 
of three domains linked by low-complexity sequences (LCS) and associates with membranes 
through an N-terminal amphipathic α-helix causing localisation both at ER membranes and 
LDs. Domain 1 includes a well conserved zinc-dependent structured region that forms two β-
sheets, as demonstrated through two independent crystal structures (Love et al., 2009, 
Tellinghuisen et al., 2004, Tellinghuisen et al., 2005). Interestingly, both of these structures 
reveal NS5A domain 1 as a dimer, though the position of each monomer relative to the other 
differs. Considerable evidence has confirmed that NS5A, like several other HCV encoded 
proteins, functionally self-associates to dimers (or oligomers) (Bhattacharya et al., 2012, Lee et 
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al., 2011, Lim et al., 2012). The structured domain 1 is considered essential for multiple stages 
of the virus lifecycle. 
Domains 2 and 3 of NS5A are predicted to be less structurally ordered, though these flexible 
regions may transiently possess significant structure (Feuerstein et al., 2012). Mutational 
analysis has implicated the C-terminus of domain 2 with a role in genome replication. By 
contrast, deletion of domain 3 has no effect on replication, but blocks virus assembly (Appel et 
al., 2008, Ross-Thriepland et al., 2013, Tellinghuisen et al., 2008). 
All three domains of NS5A are able to independently and specifically bind viral RNA, in 
particular RNA from the UTRs (Foster et al., 2010a, Huang et al., 2005, Hwang et al., 2010). 
This, in addition to the observation of separate co-localisations with NS proteins at the ER and 
core at LDs, has led to the proposal that NS5A binds and shuttles RNA genomes from the RCs 
to sites of virus assembly so as to deliver the genome to core (Appel et al., 2008, Targett-
Adams et al., 2011). Such a role may allow NS5A to act as a switch between the processes of 
genome replication and particle assembly, a theory all the more tempting due to the 
observation of two clearly distinguishable phosphorylation states of NS5A. These states can be 
resolved by denaturing gel electrophoresis into basally phosphorylated (termed p56 due to 
apparent molecular weight) and hyper-phosphorylated (p58) species. While both the kinases 
involved in phosphorylation and the sites of phosphorylation are beginning to become 
apparent (Huang et al., 2007, Ross-Thriepland and Harris, 2014), the precise roles of each 
species in the virus lifecycle and any potential effect mediating a ‘switch’ in the lifecycle have 
yet to be conclusively demonstrated. 
NS5A mediates numerous additional interactions with host factors to perturb signalling 
pathways and produce a more favourable cellular environment for virus propagation. NS5A is 
able to dampen the IFN response, in part through a 40 residue region in LCS-I and domain 2 
termed the interferon sensitivity determining region, by down regulating protein kinase R 
(PKR), which would otherwise be activated by viral double-stranded RNA leading to reduced 
translation. NS5A also down-regulates the mitogen activated protein kinase (MAPK) pathway 
through extracellular signal-regulated kinase (ERK) signalling, an implication of which is the 
stalling of the cell cycle in the G1 phase. Apoptosis is blocked by NS5A through binding and 
sequestering of p53, down-regulating the TNF-α response and perturbing phosphatidylinositol 
3-kinase signalling; while additional NS5A-mediated potential oncogenic effects include 
production of reactive oxygen species. The effects of these and other NS5A-host interactions 
are reviewed in (Macdonald and Harris, 2004). 
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Despite the lack of any documented enzyme activity, NS5A has emerged as a promising anti-
viral target for treatment of HCV. NS5A inhibitors were first identified through SGR-based high-
throughput screening (HTS) and were linked to NS5A by the observation that activity was 
based on symmetry and the identification of resistance mutants at the dimer interface of the 
N-terminus of NS5A domain 1 (Gao et al., 2010). Tagged versions of initial inhibitors were 
subsequently observed to bind solely to NS5A, but only in the context of active replication. 
Studies demonstrating effects of NS5A inhibitors on the phosphorylation state and localisation 
of NS5A have suggested they may block conformational changes or other events linked to 
certain stages of the virus lifecycle, though the mechanism of action remains unknown (Lee et 
al., 2011, Qiu et al., 2011, Targett-Adams et al., 2011). The remarkable in vitro activity of 
current NS5A inhibitors, some of which have pan-genotype 50% effective concentrations 
(EC50s) in the low pM range, creates a potency paradox whereby significantly fewer molecules 
of inhibitor than molecules of NS5A are sufficient to block all virus replication within a cell. One 
proposed explanation is an effect on all NS5A molecules within an oligomeric NS5A complex 
induced by a single binding event, almost as a ‘prion protein’ type effect. A more feasible 
explanation, though not mutually exclusive, may be that NS5A inhibitors only target the small 
proportion of NS5A functionally involved in RCs. Multiple pieces of evidence support the idea 
that NS5A inhibitors block the formation of new RCs and as such NS5A inhibitors are also 
referred to as ‘replicase inhibitors’ (Lee et al., 2011, Targett-Adams et al., 2011). More recent 
evidence suggests NS5A inhibitors exert additional effects against virus release (McGivern et 
al., 2014). Despite their impressive potency in vitro, NS5A inhibitors display a low barrier to 
resistance and as such are likely to be ineffective as a monotherapy. 
1.5.9 Non-structural 5B 
NS5B is an RNA-dependent RNA-polymerase (RdRp) and the central component of RCs 
(Behrens et al., 1996), responsible firstly for synthesising a negative strand intermediate from 
the positive sense genome and subsequently for producing positive strand replicates from the 
negative sense intermediate. NS5B is 65 kDa and membrane associated through a C-terminal 
21 residue TMD (Ivashkina et al., 2002, Schmidt-Mende et al., 2001). The N-terminal 
ectodomain is cytosolic and performs RdRp functions, with structural data showing a classic 
‘right-hand’ RNA polymerase fold with ‘finger’, ‘palm’ and ‘thumb’ subdomains (Lesburg et al., 
1999). The cytosolic region contains a highly conserved GDD motif required for binding 
divalent cations. Mutation of this motif to GND ablates this ability and prevents RdRp activity 
(Yamashita et al., 1998). Additionally, NS5B requires functional oligomerisation for RdRp 
activity (Qin et al., 2002). 
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Synthesis of the negative strand intermediate is instigated by NS5B binding to the 3’ UTR of the 
positive sense genome via the X-tail (Cheng et al., 1999). Due to the lack of proof-reading 
activity both the synthesis of negative strand intermediates and of subsequent positive sense 
copies is highly error prone. This error prone RdRp activity accounts for the high mutagenic 
rate of HCV which contributes not only to the genetic diversity between HCV genotypes but to 
the existence of quasi-species within a single host. Quasi-species have important implications 
for viral resistance to inhibitors as, rather than the selective pressure of an anti-viral having to 
produce a resistance mutant de novo, such a mutation may already exist within one such 
quasi-species allowing an immediate selective advantage. The error prone nature of NS5B and 
as a by-product the HCV quasi-species allows for rapid mutagenic change of the dominant HCV 
genome within the host and hence HCV can quickly react to environmental changes, a key 
reason for the requirement of combination therapy to successfully treat HCV. 
As the central component of RCs NS5B interacts directly or indirectly with numerous other NS 
proteins. A direct interaction with NS5A has been identified and may regulate the polymerase 
activity of NS5B depending on the phosphorylation status of NS5A (Ivanov et al., 2009, Shirota 
et al., 2002) providing further evidence of the ability of HCV to self-regulate various stages of 
the lifecycle. 
NS5B is the subject of two forms of anti-virals; nucleoside analogue inhibitors (NIs) and non-
nucleoside analogue inhibitors (NNIs).  
NNIs bind to an allosteric site between the ‘finger’ and ‘thumb’ domains of the polymerase and 
block intramolecular contacts involved in coordinated conformational flexibility required 
during synthesis of RNA (Di Marco et al., 2005). NIs potentially offer more promise as HCV anti-
virals due to the high degree of conservation of the NS5B active site which allows pan-
genotype activity with a relatively low barrier to resistance. NIs are administered as a pro-drug 
and require modification by three successive cellular kinases to form the active nucleoside 
analogue triphosphate which can be incorporated by the RdRp as a chain-terminator. Applying 
NIs as an anti-viral drug poses a series of problems; these molecules tend to have poor cellular 
permeability, are not active until the tri-phosphate stage, are influenced by cellular rNTP levels 
due to the nature of their competitive inhibition and risk incorporation into host cellular 
polymerases leading to off-target effects and toxicity. The success of the most advanced NI 
Sofosbuvir was driven principally by toxicology and pharmacology analysis, such as the use of a 
mono-phosphate pro-drug to aid absorption, distribution, metabolism and elimination (ADME) 
properties and increase levels of the intracellular triphosphate form (Coats et al., 2014). While 
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Sofosbuvir now appears set to form the backbone of all-oral HCV combination therapies, the 
inherent risks of NIs as drug molecules, as evidenced through numerous failed clinical trials of 
other NIs, should not be forgotten. 
 
1.6 Current anti-viral strategies for HCV 
The most developed therapeutic options for the treatment of HCV in IFN-RBV free therapy are 
the direct acting anti-virals (DAAs) previously described; namely NS3-4A protease inhibitors, 
NS5A ‘replicase’ inhibitors and NS5B NIs. Many of these inhibitors in combination with IFN-RBV 
or in IFN-RBV-free combinations with each other are expected to be approved shortly (clinical 
trial data for lead compounds in each series was summarised in Section 1.3). While some NS5B 
NNIs are also in clinical trials, additional DAAs comprising core inhibitors, p7 viroporin 
inhibitors, NS3 helicase inhibitors and NS4B inhibitors have, for the most part, remained in pre-
clinical stages. 
Inhibitors of HCV entry have been reported, again at a pre-clinical stage. These compounds 
exert an anti-viral effect at an undefined entry event post-attachment. While resistant isolates 
link these compounds to the C-terminal TMD of E2, it remains possible that they could function 
through a cellular target (Baldick et al., 2010, Coburn et al., 2012). 
Additional anti-HCV strategies have attempted to target essential host factors with small 
molecule inhibitors. This strategy offers the advantage of reduced likelihood of viral resistance 
and will often exert a pan-genotype effect. 
One such host factor is cyclophilin A (CypA), a chaperone protein which acts as a prolyl-
peptidyl isomerase (PPI) to rectify misfolded cis peptide bonds prior to proline residues. CypA 
was shown to be required for HCV replication as a by-product of the anti-viral activity of the 
CypA antagonist cyclosporine A (CsA) (Nakagawa et al., 2004, Watashi et al., 2003); a cyclic 
undecapeptide natural product already in clinical use as an immunosuppressive (Matsuda and 
Koyasu, 2000). The anti-viral effect of CsA is through inhibition of the PPIase activity of CypA 
and as such non-immunosuppressive analogues of CsA which still block PPIase activity have 
been progressed as anti-virals targeting HCV (Paeshuyse et al., 2006), though the lead 
compound Alisporovir (DEB025) is currently on hold in Phase III due to problems with toxicity. 
While the majority of evidence now links the mechanism of action of CsA to CypA rather than 
alternative Cyp family members, the effect on the HCV lifecycle is not fully understood 
Chapter 1 - Introduction 
 
35 
 
(Chatterji et al., 2009, Yang et al., 2008). Some reports have suggested a NS5B-Cyp interaction, 
though the common consensus is that CypA binds to domain 2 and LCS-II of NS5A where the 
PPIase activity is required for correct folding of two proline-rich regions. Resistance to CsA 
maps within this region, such as the NS5A mutant D316E (JFH1 isolate numbering), with 
biochemical and nuclear magnetic resonance (NMR) data demonstrating resistance does not 
affect NS5A-CypA binding, rather naturally favours the trans state of surrounding proline 
residues (Coelmont et al., 2010, Fernandes et al., 2007, Grise et al., 2012, Yang et al., 2010). As 
these regions of NS5A are primarily disordered, the requirement for CypA in terms of the HCV 
lifecycle remains elusive, although in vitro evidence suggests CypA induced isomerisation may 
aid the ability of NS5A domain 2 to bind RNA (Foster et al., 2011), while indications of 
competitive binding for the same sites on NS5A by CypA and NS5B are intriguing (Rosnoblet et 
al., 2012). The anti-viral effect of CsA and its analogues are further complicated by enhanced 
sensitivity in the presence of NS2, as described in Section 1.8.5. 
A prophylactic or therapeutic vaccine to HCV would be attractive not only due to the problem 
of DAA resistance but the significant costs of current DAA therapies. Evidence does exist for 
impaired HCV infection following previous spontaneous HCV clearance, suggesting cross-
protective immunity can occur naturally. However the lack of a suitable animal model makes 
vaccine development difficult, while the high HCV mutagenic rate and genetic diversity suggest 
there is a potential for escape from the immune responses induced by a vaccine and make it 
hard to produce a pan-genotype cross-protective vaccine (Feinstone et al., 2012). 
 
1.7 HCV model systems 
For the first decade of HCV research the virus lifecycle could not be reproduced in cell culture. 
For this reason early drug development targeted enzyme activities that could be reconstituted 
in vitro into suitable high-throughput screens; namely the NS3 protease, the NS3 helicase and 
the NS5B RdRp. The ability to study and screen non-discriminately for inhibitors of HCV 
genome replication was only realised upon production of the first sub-genomic replicon (SGR) 
capable of reproducing the HCV replication cycle. This was achieved through a bi-cistronic 
construct wherein the first ORF, driven by the HCV IRES from the 5’ UTR, encodes for a 
reporter gene and the second ORF, driven through an encephalomyocarditis virus (EMCV) IRES, 
contains the NS3-5B replication cassette (in addition to the non-coding 3’ UTR) (Figure 1.7). 
Important for successful establishment of autonomous RNA replication of the SGR was the use 
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of a selectable marker, neomycin phosphotransferase (NPT) and of a certain hepatoma cell 
line; Huh7 (Nakabayashi et al., 1982). The use of an NPT reporter for resistance to the 
otherwise cytotoxic G418 (Geneticin) drove the selection of culture adaptive mutations (CAMs) 
which, at least in early genotype 1-derived SGRs, were paramount for achieving detectable 
levels of replication (Lohmann and Bartenschlager, 2014, Lohmann et al., 1999). 
Since the development of the SGR several groups have documented a detrimental effect on 
replicative ability when the second ORF includes the NS2 protein so as to span NS2-5B (Figure 
1.7) (Lohmann et al., 1999, Tedbury et al., 2011). The reasons for this are unknown but are 
speculated in Section 1.5.4, while data presented in Chapter 3 will further examine this effect. 
The identification of a genotype 2a strain of HCV from a patient with fulminant hepatitis, 
termed JFH1, significantly improved levels of replication without the need for CAMs (Kato et 
al., 2003) such that the incorporation of a firefly luciferase reporter (ffLuc) in place of NPT 
allowed rapid and accurate quantification of replication kinetics (Targett-Adams and 
McLauchlan, 2005). To date the majority of HTS performed against HCV replication has used 
JFH1 or culture-adapted genotype 1 SGRs spanning NS3-5B with a variety of reporters (Kwong, 
2014). 
In 2005 the entire HCV lifecycle was successfully reproduced in cell culture using full JFH1 
molecular clones (Zhong et al., 2005), thus allowing studies on virus entry which had previously 
relied on pseudotyping (HCVpp) and exploration of virus assembly and egress. Systems for 
studying the cell culture based HCV lifecycle (HCVcc) were enhanced further though NS2-based 
chimeras J6JFH and Jc1, as described in Section 1.5.4 (Lindenbach et al., 2005, Pietschmann et 
al., 2006), while the p7-NS2 junction also proved amenable to reporter insertion (Jones et al., 
2007) (Figure 1.7). 
While Huh7 cells are by far the most permissive to the HCV lifecycle in cell culture, certain sub-
populations of this heterogeneous cell line appear more permissive than others. Clearing 
selectable SGRs from Huh7 cells with IFN or a DAA therefore yields a population of cells more 
permissive to the HCV lifecycle. This has been used to produce cleared-SGR cell lines with 
enhanced SGR replication kinetics, termed Huh7.5 cells (Blight et al., 2002). The enhanced 
replication kinetics observed in Huh7.5 cells have been partially attributed to defective RIG-I, 
leading to a reduced immunogenic response to the presence of cytoplasmic viral RNA 
(Sumpter et al., 2005). However, the re-introduction of functional RIG-I still yielded a cell line 
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more permissive than naïve Huh7 cells (Binder et al., 2007), suggesting these cells may also 
benefit from upregulated pro-viral factors or additional down-regulated anti-viral factors. 
The range of genotypes amenable to study through SGRs or chimeric HCVcc has significantly 
expanded since the development of the original construct, and continues to do so. Use of the 
HCVcc system in primary hepatocytes has also been reported providing a system with greater 
physiological relevance (Ploss et al., 2010, Podevin et al., 2010). Animal models for studying 
HCV remain limited to chimpanzees and the use of the related virus GBV-B in tamarins. The 
shortage of suitable animal models negatively impacts the later stages of HCV drug discovery, 
though the use of humanised livers in mice has recently expanded these options (Dorner et al., 
2013, von Schaewen and Ploss, 2014). 
Current studies utilising SGRs usually employ either NPT or ffLuc reporters. The SGR is placed 
under the control of a T7 promoter on a vector allowing transcripts to be produced in vitro 
from linearised DNA. For SGRs with a NPT reporter (SGR-neo), transcripts can be 
electroporated into cells which are then subjected to a selective pressure with G418. The 
resulting replicon-harbouring cell lines can be maintained indefinitely under G418 selection 
and are thus termed ‘stable’ SGRs. Transcripts of SGRs with a ffLuc reporter (SGR-luc) can be 
electroporated into cells allowing rapid and sensitive quantification of replication through 
luciferase quantification up to 72-96 hours. However, as they lack a selectable marker these 
constructs cannot be maintained as stable cell lines and transcripts must be prepared and 
electroporated at the outset of each assay. As such SGR-luc constructs are known as ‘transient’ 
SGRs. For the purposes of screening this problem has been overcome using a ffLuc-NPT fusion 
protein within the first ORF (SGR-feo). These constructs allow selection and maintenance of 
stable cell lines that constitutively produce luciferase as a measure of replication (Wyles et al., 
2009, Wyles et al., 2007) and can therefore act both as ‘transient’ and ‘stable’ SGRs (Figure 
1.7). 
As HCVcc requires the RNA to be packaged into infectious virions, minimising the size of the 
reporter gene (and hence the size of the RNA that is packaged) is thought to improve the 
number of successfully assembled infectious virions. Elevated levels of reporter signal both for 
replication kinetics and from infection of naïve cells (as a measure of released infectious virus) 
have been observed using a comparatively small Nanoluciferase (Nluc) reporter (Promega) 
(Yutaka Amako, unpublished data). As such Jc1-Nluc virus offers the highest reporter signal for 
investigation of the full HCV lifecycle.  
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Figure 1.7: Current SGR and virus constructs relevant to this study.  
SGRs with neomycin phosphotransferase (NPT; SGR-neo) are amenable to the selection of 
stable cell lines using G418. SGRs with firefly luciferase (ffLuc; SGR-luc) provide a rapid and 
sensitive reporter but require transient electroporation into cells. SGR-neo and SGR-luc have 
been produced spanning either NS3-5B or NS2-5B. SGRs with NPT-ffLuc fusion proteins (SGR-
feo) combine the benefits of selecting stable cell lines with a rapid and sensitive reporter, but to 
date are only available spanning NS3-5B. Jc1 is a chimeric strain which has enhanced lifecycle 
kinetics in cell culture, with structural proteins and the NS2 N-terminus derived from J6CF and 
the remaining portion of NS2 and NS3-5B derived from JFH1. Jc1 Nluc contains a 
Nanoluciferase reporter between p7 and NS2. 
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1.8 The NS2-3 autoprotease 
1.8.1 The NS2 cysteine protease 
Initial investigations into the processing of the HCV polyprotein identified roles for host signal 
peptidases and the NS3 protease, but the mechanism of processing at the NS2-NS3 junction 
remained unknown. In 1993 two groups reported the identification of a second virally-encoded 
protease which was independent of NS3 protease activity and proposed to be a zinc-
dependent metalloproteinase (Hijikata et al., 1993). The protease activity was found to be 
encoded within the C-terminus of NS2 but requiring the NS3 N-terminal protease domain. 
Mutation of residues histidine 952 or cysteine 993 within NS2 to alanine abolished this activity, 
leading to the proposal of a cysteine protease, while mutation of the NS3 protease active site 
residues did not affect NS2-NS3 processing (Grakoui et al., 1993). Furthermore, co-transfection 
of H952A and C993A mutants suggested trans cleavage could occur, albeit inefficiently. 
Mutagenic studies of the substrate cleavage sequence of the NS2 protease revealed that it 
could tolerate most substitutions other than those expected to cause a significant 
conformational change, such as the introduction of proline at P1 or P1’ positions or mutating 
both P1 and P1’ to alanine (Reed et al., 1995). 
Several groups subsequently set out to characterise this second viral protease. Radiolabelled  
in vitro translation revealed that while cleavage at the E2-p7-NS2 boundaries required addition 
of microsomal membranes, supporting a requirement for host factors such as signal peptidase, 
processing of the NS2-NS3 junction required only the addition of detergents, confirming that 
host factors were not a requirement for activity (Pieroni et al., 1997). To attempt to 
characterise the nature of the protease a range of protease inhibitors were tested for the 
ability to block proteolysis. A range of serine, cysteine and aspartyl protease inhibitors had no 
effect on the NS2 protease (Table 1.2). This observation is unsurprising as the NS2 C-terminal 
domain shows no homology to any of these protease families. Phenyl-methane-
sulfonylfluoride (PMSF), a covalent serine protease inhibitor, also had no effect, but an 
irreversible cysteine protease inhibitor; tosyl phenylalanine chloromethyl ketone (TPCK) did 
block processing at a concentration of 500 µM. Additional alkylating agents tosyl-L lysine 
chloromethyl ketone (TLCK), N-ethyl maleimide (NEM) and Iodoacetic acid (IAA) or 
Iodoacetamide (IAM) showed similar activity (Table 1.2). In contrast an irreversible cysteine 
protease inhibitor based around an epoxide, E64 (Figure 4.1C), showed no activity, although 
this compound was only tested at 10 µM. Additional observations noted that the protease 
activity was enhanced by the addition of DTT, suggesting the requirement of reducing 
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conditions and the correct redox state of the catalytic cysteine, while the reaction could also 
be inhibited with zinc chelators. 
Similar results were reported by successfully reconstituting protease activity with bacterially 
expressed protein. The truncation of NS2 to remove the N-terminal hydrophobic domain and 
the C-terminus of NS3 (leaving the NS2 C-terminal domain and the NS3 N-terminal domain; 
polyprotein residues 907-1206) increased the solubility of bacterially expressed protein and 
further defined the minimal unit required for protease activity. Overexpressed protein 
required purification under denaturing conditions and dilution into a glycerol and detergent 
rich buffer to instigate proteolysis (Pallaoro et al., 2001). The resulting protease reaction was 
also sensitive to TPCK, IAM and NEM inhibition (at 500 µM) as well as EDTA (2 mM) (Table 1.2). 
However unlike with in vitro observations previously made with the NS3 protease, activity was 
not inhibited by peptides that are the result of proteolysis. N-terminal product, C-terminal 
product and complete peptide substrates showed no activity in the µM range. Similar peptides 
conjugated to mechanism-based protease inhibitors also showed no activity. Mechanism-
based inhibitors, also termed suicide inhibitors, act as a substrate analogue to form a non-
reversible covalent complex through the catalytic function of the active site residues using 
reactive electrophilic warheads. However such warheads in the form of aldehydes and 
hydroxamic acid moieties as well as classic metalloprotease inhibitors conjugated to N-
terminal pentapeptides (P5-P1) did not show activity against the NS2 autoprotease (Pallaoro et 
al., 2001). 
In contrast a similar assay utilised by Thibeault et. al did reveal weak activity of substrate 
peptide sequences against in vitro NS2-mediated autoproteolysis. While a range of protease 
inhibitors were again reported to be inactive, some peptide sequences did show activity, the 
most potent of which was an N-terminal decapeptide with an EC50 of 90 µM (Thibeault et al., 
2001) (Table 1.2). These results differ from those reported by Pallaoro et. al and whether N-
terminal proteolysis products inhibit the NS2 protease remains controversial. Peptides derived 
from NS4A showed greater activity, with EC50s as low as 600 nM (Thibeault et al., 2001). 
However these peptides are likely to exert their action through a conformational effect on NS3 
rather than directly against the NS2 encoded protease, further confirming a role of the NS3 
protease domain (though not the NS3 protease activity) on the NS2 autoprotease.  
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Table 1.2: Current chemicals and peptides tested against the NS2-3 protease in vitro.  
N.D. = not determined.  
Chemical 
(peptide 
sequence) 
Action (Pieroni et al., 
1997) 
% inhibition 
(concentration) 
(Pallaoro et al., 
2001) 
% inhibition 
(concentration) 
(Thibeault et al., 
2001) 
% inhibition 
(concentration) 
Antipain Trypsin and 
papain inhibitor 
0% 
(0.15 mg/ml) 
N.D. N.D. 
Aprotinin Trypsin inhibitor 0% 
(0.5 mg/ml) 
N.D. 0% 
(1 mg/ml) 
Pepstatin Aspartyl protease 
inhibitor 
0% 
(0.5 mg/ml) 
N.D. 0% 
(0.01 mg/ml) 
Pefabloc Serine protease 
inhibitor 
N.D. N.D. 0% 
(1 mg/ml) 
Leupeptin Serine/ cysteine 
protease inhibitor 
N.D. N.D. 0% 
(0.1 mg/ml) 
E64 Epoxide-based 
cysteine protease 
inhibitor 
0% 
(10 µM) 
N.D. 0% 
(0.2 mg/ml) 
Captopril Metalloprotease 
inhibitor 
N.D. N.D. 0% 
(1 mM) 
PMSF Irreversible 
serine protease 
inhibitor 
0% 
(3 mM) 
N.D. N.D. 
TPCK Irreversible 
cysteine protease 
inhibitor 
50% 
(500 µM) 
35% 
(500 µM) 
50% 
(500 µM) 
TLCK Irreversible 
trypsin-like serine 
protease inhibitor 
5% 
(500 µM) 
N.D. 5% 
(500 µM) 
NEM Thiol alkylating 
agent 
80% 
(4 mM) 
70% 
(500 µM) 
80% 
(4 mM) 
IAA/ IAM Alkylating agent 80% 
(500 µM) 
25% 
(500 µM) 
100% 
(1 mM) 
EDTA Zn2+ chelator 60% 
(2 mM) 
60% 
(2 mM) 
100% 
(2 mM) 
EGTA Ca2+ chelator 20% 
(2 mM) 
N.D. N.D. 
1,10-
phenanthroline 
Zn2+ chelator 70% 
(2 mM) 
N.D. 80% 
(1 mM) 
(GWRLL) P5-P1 peptide N.D. 0% 
(100 µM) 
N.D. 
(SFEGQGWRLL) P10-P1 peptide N.D. N.D. 50% 
(90 µM) 
(APITAY) P1’-P6’ peptide N.D. N.D. 0% 
(1 mM) 
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1.8.2 The role of NS3 and zinc on the NS2 autoprotease 
Several studies have confirmed that NS2-NS3 proteolysis can be blocked by zinc chelators 
(Table 1.2). Mutagenesis of residues C1123, C1125 and C1171 within the N-terminus of NS3 all 
abolished NS2 autoprotease activity (Hijikata et al., 1993, Tedbury and Harris, 2007), while 
structural data of the NS3 protease domain showed that these residues co-ordinate zinc 
(Figure 1.6), alongside a water-mediated interaction with H1175. Based on the observations 
that zinc chelators blocked NS2-NS3 processing, that water-mediated co-ordination is often 
indicative of catalytic zinc and that the NS3 co-ordinated zinc is within 11 Å of the site of NS2-
NS3 proteolysis at the NS3 N-terminus, a role for the NS3 co-ordinated zinc in catalysis was 
postulated (Wu et al., 1998). However mutagenic analysis still implicated residues H952, E972 
and C993 of NS2 as the catalytic triad of a cysteine protease. 
The NS2 autoprotease was confirmed as a cysteine protease upon crystallisation of the post-
cleaved NS2 catalytic domain, termed NS2pro (Lorenz et al., 2006). This structure revealed a 
classic cysteine protease catalytic triad with a glutamic acid and a histidine positioned for 
coordination and de-protonation of a catalytic cysteine from an alternative monomer (Figure 
1.9D). As such, NS2pro appears to form two composite cysteine protease active sites at the 
dimer interface. Interestingly however, this crystal structure did not contain zinc. 
A comparative analysis of the role of zinc within both the NS2 protease and the NS3 protease 
suggested that processing at the NS2-NS3 boundary was more sensitive to zinc chelation, 
indicative of a tighter zinc association for the NS3 protease activity, perhaps through a 
conformational change which occurs post NS2-NS3 cleavage (Tedbury and Harris, 2007). In 
agreement with this proposal, mutation of H1175 in NS3 reduced NS3 protease activity with 
little effect on NS2-NS3 processing. An additional cysteine within NS2, C922, was identified as a 
requirement for NS2 autoprotease activity but was not necessary for the NS3 protease. As 
such it was suggested that NS2-encoded C992 and NS3-encoded C1123, C1125 and C1171 
coordinate zinc in the NS2-NS3 pre-cursor and are required for NS2 autoprotease activity. 
Following processing from NS2, a structural rearrangement allows NS3 to coordinate zinc 
through C1123, C1125 and C1171 as well as H1175 (Figure 1.8A). In both cases the role of zinc 
appears to be entirely structural. The addition of NS4A-derived peptides could favour the 
conformation required for NS3 protease activity, thus inhibiting NS2-NS3 autoproteolysis 
(Thibeault et al., 2001). 
The apparent requirement of the NS3 protease domain for processing of the NS2-NS3 
precursor begs the question of whether the NS2 C-terminal domain is a stand-alone protease, 
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as indicated by the post-cleaved NS2pro crystal structure. Previous analysis of the minimal 
subunit required for NS2-NS3 processing agreed with a requirement for zinc coordination as at 
least the first 181 residues of NS3 were required. 
Following this, expression of a tagged NS2 construct with only the first 40 residues of NS3 
followed by a GST tag demonstrated detectable levels of proteolysis, while proteolysis could 
be further stimulated by the addition of the remainder of NS3 (residues 41-213) or the 
remainder of the NS3 ‘zinc-binding’ domain (residues 41-180) (Schregel et al., 2009). 
Furthermore, NS2 followed by only two residues of NS3; P1’ and P2’ residues alanine and 
proline, was capable of proteolysis in the same system, though in the absence of NS3 residues 
3-40 in cis, the addition of NS3 residues 41-213 had no enhancing effect. These findings 
demonstrated that the protease activity responsible for NS2-NS3 processing is entirely 
encoded within the NS2 C-terminal domain, with the NS3 protease domain only responsible 
for enhancing proteolysis. This ‘enhancing’ effect of NS3 was further characterised, with NS2 
requiring the first 60 amino acids of NS3 in cis in order to be fully stimulated by the NS3 ‘zinc-
binding’ domain in trans. The mechanism of this enhancing role of NS3 remains ill-defined. It is 
possible NS3 contributes to some degree to the NS2 autoprotease active site, or that its role is 
mainly for optimal orientation of the substrate cleavage sequence. In any case, the NS2 
autoprotease can be regarded, to some degree, as a stand-alone protease, with the enzyme 
activity entirely encoded within the NS2 catalytic C-terminal domain present in the post-
cleaved crystal structure. 
1.8.3 Relevance of the post-cleaved NS2 crystal structure 
As previously stated, the crystal structure of the post-cleaved NS2 catalytic domain suggested 
a functionally relevant dimer.  The structure of each monomer contains two sub-domains, an 
N-terminal sub-domain comprised of two anti-parallel α-helices linked by extended loops and 
turns and a C-terminal sub-domain forming an anti-parallel β-sheet (Figure 1.8D). Within the 
dimer, the N-terminal sub-domain of one monomer interacts with the C-terminal sub-domain 
of the other; with the extended linkers joining the two sub-domains crossing in the central part 
of the ensemble (Figure 1.8B). In this way, a β-strand from the linker of one monomer forms 
part of the β-sheet in the C-terminal sub-domain of the alternate monomer. 
Essential residues H952 and E972 (NS2pro residues H143 and E163) lie on a loop within the 
extended linker, while the catalytic C993 (residue C184 in the crystal structure) is positioned 
on a loop between β-strands in the C-terminal sub-domain (Figure 1.8D). It is apparent that 
these three residues are coordinated so as to produce a cysteine protease with serine protease 
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geometry (Figure 1.9). However, H143 and E163 within the linker domain appear to coordinate 
C184 from the alternate monomer (Figure 1.8B, C). The post-cleaved NS2pro structure therefore 
represents a completely novel protein fold in addition to the first documented protease that 
forms two composite active sites at the dimer interface (Figure 1.8B) (Lorenz et al., 2006). 
The N-terminal domain helices of this structure contain a high proportion of hydrophobic 
residues. As a crystal this region contained several molecules of detergent, suggesting a 
peripheral membrane association. It was subsequently confirmed that a GFP-NS2pro fusion 
protein localises to ER or mitochondria derived membrane, that deletion of the N-terminal α-
helices of the NS2 catalytic domain abolishes this effect, and that these helices alone are 
sufficient to target GFP to membranes (Lange et al., 2014). This effect was further mapped to a 
positively charged residue at position 131 or 134 within the second N-terminal α-helix of 
NS2pro (Figure 1.8B, D). Mutagenesis at this site ablated GFP-NS2pro membrane localisation. 
This mutation also blocked NS2-NS3 polyprotein processing (though in this context, when the 
NS2 N-terminal TMD is present NS2 remained membrane bound). In contrast, this residue did 
not appear to significantly impact other, post-cleavage roles of NS2 on the virus lifecycle. 
The C-terminus of the post-cleaved NS2 crystal structure is the P1 residue of the substrate 
cleavage sequence. This residue, L217, remains within the active site cavity, forming several 
polar contacts to the side chains of H143 and C184 and to the backbone nitrogen of C184 
(Figure 1.8C). It has been proposed that this residue, and others from the C-terminal β-strand 
of NS2 which form part of the substrate sequence, may have an inhibitory effect by preventing 
further protease activity following NS2-NS3 proteolysis (Lorenz et al., 2006). A similar 
inhibitory conformation of a C-terminal residue has been observed in the Sindbis virus capsid 
serine protease active site (Tong et al., 1993) (PDB 2SNV). 
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Figure 1.8: Structural features of the NS2 autoprotease.  
A) Schematic of the NS2 and NS3 proteins. NS2 catalytic residues are shown (red bars). NS3 
residues C1123, C1125 and C1171 (black bars) coordinate zinc. For NS2 protease activity, C922 
in NS2 is the fourth zinc coordinating residue (blue lines). For NS3 protease activity following 
NS2-NS3 processing H1175 in NS3 is the fourth zinc coordinating residue (green lines). B) 
Crystal structure of the NS2pro catalytic domain homodimer. One monomer is shown with green 
carbons, the other with blue carbons. Residue 131 required for membrane association is 
highlighted in red. Catalytic residues forming a composite active site at the dimer interface are 
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highlighted in dotted boxes. N- and C-termini are shown. Surface representation is shown with 
oxygen atoms in red and nitrogen atoms in blue.  C) C-terminal L217 forms contacts with 
catalytic residues in the active site. E972 (E163) and H952 (H143) from one monomer chain and 
C993 (C184) from another can be seen forming the catalytic triad. D) Monomeric form of the 
NS2pro catalytic domain crystal structure with the same residues highlighted. Zinc coordinating 
C992 (C113) is shown in blue. For an alternative orientation of the NS2pro monomer see Figure 
3.1. Images made in Pymol from PDB 2HD0. 
 
 
As described in Section 1.8.2, the catalytic domain of NS2 present within this structure is 
sufficient for basal protease activity. The post-cleaved NS2 crystal structure, solved to a 
resolution of 2.28 Å, is therefore likely to represent a reasonable model for the proteolytic 
activity of NS2, with the caveat that following NS2-NS3 processing, the new C-terminal residue 
of NS2, L217, appears to remain coordinated within the active site, most likely to exert an 
inhibitory effect. Despite this, the active site of NS2 in the crystal structure, in particular the 
catalytic triad, appears to be present in a physiologically relevant context. Comparison of the 
catalytic triad (Figure 1.9F) to well-refined structures of classic serine and cysteine proteases 
Chymotrypsin (Figure 1.9A) and Papain (Figure 1.9B) reveal similar spatial orientation between 
these residues with respect to a cysteine protease with serine protease geometry, as in the 
Poliovirus 3C capsid structure (Figure 1.9E). Similar conformations are also observed in 
structures of serine or cysteine proteases covalently bound to mechanism-based inhibitors, 
such as the HCV NS3 serine protease in complex with Telaprevir (Figure 1.9C) and the cysteine 
protease Calpain in complex with ZLAK3001; an α-ketoamide based inhibitor (Figure 1.9D), 
indicative of a physiologically relevant orientation. 
Distances between heteroatoms of the acidic residue responsible for correct coordination of 
histidine are reported for all of the structures from Figure 1.9 in Table 1.3, as are distances 
between the histidine nitrogen and the catalytic alcohol or thiol which it deprotonates. The 
similarities between these distance constraints again emphasises that the orientation of 
catalytic residues in the NS2pro crystal structure are in an enzymatically active conformation. 
Polar contacts of L217 within the active site to the residues responsible for coordination of a 
proteolysis transition state further support this model (Figure 1.8C). The stabilisation of a 
transition state within the proteolysed peptide bond is an essential feature of these proteases, 
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and is achieved through additional polar contacts formed by the ‘oxyanion hole’. In this 
respect, a contact between L217 and the backbone nitrogen of C184 (Figure 1.8C) adds further 
evidence that the conformation of the active site in the structure remains relevant to an active 
protease state. 
The structure described herein does not contain the NS3 N-terminal domain required to 
further enhance NS2 autoprotease activity. A contribution of this region of the polyprotein to 
the active site, or even to residues forming the oxyanion hole, cannot be comprehensively 
ruled out. However, given the evidence for a catalytically active conformation of the NS2pro 
structure and of basal NS2 protease activity in the absence of NS3, this region may just be 
influencing the NS2 autoprotease through optimal orientation of the substrate sequence. 
Nonetheless, interpretation of the crystal structure of the post-cleaved NS2 catalytic domain 
as a model of the NS2 autoprotease should take into account the potential for NS3-encoded 
contributions which are not present. 
Structural data of the NS2-NS3 precursor would greatly aid understanding of the catalytic 
mechanism of the NS2 autoprotease and conformational changes occurring in NS2 and NS3 
following processing. Such a structure would be more representative of the active form of the 
NS2 autoprotease and may be of more use for structure-based drug design. With this aim in 
mind, active site mutants which prevent NS2-NS3 processing have been analysed in vitro using 
tryptophan fluorescence studies and circular dichroism, revealing all of these mutants not only 
remove key components of the catalytic triad but also have significant effects on the overall 
protein fold of the NS2-NS3 precursor. As such structural studies into active site mutants 
would not yield an enzymatically active conformation. Structural studies of the pre-cleaved 
NS2-NS3 subunit may prove more successful through the use of a specific small molecule 
inhibitor to prevent autoproteolysis without disrupting the protein fold (Foster et al., 2010b).  
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Figure 1.9: Catalytic residues of the post-cleaved NS2 protease structure in an enzymatically 
active conformation.  
A) Catalytic triad of the serine protease Chymotrypsin. (PDB 4H4F). B) Catalytic triad of the 
cysteine protease Papain. (PDB 1PPN). C) Catalytic triad of the HCV serine protease NS3 in 
complex with mechanism-based inhibitor Telaprevir. (PDB 3SV6). D) Catalytic triad of the 
cysteine protease Calpain in complex with an α-ketoamide mechanism-based inhibitor. (PDB 
2R9C). E) Catalytic triad of the Poliovirus 3C capsid protease, a cysteine protease with serine 
protease active site geometry. (PDB 1L1N). F) Catalytic triad of the HCV post-cleaved NS2 
autoprotease. (PDB 2HD0). 
Chymotrypsin
Serine protease
Papain
Cysteine protease
HCV NS3 protease - Telaprevir
Serine protease
Poliovirus 3C capsid
Cysteine protease with Serine 
protease geometry
HCV NS2 protease
Cysteine protease with Serine 
protease geometry
Calpain – α-ketoamide
Cysteine protease
A B
C D
E F
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Table 1.3: Distance constraints of protease catalytic triads.  
Distances for indicated bonds of each protease structure from Figure 1.9. Distances were 
derived from PDB codes indicated in Figure 1.9 and calculated in Pymol. 
 
 
 
Protease structure Distance 1 (Å) Distance 2 (Å) Distance 3 (Å) 
Chymotrypsin 3.2 2.7 3.7 
Papain 3.9 2.6 3.8 
NS3-Telaprevir 3.4 2.6 3.9 
Calpain-α-ketoamide 4.1 2.7 3.6 
Poliovirus 3C capsid 4.7 2.7 3.6 
NS2 autoprotease 3.9 2.7 3.7 
 
1.8.4 Evidence of NS2 homo-dimerisation 
Based on the formation of a composite active site within the crystal structure, activity of the 
NS2 autoprotease would be expected to require NS2 homo-dimerisation. Biochemical analysis 
by analytical ultracentrifugation and cross-linking experiments with the bacterially expressed 
NS2pro used for crystallisation confirmed a dimeric species in solution. To confirm this 
requirement within the context of cellular NS2-NS3 processing, separate HCV polyproteins 
containing H143A or C184A mutants respectively were co-expressed, with detectable levels of 
NS2-NS3 processing observed. As these catalytic residues are drawn from different monomers 
within the composite active site, a dimer formed from a H143A monomer and a C184A 
monomer should have one active site with two ablated catalytic residues and one functional 
active site. Both of these mutants alone were unable to process NS2-NS3, so the observation 
of processed NS2 and NS3 when the constructs were co-expressed is evidence that the two 
defective constructs can form a dimer and that functional NS2 proteolysis can be performed 
through a composite active site formed by the two constructs (Lorenz et al., 2006). 
Additional evidence supports the theory that NS2 dimerisation may be required for protease 
function. Previous analysis of the NS2 autoprotease in vitro had noted that the reaction was 
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concentration dependent (Pallaoro et al., 2001), while similar in vitro studies have confirmed 
the observation of dimers formed from a construct spanning the NS2 catalytic domain and the 
NS3 N-terminal protease domain using cross-linking reagents (Foster et al., 2010b). Many of 
the residues located at the dimer interface within the crystal structure are conserved across 
genotypes. An additional study, which confirmed that cellular overexpression of NS2 and of 
the NS2pro C-terminal domain produced dimers, found that mutagenesis of conserved residues 
at the dimer interface reduced levels of NS2 dimerisation and impacted HCV replication and 
hence the release of infectious virus (Gorzin et al., 2012). While the above data support the 
ability of NS2 to form dimers, demonstrating this at physiologically relevant concentrations has 
proved challenging. 
1.8.5 NS2 as a target for anti-virals 
Inhibitors of the NS3 protease are already approved for use in the treatment of certain HCV 
genotypes. Targeting a virally-encoded protease in order to block polyprotein processing is 
therefore an established route to exert an anti-viral effect and produce therapeutic effects in 
the clinic. 
While the NS2 autoprotease is responsible only for processing at the NS2-NS3 junction, 
numerous mutagenic studies have demonstrated that when NS2 autoprotease activity is 
abolished, virus replication cannot proceed and infectious virus is not produced (Jones et al., 
2007, Kolykhalov et al., 2000, Welbourn et al., 2005). As replication can occur in the absence of 
NS2 with SGRs comprising NS3-5B, the block on replication can be attributed to either an 
inhibitory effect of NS2 or a lack of mature NS3. While an inactive NS2 autoprotease appeared 
to have no effect on NS3 protease activity in one in vitro study (Tedbury and Harris, 2007), an 
alternative in vitro study observed a 4-5 fold decrease in NS3 mediated catalysis when 
unprocessed from NS2, despite similar binding kinetics for the NS3 protease substrate peptide 
(Welbourn et al., 2005). This effect was proposed to be due to a reduced ability of NS3 to bind 
to NS4A whilst still in complex with NS2. These results suggest that efficient NS3-mediated 
processing requires maturation from the NS2-NS3 precursor in order for NS3 to bind NS4A, in 
line with earlier observations that NS3-NS4A interactions require the NS3 N-terminus 
(Neddermann et al., 1999). However, analysis of polyprotein processing in SGRs with an 
inactive NS2 autoprotease revealed the NS3 protease was still active to some degree. 
Therefore, inactivation of the NS2 autoprotease so as to prevent maturation of NS3 does not 
appear to directly affect the NS3 protease active site, but may significantly impair its activity, 
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most likely by decreasing NS3 affinity for the NS4A cofactor (Welbourn et al., 2005). Such 
impairment might be of greater relevance in vivo than in cell culture systems. 
Additionally, an inhibitory effect of the unprocessed NS2-NS3 precursor has been proposed. As 
previously stated, unprocessed NS2-NS3 is rapidly degraded through a proteasome dependent 
mechanism (Section 1.5.4). When mutant SGRs were analysed for protein levels at a range of 
timepoints, wildtype SGR containing NS2-5B showed a gradual accumulation of NS3. The same 
SGR with defective NS5B RdRp (GND mutant) did not show an increase in NS3 as no replication 
occurs, but NS3 translated from the initial input RNA was stable for 24-48 hours. By contrast, 
the same SGR with a defective NS2 autoprotease (H952A mutant), which also could not 
replicate, displayed a loss of the NS2-NS3 precursor after 4-8 hours, an effect that could be 
reversed by pharmacological inhibition of the proteasome (Welbourn et al., 2005). An inactive 
NS2 autoprotease preventing maturation of NS3 may lead to rapid, proteasome-mediated 
degradation of the NS2-NS3 precursor. This could have important implications for the ability of 
the virus to accumulate sufficient NS proteins to allow replication to occur and may have an 
additional effect on NS3-mediated processing of host factors that create a more favourable 
environment for the HCV lifecycle, such as processing of components of innate immune 
signalling pathways, as discussed in Section 1.5.5. In line with this, a full HCV transcript devoid 
of NS2 autoprotease activity (containing H952A and C993A mutants) failed to establish 
infection when introduced into chimpanzees through intrahepatic injection. By comparison, 
wildtype HCV transcripts with a functional NS2 autoprotease produced elevated ALTs, HCV-
specific seroconversion and viremia, demonstrating prolonged infection (Kolykhalov et al., 
2000). 
Based on these observations, several groups have postulated the NS2 autoprotease as an 
attractive anti-viral target (Cheng et al., 2011, Lorenz, 2010, Lorenz et al., 2006, Rice, 2011, 
Schregel et al., 2009, Welbourn et al., 2005, Welbourn and Pause, 2006). The NS2 
autoprotease represents a stand-alone protease with an essential function in the HCV lifecycle 
and no homology to any human proteases. Initial concerns regarding the limited window of 
opportunity in which to drug an autoprotease with rapid processing kinetics have been 
dampened by the growing evidence that NS2 may require an accumulation of polyprotein, as 
evidenced by the suggestion that NS2 may have to dimerise to form composite active sites 
(Lorenz, 2010). 
The development of cell-based high-throughput screens targeting the NS2 autoprotease to 
attempt to identify NS2-specific anti-virals has been reported. One assay involved co-
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expression of a reporter and substrate plasmid in Cos-1 cells. The reporter plasmid encodes 
chloramphenicol acetyltransferase downstream of a human T-cell leukemia virus type-1 (HTLV-
1) long terminal repeat promoter. The substrate plasmid contained NS2 and its cleavage 
sequence followed by the Tax1 protein of HTLV. NS2-mediated cleavage liberated Tax1 so as to 
promote reporter expression (Hirowatari et al., 1995). An alternative assay selected stable cell 
lines in Jurkat cells expressing a β-lactamase reporter, followed by NS2-NS3 and a destabilising 
ubiquitin-like domain so that NS2-mediated processing stabilised the reporter (Whitney et al., 
2002). However, neither of these groups has subsequently reported the identification of 
specific inhibitors targeting the NS2 protease activity. 
A panel of protease inhibitors have already been tested against NS2 protease activity in vitro 
and were inactive (Table 1.2), consistent with the lack of homology of NS2 to these protease 
families. Some covalent inhibitors such as thiol alkylating agents blocked NS2-mediated 
proteolysis. An epoxide based cysteine protease inhibitor E64 was inactive, whilst a covalent 
serine protease inhibitor TLCK did block function. These findings could be explained by the 
active site observed in the post-cleaved NS2 crystal structure, which reveals a cysteine 
protease catalytic triad with serine protease geometry. Whether covalent protease inhibitors 
could prove useful in the development of an NS2 autoprotease inhibitor will be examined in 
Chapter 4. 
In vitro studies have also analysed the effect of substrate peptides, with inconclusive results. 
Different groups have reported no activity or relatively weak activity of peptide substrates 
against the NS2 autoprotease. Whether peptide-mimetics represent a viable route to an 
inhibitor, similar to the success observed with NS3 protease inhibitors, remains to be seen, 
though early indications are that this will prove more challenging due to the nature of the 
protease and the assays required. 
Some inhibitors of NS2-mediated functions have been reported based on host factor 
interactions. In vitro translation studies with rabbit reticulate lysates identified the 
requirement of ATP for efficient processing. This was linked to the requirement of ATP 
hydrolysis for the chaperone heat-shock protein 90 (Hsp90). Immunoprecipiation of Hsp90 in 
this in vitro system demonstrated a direct interaction with the NS2-3 precursor, which could be 
abrogated by Hsp90 inhibitors geldanamycin, herbimycin A and radicicol. Furthermore, these 
inhibitors blocked NS2 autoprotease activity in vitro and were more potent when added during 
translation, suggesting a role in ensuring correct folding of the NS2 autoprotease (Waxman et 
al., 2001). Cell-based assays where the stability of a reporter is mediated by the NS2 protease 
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activity have also observed an effect of Hsp90 inhibitors (Waxman et al., 2001, Whitney et al., 
2002). The relevance of this effect in the context of HCV replication is examined in Chapter 3. 
Additionally, correct folding of the NS2 autoprotease has been linked to CypA. As described in 
Section 1.6, CypA antagonists potently block HCV replication in cell culture. While the mode of 
action is somewhat ambiguous it is thought to be mediated through preventing CypA 
isomerisation of proline residues in NS5A domain 2 and LCS-II. However, infectious JFH1 virus 
has been noted as significantly more sensitive to inhibition by CsA (and analogues thereof) 
than JFH1 derived SGRs containing NS3-5B (Ciesek et al., 2009, Kaul et al., 2009). This shift in 
sensitivity was narrowed down to the NS2 gene, as a JFH1 SGR comprising NS2-5B was 5-10-
fold more sensitive to CsA inhibition than the same SGR comprising NS3-5B (Ciesek et al., 
2009). This effect was ablated by genetically separating NS2 and NS3 so as to bypass the 
requirement for NS2 autoprotease activity. A role for CypA in the correct folding of NS2, which 
is essential when the NS2 autoprotease is required for replication, was postulated. In Chapter 
3 data will be presented exploring the role of CypA on the folding and function of the NS2 
autoprotease and the role of NS2 on virus sensitivity to CsA. 
 
1.9 Rational drug design and virtual high throughput screening 
In the absence of a suitable starting point for the identification of an inhibitor of the NS2 
autoprotease such as a classic cysteine protease inhibitor or substrate peptide derivative, the 
development of a NS2-acting DAA requires identification of a novel, active molecule. Due to 
the technical difficulties in developing assays suitable for measuring levels of NS2-mediated 
proteolysis, a HTS programme for inhibitor identification would be challenging. However, in 
vitro assays for NS2 autoproteolysis may be amenable to a lower throughput form of 
screening. This can be achieved through the use of computer aided drug design (CADD). CADD 
is increasingly used in the drug discovery process to reduce the cost and workload of 
identifying “hit” molecules (Ou-Yang et al., 2012). As with HTS, the aim is to identify a novel 
lead molecule, usually with modest activity in the µM range, for progression through structure 
activity relationship (SAR) analysis into a lead compound. CADD has been documented to 
increase the hit rate of screening by filtering out molecules unlikely to show activity and 
focussing screening libraries on molecules predicted to have increased likelihood of activity. 
However, rather than producing a larger number of hit compounds from a screening 
programme, CADD is usually applied to allow identification of a similar number of active 
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molecules through a much more manageable screening library (Sliwoski et al., 2014). CADD 
requires existing information about the system in one of two forms; ligand-guided CADD 
requires a known active compound and searches for chemically and conformationally similar 
molecules. Structure-guided CADD requires structural information of the target protein but is 
applicable in the absence of a known active compound. 
Structure-guided CADD can be applied to structural information of the target in one of two 
ways. HTS libraries can be filtered to yield a more desirable subset of molecules using in silico 
virtual high-throughput screening (vHTS) with the aim of ranking large screening libraries 
based on modelling the most energetically favourable binding pose of each molecule to the 
target structure. Alternatively, de novo rational drug design can be employed to produce 
entirely novel chemical scaffolds designed to produce favourable interactions with the target 
structure.  
1.9.1 De novo design 
De novo design usually takes into account favourable properties of a “hit” compound, broadly 
defined as “lead-like space” (Nadin et al., 2012). These properties (e.g. LogP -1 to 3 and Mw 
200-350) are usually accounted for to some degree within HTS libraries and hence are present 
within the virtual libraries used for vHTS. Despite this, de novo design allows for almost 
unlimited possibilities and hence molecules produced most likely require synthesis before they 
can be tested. Even when accounting for synthetic attainability during design, synthesising a 
reasonable sized library of de novo designed compounds for biological testing is relatively 
costly and time-consuming. 
The de novo design software SPROUT has previously been reported for identification of novel 
active ligands (Heikkila et al., 2006, Mok et al., 2013). SPROUT is comprised of a number of 
modules capable of first defining a binding site by molecular recognition properties (e.g. 
defining hydrogen bond donors and acceptors and hydrophobic regions) before orientating 
rigid templates so as to best match these molecular properties. The rigid templates, anchored 
to their respective target sites, are then joined with a ‘skeleton’ to create a complete 
molecule. Numerous output solutions are produced as each rigid template may be joined 
through several skeleton scaffolds (Gillet et al., 1994). This method allows definition of certain 
key sites within the target receptor and allows these sites to be preferentially targeted 
manually. 
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To overcome the fact that molecules designed de novo in SPROUT are unlikely to be 
commercially available, features deemed key to the modelled interaction can be retained in 
compounds from vHTS libraries through the use of ligand-guided CADD using programs such as 
ROCS (Rapid Overlay of Chemical Structures) to rank chemical and structural similarity (Rush et 
al., 2005). However, results of ligand-guided CADD using a de novo designed molecule as the 
input, for which neither activity nor the binding pose are experimentally defined, should be 
treated with caution and hence may require screening of a library of predicted hits to identify 
true active compounds. 
1.9.2 Virtual high-throughput screening 
Algorithms for vHTS and de novo drug design respectively both rely on ‘docking’ as a form of 
scoring the interactions of a candidate ligand with the target structure. The process of docking 
can be divided into two requirements; the production of a feasible binding pose, and the 
correct scoring of both the best pose for each ligand, and this ligand pose relative to all other 
ligand poses.  Producing a binding pose requires exploring conformational flexibility of the 
ligand. Ligand flexibility can be explored through systematic algorithms whereby rigid 
fragments of the ligand can be docked individually before being linked to score an overall pose, 
a method implemented within the vHTS software eHITS (Zsoldos et al., 2006). Ligand flexibility 
can also be explored through pre-generation of a defined number of conformers for each 
ligand prior to docking using OMEGA (Hawkins et al., 2010). Alternatively, a random approach 
can be taken to sampling the space available through repetitive cycles of random rotation or 
translation one bond at a time before scoring, as with Autodock (Totrov and Abagyan, 1997) 
and Glide (Friesner et al., 2004).  
While producing the correct binding pose of a ligand is important for docking, it is not 
sufficient if the correct binding pose is not preferentially scored above incorrect poses, nor is it 
of use for vHTS if poses cannot be reliably scored between different ligands. Scoring of ligand 
poses has a number of limitations that provide the main drawback to CADD. Most commonly, 
a molecular mechanics (MM) force-field is employed to calculate the difference between the 
energy of the receptor-ligand complex and the ligand alone so as to account for unfavourable 
conformational changes within the ligand upon binding. Such a force-field, based around a 
Monte Carlo randomised algorithm, is employed in the scoring of Autodock poses for example. 
These energies are calculated from relatively simple interactions such as electrostatic, 
hydrophobic and van der Waals interactions. Importantly these scoring systems are based 
solely around enthalpic contributions. The entropic effects of displacing water molecules, both 
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from the ligand and the protein target, are not accounted for. This can be a major drawback as 
some ligand-protein interactions can be dominated by this entropy effect (Kitchen et al., 
2004). Other scoring systems, such as those employed within eHITS, use knowledge-based and 
empirical scoring that fit experimental data and can be tailored to the system. For example, 
while the scoring system of eHITS still scores chemical properties such as hydrogen bonds, it 
also accounts for variability in the atomic coordinates of the crystal structure with respect to 
these interactions, and can also account for entropic effects to some degree (Zsoldos et al., 
2006). 
Difficulties in accurately scoring docking poses means that some molecules are scored 
incorrectly and hence the ranking of vHTS libraries does not directly translate into the 
observed degree of activity. Despite this numerous studies have demonstrated the ability of 
vHTS to significantly enrich screening libraries with “hit” compounds. 
One example comes from a comparative study of HTS and vHTS for screening against 
angiogenin, an enzyme responsible for inducing angiogenesis. A HTS campaign involving 
18,111 compounds produced 12 hits once verified and after removal of false positives, a hit 
rate of 0.066%. Of the 12 hit compounds, 5 were ranked in the top 2% from vHTS using 
structures from the same screening library (Jenkins et al., 2003). In real terms, HTS yielded one 
genuine hit compound for every 1,509 compounds screened. In contrast, screening of a vHTS-
enriched library yielded five hits from 362 compounds, a hit rate of 1.38%. These hit rates are 
fairly typical for both HTS and vHTS. The use of CADD has been instrumental in the discovery of 
small molecule inhibitors in a range of systems (Schneider and Bohm, 2002) including HIV 
protease inhibitors and non-peptide based inhibitors of cysteine proteases as anti-infectives 
(Agarwal and Fishwick, 2010). 
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1.10 Project Aims 
The NS2 autoprotease is a stand-alone protease essential for the HCV lifecycle with no 
homology to human proteases and as such represents an attractive drug target. To the best of 
our knowledge there are currently no small molecule inhibitors of the NS2 autoprotease in 
pre-clinical development. Despite concerted efforts, identification of NS2 inhibitors has been 
hampered by contradicting results and weak activities of classical protease inhibitors and 
substrate peptides, suggesting these approaches may not be successful in developing a DAA 
targeting NS2. Furthermore, screening for inhibitors of the NS2 autoprotease has been limited 
by the technical difficulties of conducting HTS in challenging in vitro assays and the lack of a 
cell-based HTS relevant to the HCV lifecycle. This study therefore set out to identify novel small 
molecule inhibitors directly acting against the NS2 autoprotease and assess the viability of 
inhibiting the NS2 autoprotease to exert an anti-viral effect.  
To directly assess inhibitory activity against the NS2 autoprotease a method of quantifying 
NS2-mediated proteolysis in vitro is required. Such an assay must have sufficient sensitivity 
and reproducibility to accurately determine the potency of an inhibitor by determining EC50 
following treatment at a range of concentrations, thus allowing comparison of the inhibitory 
activity from a series of compounds. 
As in vitro assays quantifying NS2 autoprotease activity are low-throughput, the application of 
in silico CADD based on the post-cleaved NS2 crystal structure as a model for the NS2 
autoprotease should improve hit rates and allow fewer compounds to be screened to identify 
an NS2 autoprotease inhibitor.  Current data suggests the NS2 crystal structure to be relevant 
to the enzyme activity of the NS2-NS3 precursor, particularly with regard to the catalytic triad. 
Therefore CADD will be applied to a model of the NS2 autoprotease based on the post-cleaved 
NS2pro crystal structure to enrich a relatively small screening library. 
The majority of HTS programmes against HCV replication have used SGRs containing NS3-5B 
and as such would not identify potential inhibitors of NS2 autoprotease-dependent replication. 
To assess the ability of a small molecule inhibitor of the NS2 autoprotease to exert an anti-viral 
effect, compounds will be tested against a SGR comprising NS2-5B. These SGRs require 
optimisation and validation for use in a cell-based screening assay. Such an assay would 
benefit from a measure of selectivity towards NS2-dependent genome replication.  SGRs 
containing NS2-5B will also be utilised to explore the potency of potential inhibitors against 
NS2-dependent genome replication as well as to investigate mode-of-action. 
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Finally, to confirm anti-viral effects of an NS2 autoprotease inhibitor, compounds will be tested 
for inhibitory activity against the complete HCV lifecycle using the HCVcc system. These 
systems are only available for particular HCV genotypes and their application will therefore be 
reliant on inhibitory activity against the NS2 autoprotease of genotype 2a (JFH1). 
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2.1 General Materials 
2.1.1 Bacterial strains 
Eschericia Coli (E. Coli) DH5α; Genotype F – φ80lacZ∆M15, recA1, endA1, hsdR17 (rk
-,mk
+), 
phoA, supE44, thi-1, gyrA96, relA1, (∆lacZYA-argF), U169, λ- used for cloning were purchased 
from Life Technologies. 
Chemically competent bacteria were produced using the Z-competent kit (Zymo Research). 
2.1.2 Mammalian cell lines 
Huh7 cells are a human hepatocellular carcinoma cell line (Nakabayashi et al., 1982) previously 
shown to support autonomous replication of HCV sub-genomic replicons (SGRs) (Lohmann et 
al., 1999). 
Huh7.5 cells are a sub-population of Huh7s produced by clearing SGR from Huh7 cells with 
IFNα which support enhanced HCV replication (Blight et al., 2002) and were a kind gift from 
Charles Rice, The Rockefeller University, New York. 
SGR-feo-Con1(BM4-5) [NS3-5B] and SGR-feo-JFH1 [NS3-5B] stable cell lines were produced as 
a polyclonal population in Huh7.5 cells by Yutaka Amako at the University of Leeds using 
constructs provided by David Wyles, University of California, San Diego. 
2.1.3 Virus sequences 
HCV sequences were obtained from the EU HCV database with the following Genbank 
accession numbers; 
JFH1 – AB047639 HC-J6 – D00944 ED43 - Y11604 
Con1 – AJ238799 H77 - AF011752 SA13 - AF064490 
J4L6S – AF054247 NZL1 - D17763 EUHK2 - Y12083 
 
FK5.1 is a culture adapted strain derived from Con1 with CAMs in NS3 (E176G and I254T) and 
CAMs in NS5A (N137D and S225P) (Krieger et al., 2001). Con1(BM4-5) is an alternative culture 
adapted strain derived from Con1 with a single deletion in NS5A (∆S230) (Guo et al., 2001). 
The NS2 crystal structure (PDB 2HD0) is from HCV-J, a genotype 1b partial patient isolate which 
possesses greatest sequence identity to accession number FJ931730. 
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2.1.4 SGR and virus constructs 
SGR-luc-JFH1 [NS3-5B] was used as reported (Targett-Adams and McLauchlan, 2005) as was a 
derivative thereof; mSGR-luc-JFH1 [NS3-5B] (Hughes et al., 2009). The JFH1 NS2 gene was 
previously introduced into SGR-neo-JFH1 [NS3-5B] (Kato et al., 2003) and SGR-luc-JFH1 [NS3-
5B] (Targett-Adams and McLauchlan, 2005) to produce SGR-neo-JFH1 [NS2-5B] and SGR-luc-
JFH1 [NS2-5B] (Tedbury et al., 2011). SGR-neo-FK5.1 [NS3-5B] and SGR-luc-FK5.1 [NS3-5B] are 
culture adapted SGRs derived from the Con1 strain containing CAMS in NS3 (E176G andT254I), 
and in NS5A (N137D and S225P) (Krieger et al., 2001) into which the Con1 NS2 gene has been 
introduced to yield SGR-neo-FK5.1 [NS2-5B] and SGR-luc-FK5.1 [NS2-5B] (Tedbury et al., 2011). 
SGR-feo-JFH1 [NS3-5B] and SGR-feo-Con1(BM4-5) [NS3-5B] were used as reported (Wyles et 
al., 2007). Con1 (BM4-5) is a culture adapted Con1 SGR with NS5A ∆S230. A replicon with 
NS5A-encoded CsA resistance mSGR-luc-JFH1 [NS3-5B] (D316E) has been previously reported 
(Ross-Thriepland et al., 2013). 
Jc1-NLuc was produced at the University of Leeds by Yutaka Amako and is based on the Jc1 
construct previously reported (Pietschmann et al., 2006). 
2.1.5 Expression constructs 
pNS2-3 derived from J4L6S (henceforth referred to as J4) and JFH1 isolates in the pET23a 
vector were used as reported (Foster et al., 2010b, Tedbury and Harris, 2007). pGST-CypA in 
pGEX59 has been previously reported (Foster et al., 2011). 
2.1.6 Antibodies 
Anti-NS5A serum (Sheep) (in house) was used at 1:5000. 
Anti-FLAG M2 (Mouse) (F1803 – Sigma Aldrich) was used at 1:5000. 
Anti-JFH1 NS2 serum (Rabbit) (Volker Lohmann, University of Heidelberg, (Jirasko et al., 2008)) 
was used at 1:500. 
Anti-GAPDH (Mouse) (9484 – mAbcam) was used at 1:20,000. 
Anti-cyclophilin A (Rabbit) (2175S – New England Biolabs) was used at 1:1000. 
Anti-NS3 serum (Sheep) (in house) was used at 1:3000 
Anti-neomycin phosphotransferase II (Rabbit) (06-747 -UpState) was used at 1:1000. 
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2.1.7 Chemicals 
Imidazole, G418 disulphate salt, Thiazolyl Blue Tetrazolium Bromide (MTT formazan, 98%), 
1,10-phenanthroline and cyclosporine A (CsA) were purchased from Sigma-Aldrich. 
Ethyldiamine tetraacetic acid (EDTA) was from VWR. L-cysteine was from AnalaR. 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulphonate (CHAPS) was purchased from 
Glycon. Isopropyl β-D-1-thiogalactopyranoside (IPTG) was from Generon. Guanidine 
hydrochloride (98%) was from Alfa Aesar. Dimethyl sulphoxide (DMSO, > 99.7%) was from 
Fisher. Ampicillin was from Melford Laboratories. Tosyl phenylalalnine chloromethane ketone 
(TPCK) was purchased from AppliChem. HCV DAA Telaprevir was purchased from 
MedChemExpress. HCV DAA Daclatasvir was from SelleckChem. Screening compound libraries 
were from ChemBridge ‘Screening Compounds’ library and purchased as dry powder. 
2.1.8 Purification resins 
HisTrapTM FF 1ml columns, Chelating SepharoseTM Fast Flow and Glutathione SepharoseTM 4B 
were purchased from GE Healthcare.  
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2.2 General Methods 
2.2.1 Nucleic acid manipulation 
2.2.1.1 Oligonucleotide primers 
DNA oligonucleotides were purchased from Integrated DNA Technologies, resuspended in 
deionised water (dH2O) to 100 µM and stored at -20 °C. 
2.2.1.2 Site directed mutagenesis 
QuikChange Mutagenesis (Agilent Technologies) was used for introduction of single amino acid 
mutations. Complementary primers 30-42 nucleotides in length housing required nucleotide 
changes centrally were used to perform a PCR with initial denaturation at 95 °C for 30 seconds 
then 5 cycles of; denaturation at 95 °C for 30 seconds; annealing at 42-52 °C for 1 minute; 
extension at 68 °C for 25 minutes. Following this a further 13 cycles were performed as before 
with an elevated annealing temperature of 55 °C. Parental DNA was then removed by DpnI 
digestion (20 U, 37 °C, 1 hour) before PCR products were transformed into competent DH5α 
bacteria as described in Section 2.2.1.9. 
2.2.1.3 Agarose gel electrophoresis 
DNA agarose gels contained 0.8% (w/v) agarose in 1 x TAE buffer (40 mM Tris, 0.11% (v/v) 
acetic acid, 1 mM EDTA) and 1:10,000 SYBR® Safe DNA Gel Stain (Invitrogen). Gels were run in 
1 x TAE buffer at 8 V/cm. DNA samples were loaded in gel loading buffer (0.025% (w/v) Orange 
G, 5% (v/v) glycerol in 1 x TAE) and compared to Hyperladder I markers (Bioline). DNA gels 
were typically run at 100 V for 50 minutes. 
2.2.1.4 DNA extraction from agarose gels 
DNA bands were visualised with blue light to avoid UV irradiation. Bands were excised with 
minimal agarose and DNA purified using ZymocleanTM Gel DNA Recovery Kit (Zymo Research) 
following the manufacturer’s instructions. 
2.2.1.5 Restriction Digestion 
All restriction enzymes were from New England Biolabs (NEB). Reactions were carried out in 20 
µl volume at 37 °C using recommended and relevant buffers and enzyme units. All reactions 
were performed for a minimum of 1 hour. 
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2.2.1.6 Phenol:Chloroform extraction 
Purification of DNA was achieved by addition of equal volume phenol:chloroform:isoamyl 
alcohol (25:25:1), briefly vortexed and centrifuged 13,000 rpm 5 minutes. The upper aqueous 
layer was removed and equal volume chloroform added, vortexed and centrifuged 13,000 rpm 
5 minutes. Again the aqueous layer containing DNA was removed and 2 x volume ethanol and 
0.1 x volume 3 M sodium acetate were added before incubation at -20 °C and recovery of 
precipitated DNA by centrifugation at 13,000 rpm for 20 minutes. Recovered DNA pellet was 
washed in 70% ethanol and centrifuged 13,000 rpm 10 minutes before resuspension in an 
appropriate volume of dH2O. 
2.2.1.7 DNA ligation 
Ligations between digested vector and DNA inserts were performed at 1:3 and 1:6 molar ratios 
using 1 unit of T4 DNA ligase (Invitrogen) at either 27 °C, 18 °C or 4 °C for 1-16 hours. Following 
ligation one tenth of the ligation reaction was transformed into competent DH5α bacteria 
alongside a vector only ligation control transformation. 
2.2.1.8 Transformation of competent bacteria 
Chemically competent bacteria were prepared by the manufacturer’s instructions using Z-
CompetentTM E. Coli Transformation Buffer Set (Zymo Research) and stored at -80 °C. Typically, 
10-50 ng of DNA was added to 50 µl competent bacteria on ice before spreading over Luria 
Bertani (LB)-agar plates supplemented with 100 µg/ml ampicillin. Transformations of DNA 
constructs containing HCV NS5A sequences were grown at 30 °C. Transformations of all other 
cultures were grown at 37 °C. 
2.2.1.9 Purification of plasmid DNA 
Plasmid DNA was produced from a single colony of transformed competent DH5α bacteria 
grown in a suitable volume of LB media with 100 µg/ml ampicillin for roughly 16 hours at 37 
°C. Plasmid DNA containing HCV NS5A sequences was cultured at 30 °C. Plasmid DNA was 
purified on a small scale via alkaline lysis using the GeneJET Plasmid Miniprep Kit (Thermo 
Scientific) or a larger scale using Plasmid Midi Kit (Qiagen) using the manufacturers protocol.  
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2.2.1.10 Oligonucelotide quantification 
Concentration and purity of oligonucleotides was assessed by measuring absorbance at 280 
nm and 260 nm using a NanoDrop 1000 Spectrophotometer (Thermo Scientific). 260/280 nm 
ratio was used to assess oligonucleotide purity. 
2.2.1.11 DNA sequencing 
All DNA constructs were confirmed by Sanger sequencing with appropriate primers using 
Beckman Coulter Genomics Sequencing service. 
2.2.1.12 RNA manipulations 
For handling of RNA all surfaces and equipment involved was first treated with RNase AWAY 
(Molecular BioProducts). Solutions used for RNA manipulation such as dH2O or Phosphate 
Buffered Saline (PBS) were treated with 0.1% (v/v) diethyl pyrocarbonate (DEPC) and 
incubated shaking at 37 °C for 16 hours. DEPC was removed by autoclaving. 
2.2.1.13 Preparation of DNA template 
For in vitro transcription of RNA, DNA template plasmids were linearised in a 50 µl volume with 
appropriate restriction enzymes. Sub-genomic replicon (SGR) or virus constructs derived from 
the JFH1 isolate were linearised with XbaI at 37 °C for 1-16 hours. SGRs derived from Con1 or 
FK5.1 isolates were linearised with high fidelity ScaI for 1-4 hours at 37 °C. Restriction enzymes 
were inactivated at the suggested temperature for 20 minutes, cooled at room temperature 
for 10 minutes then on ice for a further 10 minutes. To remove overhang regions of the 
linearised DNA, reaction volume was increased to 100 µl with dH2O and treated with 10 U 
Mung Bean Nuclease (NEB) at 30 °C for 45 minutes before inactivation by addition of 0.1% 
(w/v) SDS. Linearised DNA was purified by phenol/chloroform extraction as described in 
Section 2.2.1.7 and resuspended in DEPC treated dH2O. 
2.2.1.14 In vitro transcription of RNA 
In vitro transcription was performed using 1 µg of linearised DNA template and the T7 
RiboMax Express system kit (Promega). Transcription proceeded at 30 °C for 90-120 minutes 
before treatment with DNase at 37 °C for 15-30 minutes as per manufacturer’s instructions. 
Following DNase treatment RNA was purified by phenol/ chloroform extraction as in Section 
2.2.1.7 with the exception of the use of phenol:chloroform at pH 5.2. Purified RNA in the 
aqueous phase was precipitated by addition of 1 x volume isopropanol and 0.1 x volume 3 M 
sodium acetate pH 5.2 on ice for 5 minutes before centrifugation at 13,000 rpm for 10 
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minutes. RNA pellets were washed in 70% ethanol and resuspended in 18-20 µl DEPC-dH2O. 
RNA was stored at -80 °C. 
2.2.1.15 RNA agarose gel electrophoresis 
RNA transcripts were analysed on a denaturing 3-(N-morpholino) propanesulphonic acid 
(MOPS) formaldehyde gel. 1% (w/v) agarose was added to 30 ml MOPS buffer (40 mM MOPS, 
10 mM sodium actetate, 1 mM EDTA) and microwaved at 340 W until dissolved. Once cool, 
6.5% (v/v) formaldehyde and 1:104 SYBR® Safe DNA Gel Stain were added. RNA (typically 1 µg) 
was boiled at 65 °C for 10 minutes in RNA loading buffer (47.5% (v/v) formamide, 9 mM EDTA, 
0.0125% (w/v) SDS, 0.0125% (w/v) Xylene Cyanol, 0.0125% (w/v) Bromophenol Blue) before 
loading alongside 1 µg ssRNA Ladder (NEB). RNA gels were resolved at 80 V for 1 hour. 
2.2.1.16 Reverse transcription polymerase chain reaction 
Reverse transcription polymerase chain reaction (RT-PCR) was used to produce cDNA from 
extracted cellular RNA. Reaction mixtures comprised 0.5 mM deoxynucleotide triphosphates 
(dNTPs), 200 ng random hexamer primers (Thermo Scientific) or 1 µM gene-specific primers 
and 1 µg of RNA in 13 µl dH2O and were incubated at 65 °C for 5 minutes and a further 5 
minutes on ice. 10 mM DTT was then added and the reaction volume increased to 19 µl in First 
Strand Buffer (Invitrogen). Reactions were incubated at 25 °C for 2 minutes before addition of 
200 U Superscript® II RNase H Reverse Transcriptase (Invitrogen). Reactions were then 
incubated at 25 °C for 10 minutes, 42 °C for 50 minutes and 70 °C for 15 minutes. cDNA was 
stored at -20 °C. 
 2.2.1.17 Polymerase Chain Reaction 
Polymerase chain reaction (PCR) was used to amplify cDNA from RNA reverse transcriptions 
using a ‘touchdown’ PCR cycle. PCR reaction mixtures comprised 0.3 mM deoxynucleotide 
triphosphates (dNTPs), 400 nM of each primer, 2 µl of cDNA reaction mixture (or 100 ng 
control vector DNA) and 1 U Vent® DNA polymerase in a reaction volume of 50 µl ThermoPol® 
Reaction Buffer (NEB). Reactions were denatured for 1 minute at 94 °C followed  by 20 cycles 
of a 30 second denaturation step at 94 °C, 30 seconds at a variable annealing temperature 
starting at 65 °C and dropping 0.5 °C each cycle (65-55 °C) and a 1 minute extension step at 72 
°C. Following this a further 15 cycles were performed at an annealing temperature of 55 °C. A 
final extension step at 72 °C for 5 minutes was performed. 
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2.2.2 Protein Biochemistry 
2.2.2.1 SDS-PAGE analysis 
Unless otherwise stated SDS-PAGE analysis was carried out using reducing Tris-Glycine 15% 
polyacrylamide gels (15% (v/v) acrylamide, 0.1% (w/v) SDS, 0.1% (w/v) ammonium persulphate 
(APS), 0.01% (v/v) N,N,N’,N’-tetramethylethylenediamine (TEMED), 376 mM Tris-HCl, pH 8.8) 
with a 6% stacking gel (6% (v/v) acrylamide, 0.1% (w/v) SDS, 0.1% (w/v) APS, 0.01% (v/v) 
TEMED, 376 mM Tris-HCl, pH 6.8). Gels were run in 1 x SDS-PAGE running buffer (25 mM Tris, 
192 mM glycine, 0.1% (w/v) SDS), typically at 200 V for 1 hour. Protein samples were loaded in 
¼ volume 4 x Laemmli buffer (8% (w/v) SDS, 30% (v/v) glycerol, 20 mM dithiothreitol (DTT), 
0.02% (w/v) Bromophenol Blue, 200 mM Tris-HCl, pH 6.8) and boiled for 5 minutes at 95 °C 
before loading. Protein size was compared to ColorPlus Prestained Protein Marker, Broad 
Range (7-175 kDa) (NEB). 
2.2.2.2 Coomassie Blue staining 
To visualise all proteins present gels were stained with Coomassie Brilliant Blue R-250 stain 
(50% (v/v) methanol, 10% (v/v) acetic acid, 0.05% (w/v) Brilliant Blue R-250) for over 1 hour. 
Gels were de-stained in 45% (v/v) methanol, 10% (v/v) acetic acid. 
2.2.2.3 Western blot analysis 
Resolved gels were transferred to polyvinylidene fluoride (PVDF) Immobilon®-FL Transfer 
Membrane (Immobilon) using a TE77X semi-dry transfer unit (AA Hoefer) at 15 V, 0.5 A for 1 
hour. Transfer membrane was activated in methanol and gels and transfer were soaked in 
Transfer buffer (20% (v/v) methanol, 25 mM Tris, 192 mM glycine). Transferred membranes 
were blocked in 50% (v/v) Odyssey® Blocking Buffer (LI-COR) in TBS. Primary and secondary 
antibodies were incubated for at least 1 hour at room temperature or overnight at 4 °C at the 
appropriate dilution in 25% (v/v) Odyssey® Blocking Buffer in TBS. Between steps unbound 
antibodies were washed off by 3-5 x 10 ml washes in TBS supplemented with 0.1% (v/v) 
Tween®-20. Following removal of all unbound antibodies, membranes were washed briefly in 
dH2O then allowed to dry. Membranes were imaged using an Odyssey imager (LI-COR). 
2.2.2.4 Acetone precipitation 
To precipitate protein from denaturing conditions, 2 x volume cold acetone was added, briefly 
vortexed and incubated -20 °C for at least 1 hour. Samples were centrifuged at 13,000 rpm 30 
minutes, washed in 70% (v/v) ethanol and resuspended in the initial volume of 1x Laemmli 
buffer. 
Chapter 2 – Materials and Methods 
 
 
68 
 
2.2.2.5 Protein concentration 
Protein samples were concentrated using Vivaspin 20 ml concentrators (Sartorius stedim 
biotech) with a 10,000 molecular weight cut-off. Concentrators were centrifuged at 4,000 rpm 
at 4 °C until reduced to the required volume. 
2.2.2.6 Buffer dialysis 
Protein solution buffer was altered by dialysis in 2 L of required buffer at 4 °C overnight using 
Snakeskin Dialysis Tubing (Thermo Scientific) with a 10 kDa cut-off. 
2.2.2.7 Protein quantification 
Protein concentration was quantified by comparison to a bovine serum albumin (BSA) 
standard curve using the Pierce®BCA Protein Assay Kit (Thermo Scientific). Protein samples 
were diluted in dH2O appropriately to 50 µl volume and mixed with 50 µl complete BCA 
solution in a 96 well plate before incubating at 37 °C for 30-45 minutes. Absorbance was 
measured at 570 nm using an infinite f50 platereader (Tecan). 
Alternatively, for quantification of protein under denaturing conditions, 5 µl protein samples 
(and BSA standards in the appropriate denaturant) were added to a 96 well plate before 
addition of 250 µl Bradford reagent (5% (v/v) methanol, 0.5% (w/v) Coomassie Blue G250, 
8.5% (v/v) phosphoric acid (H3PO4)). Plates were incubated whilst shaking for 5 minutes at 27 
°C before measuring absorbance at 570 nm. 
2.2.3 Tissue culture techniques 
2.2.3.1 Microscope 
Cultured cells were visualised using an OPTIKA XDS-2 microscope. 
2.2.3.2 Passaging of mammalian cells 
Mammalian cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with 10% (v/v) fetal bovine serum (FBS), 100 IU penicillin ml-1, 100 µg streptomycin ml-1 and 1% 
(v/v) non-essential amino acids. Cells were cultured in a humidified incubator at 37 °C with 5% 
CO2. Cells were typically passaged in a T175 flask and before reaching confluency media was 
removed and cells were washed in PBS. The cell monolayer was then incubated for 5 minutes 
at 37 °C in 0.5 mg/ml trypsin to detach cells before inactivating trypsin through the addition of 
excess complete media. Cells were typically subcultured 1:10 into fresh flasks. 
Chapter 2 – Materials and Methods 
 
 
69 
 
2.2.3.3 Freezing of cell stocks 
A minimum of 1 x 106 cells were frozen in cell storage media (10% (v/v) DMSO, 30% (v/v) FBS in 
full media). Cell stocks were stored at -80 °C. 
2.2.3.4 RNA electroporation of mammalian cells 
Cells were counted by 1:1 dilution into HyClone® Trypan Blue Solution before live cells were 
counted. Cells were pelleted at 1500 x g for 5 minutes then washed twice in 10 ml ice cold 
DEPC-treated PBS. Cells were resuspended to a final concentration of 1 x 107 cells/ml in ice 
cold RNase free PBS. For SGR electroporations 2 µg RNA was added to 4 x 106 cells in a chilled 
4 mm electroporation cuvette (Geneflow). For infectious virus construct electroporations 5 µg 
RNA was used. Electroporation was performed at 950 µF and 270 V with a BioRad Gene Pulser. 
Cells were gently resuspended in full media using a Pasteur pipette before seeding at the 
required density. 
2.3 In vitro methods 
2.3.1 In vitro NS2-3 autoprocessing assay 
2.3.1.1 Bacterial strains 
NS2-3 overexpression was performed in z-competent BL21 DE3 pLysS E. Coli. 
2.3.1.2 Plasmid constructs 
The NS2-3 coding sequence of JFH1 NS2-3 (JFH1 residues 906-1209) and J4 NS2-3 (J4L6S 
residues 904-1206) along with a 3’ Flag-tag were previously cloned into pET23a (pNS2-3) by 
Phillip Tedbury (Tedbury et al., 2007). All constructs were confirmed by Sanger sequencing. 
Plasmid containing bacteria were grown under ampicillin selection. 
2.3.1.3 NS2-3 overexpression 
A 50 ml culture of BL21 pLysS transformed with pNS2-3 was grown overnight at 37 °C and used 
to inoculate 500 ml LB media supplemented with 1% (w/v) glucose and 50 µg/ml ampicillin. 
Cultures were grown whilst shaking at 37 °C to OD600 of 1.0. Cultures were cooled at 4 °C for 30 
minutes before addition of 1 mM Isopropyl-β-D-1-thiogalactopyranoside (IPTG) to induce 
overexpression through the lac operon. Induction was performed for 3 hours at 37 °C before 
harvesting bacteria by centrifugation at 6000 x g for 10 minutes at 4 °C. Bacterial pellets were 
stored at -20 °C.  
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2.3.1.4 NS2-3 purification of inclusion bodies 
Bacterial pellets were re-suspended in 5 ml/g Lysis Buffer (1% (v/v) Triton X-100, 20 mM 
MgSO4, 5 mM DTT, 100 mM Tris-HCl, pH 8.0) supplemented with 1 µg/ml lysozyme and 20 
µg/ml DNase I before incubating for 20 minutes on ice. Membranous components of lysed 
bacteria were pelleted by centrifugation at 22,000 x g for 1 hour at 4 °C. Pellets were washed 
twice in 10 ml/g ice cold Wash Buffer 1 (2% (v/v) Triton X-100, 2 M Urea, 5 mM EDTA, 5 mM 
DTT, 100 mM Tris-HCl, pH 8.0) by re-suspension and centrifugation at 22,000 x g for 30 
minutes at 4 °C. Pellets were washed a final time in 5 ml/g ice cold Wash Buffer 2 (5 mM EDTA, 
5 mM DTT, 100 mM Tris-HCl, pH 8.0) by re-suspension and centrifugation at 22,000 x g for 1 
hour at 4 °C. Pelleted inclusion bodies were solubilised in ice cold Extraction Buffer (6 M 
guanidine hydrochloride (GdnHCl), 500 mM NaCl, 50 mM Tris-HCl, pH 8.0) and centrifuged at 
40,000 x g for 1 hour at 4 °C. Resulting supernatant was filtered through a 0.22 µm filter before 
progressing to His-tag purification. Extracted inclusion bodies were stored at 4 °C for no longer 
than 16 hours. 
2.3.1.5 NS2-3 His-tag purification 
Filtered inclusion bodies in Extraction Buffer were loaded onto either 5 ml Chelating 
SepharoseTM Fast Flow resin charged with Nickel following the manufacturer’s instructions or 
onto a HisTrapTM FF 1 ml column.  
Resins were loaded by rotating loose resin with extracted inclusion bodies for 1 hour at 4 °C. 
Resin was then pelleted at 4,000 x g for 5 minutes at 4 °C before flowthrough supernatant was 
removed. Washes and elutions were performed by batch in the same manner. 
Columns were charged using a Bio-Rad Econo Gradient Pump at a flow rate of 1 ml/min at 27 
°C. Washes and elutions were performed in the same manner. 
Following loading resins or columns were washed with 1-5 ml fractions of Extraction Buffer 
containing increasing amounts of imidazole. Imidazole gradients ran from 5 mM imidazole to 
500 mM imidazole. Fractions were acetone precipitated, re-suspended in the same volume of 
1x Laemmli loading buffer and analysed by Coomassie stain of 15% SDS-PAGE and anti-FLAG 
western blot. Fractions with sufficient protein quantity and purity were pooled and 
concentrated if necessary to 20 µM. NS2-3 was stored in 20 µl aliquots at -80 °C. 
2.3.1.6 NS2-3 refolding reaction 
NS2-3 at 20 µM in Extraction Buffer was diluted 1:100 into 100 µl Refolding Buffer #6. 
Refolding Buffer was optimised as in section 3.2.1 from the following solutions; 
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Refolding Buffer #1: 30% (v/v) glycerol, 250 mM NaCl, 3 mM L-cysteine, 0.5% (w/v) CHAPS, 50 
µM ZnCl2, 50 mM HEPES-NaOH pH 7.0 
Refolding Buffer #2: 30% (v/v) glycerol, 250 mM NaCl, 3 mM glycine, 0.5% (w/v) CHAPS, 50 µM 
ZnCl2, 50 mM HEPES-NaOH pH 7.0 
Refolding Buffer #3: 30% (v/v) glycerol, 250 mM NaCl, 3 mM L-cysteine, 0.5% (v/v) Triton-X-
100, 50 µM ZnCl2, 50 mM HEPES-NaOH pH 7.0 
Refolding Buffer #4: 30% (v/v) glycerol, 250 mM NaCl, 3 mM L-cysteine, 0.5% (w/v) CHAPS, 50 
µM ZnCl2, 50 mM HEPES-NaOH pH 8.0 
Refolding Buffer #5: 30% (v/v) glycerol, 250 mM NaCl, 3 mM L-cysteine, 0.5% (w/v) CHAPS, 50 
µM ZnCl2, 50 mM HEPES-NaOH pH 7.0, 1 mM DTT 
Refolding Buffer #6: 30% (v/v) glycerol, 250 mM NaCl, 3 mM L-cysteine, 0.5% (w/v) CHAPS, 50 
µM ZnCl2, 50 mM HEPES-NaOH pH 7.0, 10 mM DTT  
0 hour (0h) samples were stopped immediately by the addition of 20 µl 5 x Laemmli loading 
buffer. Reactions were incubated at 27 °C for 16 hours unless otherwise stated before halting 
the reaction with Laemmli loading buffer. Samples were boiled for 5 minutes at 95 °C and 
analysed by 15% SDS-PAGE and anti-FLAG western blot. 
2.3.1.7 Compound treatment of NS2-3 refolding reaction 
Dose response curves were made as DMSO stock solutions at 133.3 x final concentration. 0.75 
µl compound stock in DMSO was added to the 100 µl Refolding Buffer and mixed prior to 
addition of NS2-3. Refolding reactions were then treated as in Section 2.3.1.6. 
2.3.1.8 Western blot analysis and quantification of autoprotease activity 
Once reactions were halted samples were boiled unless otherwise stated and 15 µl was 
analysed by 15% SDS-PAGE as described in Section 2.2.2.1. Western blot was performed as in 
Section 2.2.2.3 using 1:5000 anti-FLAG M2 primary antibody and 1:104 IRDye 680RD Donkey 
anti-Mouse secondary antibody. Bands corresponding to NS2-3-FLAG and NS3-FLAG were 
quantified and normalised to DMSO control values. Data was modelled to calculate EC50 by 
fitting a nonlinear regression using the FindECanything function of Prism 6 (GraphPad). Use of 
antibodies conjugated to infrared fluorescent dyes with the Odyssey Infrared Imaging system 
(LI-COR Biosciences) produces an accurate, sensitive quantification of protein levels across a 
linear range (Schutz-Geshwender, 2004). 
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2.3.2 pGST-CypA overexpression and purification 
2.3.2.1 GST-CypA overexpression 
50 ml cultures of wildtype pGST-CypA and H126Q pGST-CypA in BL21 DE3 cells were used to 
inoculate a 500 ml LB supplemented with 50 µg/ml ampicillin. Cultures were grown whilst 
shaking at 37 °C to OD600 of 0.8. Cultures were cooled at 4 °C for 30 minutes before addition of 
1 mM IPTG for a 4 hour induction at 20 °C. Bacteria were harvested by centrifugation at 6000 x 
g for 10 minutes at 4 °C and pellets stored at -20 °C. 
2.3.2.2 GST-CypA purification 
Bacterial pellets were re-suspended in 10 ml per 500 ml culture phosphate buffered saline 
(PBS) supplemented with 1% (v/v) Triton-X-100, 2 µg/ml Anrafinin (Sigma-Aldrich), 0.2 mM 
Pefabloc® (Roche), 1 µg/ml Leupeptin (Sigma-Alrich) and 1 µg/ml Pepstatin A (Sigma-Alrich). 
Suspensions were sonicated on ice with 6 x 20 second pulses at 10 microns separated by 20 
seconds. Soluble material was isolated by centrifugation at 16,000 x g for 30 minutes at 4 °C. 
Soluble material was passed through a 0.22 µm filter and loaded onto 5 ml Glutathione 
SepharoseTM 4B resin by rotation at 4 °C for 1 hour. Resin was pre-equilibrated by 3 x 5 minute 
rotations at 4 °C in PBS followed by 5 minute rotation at 4 °C in PBS + 1% (v/v) Triton-X-100. 
Loaded resin was washed 2 x by rotation in 10 ml PBS + 1% (v/v) Triton-X-100 for 5 minutes at 
4 °C, then 2 x 10 ml PBS for 5 minutes at 4 °C followed by 2 x 10 ml 50 mM Tris-HCl pH 8.0 for 5 
minutes at 4 °C. GST-CypA was eluted from the resin by 2 x rotations in 5 ml 50 mM Tris-HCl pH 
8.0 supplemented with 40 mM reduced glutathione (Acros Organics) for 10 minutes at 4 °C. 
Purified GST-CypA was stored at 4 °C. 
2.4 Mammalian tissue culture methods 
2.4.1 Compound treatment of mammalian cells 
2.4.1.1 Seeding cells 
Cells were trypsinised and diluted 1:1 with Hyclone® Trypan Blue Solution to stain dead cells. 
Live cells were counted using a Marienfeld Haemocytometer. Unless otherwise stated cell 
solutions were diluted to 2 x 105 cells/ml. 100 µl of this cell suspension was seeded in each well 
of a 96-well plate to give 2 x 104 cells/well. Cells were left a minimum of 4 hours before media 
was changed or compound was added. 
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2.4.1.2 Preparation of DMSO standard curves 
All compound dose-response curves contained standard final DMSO, typically at 0.25% (v/v). 
To ensure standard levels of DMSO, concentration ranges were produced by serial dilution in 
DMSO at 400 x final concentration. 400 x stock concentration ranges were diluted 400-fold in 
media to produce the final concentrations through several dilution steps; typically 1:20 into an 
intermediate plate and 1:20 into the final plate. All reported EC50 and CC50 curves in cell-based 
systems were performed in duplicate with mean and standard deviation plotted. DMSO only 
control is plotted on the y axis. 
2.4.1.3 Luciferase endpoint 
Media was removed and wells were washed 3 x with 100 µl PBS before addition of 30 µl 1 x 
Passive Lysis Buffer (PLB; Promega). Plates were stored frozen at -20 °C. All luciferase dose 
response curves were read in a white 96-well microplate using a BMG Labtech Fluostar plate 
reader injecting 40 µl of LAR-I reagent (Promega) and recording light emission over 6 seconds. 
Emission data from 1.6 – 6.0 seconds was averaged and data was normalised to DMSO 
controls. Data was modelled to calculate EC50 by fitting a non-linear regression using the 
FindECanything function of Prism 6 (GraphPad). 
2.4.1.4 Selection of stable cell lines 
10 µg of RNA of a SGR-feo construct was electroporated into Huh7.5 cells as described in 
Section 2.2.3.4. Cells were seeded in 10 ml in a 10 cm dish for 24 hours before media was 
changed and supplemented with 500 µg/ml G418. During selection cells were subcultured as 
required, with discarded cells analysed for luciferase signal. Upon the formation of G418 
resistant colonies, either individual colonies were picked to yield monoclonal populations or 
selection was continued before a polyclonal population was harvested. 
2.4.1.5 RNA extraction 
Relevant SGR-feo cell lines were seeded at a density of 4 x 104 cells/ml in either a 12-well plate 
or a 10 cm dish. Cells were washed 2 x in 10 ml PBS and incubated for 10-15 minutes in 1 ml 
TRIzol® Reagent (Invitrogen) gently shaking at 27 °C. TRIzol extractions were stored as 500 µl 
aliquots at -80 °C. RNA was purified from extractions by RNA chloroform extraction as in 
Section 2.2.1.14. 
2.4.1.6 Western blot analysis 
Cells were seeded at a density of 80 x 104 cells/ml for up to 48 hours before washing in PBS 
and lysing in a relevant volume of PLB. PLB lysates were stored at -20 °C. Lysates underwent 
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centrifugation at 4000 rpm for 2 minutes and insoluble material was discarded. Lysates were 
quantified by BCA assay against BSA standards as in Section 2.2.2.7. Required amounts of 
protein were analysed by SDS-PAGE and western blot analysis as in Sections 2.2.2.1 and 
2.2.2.3. 
2.4.2 Mammalian cell toxicity analysis 
2.4.2.1 MTT assay 
Cells were seeded in a clear 96 well plate as described in Section 2.4.1.1 and treated with 
required concentrations of the compound of interest as in Section 2.4.1.2. At the required 
timepoint, typically 48 hours, media was removed and replaced with 150 µl high glucose, no 
glutamine, no phenol red DMEM (Gibco®) before addition of 30 µl 6 mM Thiazolyl Blue 
Tetrazolium Bromide. 6 mM Thiazolyl Blue Tetrazolium Bromide was prepared by dissolving 
Thiazolyl Blue Tetrazolium Bromide to 12 mM in PBS, filtering through a 0.22 µm filter and 
dilution to 6 mM with high glucose, no glutamine, no phenol red DMEM. Cells were incubated 
in 1 mM Thiazolyl Blue Tetrazolium Bromide for ≥ 2 hours before media was removed and 
Thiazolyl Blue Tetrazolium Bromide crystals were dissolved in 100 µl DMSO by shaking for 10 
minutes at 27 °C. Plates were then read at 570 nm using an infiniteF50 platereader (Tecan). 
Data was normalised to DMSO controls and modelled using a non-linear regression to fit a CC50 
using Prism 6 (GraphPad). 
2.4.2.2 ATPLite assay 
ATPLite Luminescence ATP Detection Assay System was performed following the 
manufacturer’s instructions (Perkin Elmer) with luminescence quantified using a BMG Labtech 
Fluostar plate reader. Data was normalised to DMSO controls and modelled using a non-linear 
regression to fit a CC50 using Prism 6 (GraphPad). 
 
2.5 Biosafety level 3 (BSL3) mammalian tissue culture methods 
2.5.1 Compound treatment of mammalian cells under BSL3 
Infectious virus construct transcripts were electroporated into Huh7.5 cells as described in 
Section 2.2.3.4 and seeded to the same cell density in 96 well plate format in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS), 100 
IU penicillin ml-1, 100 µg streptomycin ml-1 and 1% (v/v) non-essential amino acids and 20 mM 
Chapter 2 – Materials and Methods 
 
 
75 
 
Hepes Buffer (Lonza). Cells were transferred to BSL3 containment within 4 hours post 
electroporation (h.p.e.). Cells were treated with compound as in Section 2.4.1.2 with the 
exception of a final volume not exceeding 100 µl and luciferase endpoint taken as in Section 
2.4.1.3. 
2.5.2 BSL3 MTT mammalian cell toxicity assay 
MTT assay was performed as in Section 2.4.2.1. After incubation in 1 mM Thiazolyl Blue 
Tetrazolium Bromide for ≥ 2 hours media was removed and virus inactivated with 100 µl/well 
4% paraformaldehyde (PFA) for ≥ 10 minutes. PFA solution was gently removed and Thiazolyl 
Blue Tetrazolium Bromide crystals were dissolved in 100 µl DMSO by shaking for 10 minutes at 
27 °C. Plates were then read at 570 nm using an infiniteF50 platereader (Tecan) and analysed 
as in section 2.4.2.1. 
2.5.3 Infection of naïve mammalian cells 
Following 48 hour treatment with a range of compound concentrations in 96 well format, 100 
µl virus containing supernatant was removed and added to 2 x 104 Huh7.5 cells in 96 well 
format. Following 16 hour incubation, cells were washed in PBS and luciferase endpoint taken 
as in Section 2.4.1.3. 
 
2.6 Chemistry Materials 
Reagents and anhydrous solvents were purchased from commercial sources and used without 
further purification. Magnesium Sulphate was from Fisher Ltd. 1-Hydroxybenzotriazole, 1-(3-
dimethylaminopropyl)-3-ethy-carbodiimide hydrochloride and meta-chloroperbenzoic acid 
(mCPBA) were from Sigma Aldrich. 4-Spiroindene-piperidine hydrochloride (SM-2) was from 
KeyOrganics. 1-Methyl-1-cyclohexanecarboxylic acid (SM-1) and cyclohexane carboxylic acid 
were from Sigma Aldrich. 
 
2.7 Chemistry Methods 
Thin-layer chromatography (TLC) was performed using aluminium pre-coated silica gel plates 
(Machery-Nagek, 0.2 mm thickness) (Merck Chemicals) using the indicated solvents, with 
retention factor (Rf) reported. Column chromatography was carried out using geduran silica 
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gel 60 (40-63 µm) (Merck Chemicals) using the same solvent as used for TLC. Melting points 
were determined using a Reichert Hot Stage apparatus. 
Proton (1H) and carbon (13C) NMR spectra were recorded on a 300 / 75 MHz Bruker DPX300 
Fourier transform spectrometer with an internal deuterium lock. Chemical shifts are reported 
in parts per million (ppm) with reference to an internal tetramethylsilane (TMS) standard. For 
proton spectra (δH), the integration (e.g. 1H), multiplicities (e.g. s, singlet, d, doublet, t, triplet, 
m, multiplet etc.) and coupling constants (J, measured in Hertz) are reported. For carbon 
spectra (δC) the assigned carbon for each peak is indicated. NMR samples were prepared in 
deuterated chloroform (CDCl3) from Sigma-Aldrich. 
Mass spectrometry was performed in DMSO using a VG Autospec mass spectrometer by 
electron spray ionisation at 70 eV. LC-MS was carried out using an Agilent Technologies 1200 
series HPLC with UV detection from 190-750 nm coupled to a Bruker Ultra HCT mass 
spectrometer. 
Synthetic procedures are described In Appendix I. 
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3.1 Introduction 
The NS2 autoprotease has long been postulated as a potential therapeutic target for the 
treatment of HCV infection. As understanding of the nature of the NS2-encoded protease has 
grown, this essential enzyme activity has appeared a more feasible target. The protease 
activity is required in the virus lifecycle, acts at the stage of polyprotein processing and 
appears to further regulate the role of the NS3 protease in this stage of the lifecycle (Jones et 
al., 2007, Kolykhalov et al., 2000, Welbourn et al., 2005). Inhibitors of polyprotein processing 
by NS3-mediated proteolysis have already demonstrated a beneficial therapeutic effect in the 
clinic as evidenced by the use of NS3 protease inhibitors in new therapies. The catalytic 
domain of NS2 has a novel fold, unusual cysteine protease active site geometry and no 
homology to any human proteases indicating that it may be amenable to a selective small 
molecule inhibitor (Lorenz, 2010, Lorenz et al., 2006). While a cis-acting unimolecular 
autoprotease reaction may be expected to process as soon as correctly folded, and hence 
display a narrow time-window in which to block the proteolysis event, indications that the NS2 
autoprotease may be regulated by the amounts of polyprotein, function in a concentration 
dependent manner and require multimerisation suggest this window may be extended 
(Lorenz, 2010). 
The success of NS3 protease inhibitors and NS5B NIs was initially driven through in vitro assays 
amenable to HTS. Despite similar efforts the conditions required to reconstitute proteolysis 
and the nature of the NS2 protease have hampered the application of in vitro assays for the 
NS2 autoprotease into a HTS system. In vitro systems for studying the NS2 autoprotease 
include in vitro translation, which can include addition of cellular factors through microsomal 
membranes, or the reconstitution of enzyme activity in vitro using bacterially expressed and 
purified recombinant proteins (Pallaoro et al., 2001, Pieroni et al., 1997, Tedbury and Harris, 
2007, Thibeault et al., 2001). Alternatively tagged NS2-based expression constructs can be 
transfected into cell lines or expressed through vaccinia systems and analysed by 
immunoprecipitation and western blot analysis (Gorzin et al., 2012, Schregel et al., 2009). 
While there are advantages to screening compounds in a cell-based system with regards to 
progression as a drug candidate, as these systems account for compounds exerting cellular 
toxicity or poor membrane permeability, they contribute a greater degree of complexity to 
both the process and analysis of initial screening. In addition in vitro assays generally allow 
screening of compounds at higher concentrations. Furthermore, the complexity of a cell-based 
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system, and to some degree in vitro systems requiring addition of cellular components, makes 
it more difficult to answer the fundamental question of whether a small molecule can block 
the process of NS2-NS3 processing regardless of its viability as a drug candidate. Therefore, to 
explore whether the proteolytic activity of the NS2 autoprotease can be inhibited by a small 
molecule, a system involving purified recombinant protein and reconstitution of enzyme 
activity in vitro was chosen. 
The first section of this chapter (3.2.1) describes the purification of recombinant proteins 
encoding a fragment of the NS2-NS3 precursor sufficient for NS2 autoprotease-mediated 
processing (NS2-3). The optimisation of refolding this protein so as to initiate NS2-mediated 
proteolysis with respect to its use in an assay amenable to screening compounds is described. 
The activity of some previously reported inhibitors of the NS2 protease reaction are explored 
with respect to their use as a positive control.  
The aforementioned benefits of a cell-based assay (ruling out compounds exerting cellular 
toxicity, instability or poor membrane permeability) can be achieved with a SGR based assay. 
Compounds can be tested against a SGR comprising NS2-5B to identify those that inhibit NS2-
dependent HCV genome replication. As described in Figure 1.7, SGRs that contain NS2-5B are 
already available and have been used to prove that the NS2 autoprotease activity is required 
for genome replication both for the genotype 2a isolate JFH1 and a genotype 1b culture 
adapted isolate termed FK5.1 (Tedbury et al., 2011). SGRs comprising NS2-5B currently have 
either a NPT reporter, which is not amenable to a rapid and sensitive measure of replication, 
or luciferase, which cannot be maintained as a stable cell population and hence requires 
transient electroporation of RNA transcripts prior to each assay. The process of 
electroporation of SGR transcripts into cells not only increases the complexity of a screening 
assay, particularly with regards to HTS, but introduces additional variability into the system. 
Screening against NS2-5B SGRs would therefore benefit from a fusion reporter (feo) allowing a 
stable cell line to be maintained and providing sensitive quantification of genome replication. 
In optimising SGRs containing NS2-5B for screening, maximisation of the replication kinetics 
and hence the luciferase signal should be considered to obtain the greatest signal-to-noise 
ratio. 
Section 3.2.2 of this chapter describes the cloning, selection and validation of SGR-feo [NS2-
5B] stable cell lines with respect to their use in a cell based screen against NS2-dependent HCV 
replication. 
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The use of a positive control in cell-based screening assays is more problematic as no specific 
small molecule inhibitors of the NS2 autoprotease have been described to date. However, 
indications that host factor chaperones contribute to correct folding of NS2 and help modulate 
protease activity could allow the use of chaperone antagonists. Both Hsp90 and CypA have 
been postulated to play a role in the correct folding of NS2, with antagonists shown to block 
NS2-NS3 processing in cell culture and have an additional effect in SGRs containing NS2-5B 
respectively (Ciesek et al., 2009, Waxman et al., 2001). 
Section 3.2.3 of this chapter explores the potential of these chaperone antagonists to serve as 
a positive control against NS2-dependent HCV replication. This section also examines in 
greater detail the potential effect of CypA on the NS2 protein with implications for the anti-
viral effect of CsA and its analogues, and explores the anti-viral activity of Hsp90 inhibitors in a 
system relevant to HCV replication. 
 
 
 
 
 
  
Chapter 3 – Development and validation of screening assays for identification of NS2-targeting 
compounds 
 
 
81 
 
3.2 Results 
3.2.1 NS2-NS3 in vitro autoprocessing assay 
The cloning, overexpression, purification and optimisation of refolding of the NS2-3 
recombinant protein has been previously reported (Foster et al., 2010b, Tedbury and Harris, 
2007). As depicted in Figure 3.1, these constructs encode the C-terminal ‘catalytic’ domain of 
NS2 and the N-terminal protease domain of NS3. For the genotype 2a JFH1 isolate (EU HCV 
database accession number AB047639) this corresponds to residues 906-1209 of the HCV 
polyprotein, while the genotype 1b J4 isolate (EU HCV database accession number AF054247) 
encodes residues 904-1206. Constructs are preceded at the N-terminus with four lysine 
residues and a hexa-histidine tag and flanked at the C-terminus by a FLAG epitope 
(DYKDDDDK) for purification and detection purposes respectively. 
Within the pNS2-3 expression construct, NS2-3-FLAG derived from the JFH1 isolate has a 
molecular weight of 35,030.49 Da (35 kDa). Successful reconstitution of the NS2 autoprotease 
activity will initiate proteolysis at the NS2-NS3 junction, leading to processing of the P5 - P5’ 
substrate sequence GWKLLAPITA by cleavage of the scissile bond between the P1 leucine of 
NS2 and the P1’ alanine of NS3. The His-tagged NS2 product has a predicted molecular weight 
of 15,005.62 Da (15 kDa). The FLAG-tagged NS3 product has a molecular weight of 20,042.89 
Da (20 kDa) (Expasy Bioinformatics Resource Portal). 
Similarly, NS2-3-FLAG derived from the J4 isolate of pNS2-3 has a molecular weight of 
34,911.31 Da (35 kDa) and is processed to a His-NS2 product 15,049.67 Da (15 kDa) in 
molecular weight and a NS3-FLAG product 19,879.66 Da (20 kDa) in molecular weight. The J4 
isolate of NS2-3 has an alternative P3 residue, with the P5 – P5’ cleavage sequence 
GWRLLAPITA. 
A model of the unprocessed NS2-3 protein based on separate crystal structures of the post-
cleaved NS2 protease domain ((Lorenz et al., 2006), PDB 2HD0) and the protease domain of 
NS3 in complex with NS4A is shown in Figure 3.1B. NS2-3 is purified in denaturant, meaning 
structural elements may not be present until dilution into refolding buffer. 
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Figure 3.1: NS2-3 protein overexpression construct.  
A) NS2-3 comprises the C-terminal catalytic domain of NS2 and the N-terminal protease 
domain of NS3. The N-terminus is flanked by four lysine residues and a hexa-histidine tag (K4H6) 
and the C-terminus by a FLAG epitope. Residues of the catalytic triad of the NS2 autoprotease 
are marked in red. The site of proteolysis is indicated by the arrow, with P5 - P5’ residues for 
JFH1 and J4 isolates shown. B) Cartoon of NS2-3 based on crystal structures of NS2 (PDB 2HD0) 
and NS3 (PDB 3RC4). The catalytic cysteine of NS2 is shown in orange. Catalytic residues of the 
NS3 protease, highlighted in red, and the NS4B binding site, highlighted in blue, are on the 
reverse face of NS3. N-terminal and C-terminal tags and P5 – P5’ residues are shown. P1’, P2’ 
and P3’ residues at the N-terminus of NS3 are not present in the crystal structure. Surface 
representation is shown with oxygen atoms in red and nitrogen atoms in blue.  
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Overexpression and purification of NS2-3, as described in Section 2.3.1, followed a minor 
modification of previously reported methods in E. coli BL21 (DE3) pLysS cells. Following a 3 
hour induction with IPTG at 37 °C cells were lysed and centrifuged at 22,000 x g to pellet 
inclusion bodies. Inclusion bodies were washed in a solution of 2 M Urea before solubilisation 
in 6 M guanidine hydrochloride (GdnHCl). Purified inclusion bodies contained predominantly 
un-processed 35 kDa NS2-3 along with the presence of an additional smaller species (Figure 
3.2). In line with some previous observations this is most likely a NS2-3 truncation product 
(Foster et al., 2010b).  
Purification of NS2-3 under denaturing conditions worked equally efficiently either by batch 
purification using a Ni2+ charged sepharose resin or commercially available pre-packed 1 ml Hi-
Trap columns. Significant levels of NS2-3 were frequently observed in flowthrough fractions, 
but the high yields obtained from purification suggest the capacity of the column may have 
been reached. Washing with increasing concentrations of imidazole gradually eluted NS2-3, 
with the majority of protein eluted after 500 mM imidazole washes. Purified NS2-3 contained 
both the truncation product and higher molecular weight species. These may correspond to 
dimers or aggregates as a significant proportion can be removed by the addition of 10 mM DTT 
to increase levels of monomeric NS2-3 (Figure 3.2B). 
NS2-3 purification fractions were selected based on optimal purity and concentrated or diluted 
as required to 20 µM (0.7 mg/ml). Refolding reactions were initiated by 1:100 dilution into 
detergent rich refolding buffer. Optimisation of the refolding reaction tested several different 
buffer compositions as outlined in Section 2.3.1.6. Buffers were tested using J4 NS2-3 following 
16 hour refolding reactions by western blot analysis for the appearance of NS3-FLAG, one of 
the proteolysis products. Refolding reactions were compared to a reaction in Refolding Buffer 
#6 which was immediately halted (0h) by the addition of Laemmli SDS loading buffer (Figure 
3.3). 
Optimisation of the buffer confirmed previous observations that DTT was required, with 
greater cleavage efficiency observed with 10 mM DTT (Refolding Buffer #6) over 1 mM DTT 
(Refolding Buffer #5) (Figure 3.3). Successful refolding and autoproteolysis was also 
temperature optimised, with greatest autoprotease activity observed at room temperature 
(Figure 3.3B).  
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Figure 3.2: NS2-3 purification.  
A) Key J4 NS2-3 overexpression and inclusion body isolation fractions analysed by Coomassie 
stain of SDS-PAGE. Induced cell pellets (lane 1) were lysed (lane 2) and inclusion bodies pelleted 
to remove soluble material (lane 3). Pelleted inclusion bodies were washed three times (lanes 4-
6) before solubilising in 6 M GdnHCl and centrifugation to separate soluble inclusion bodies 
(lane 8) and remaining cellular debris (lane 7). Inclusion bodies were passed through a 0.45 
micron filter (lane 9). B) Coomassie staining of SDS-PAGE analysis for NS2-3 purification 
fractions. Inclusion bodies were loaded onto Ni2+ charged resin or a Ni2+ affinity column (lanes 
10-11). Bound NS2-3 was washed in GdnHCl containing increasing concentrations of imidazole 
(lanes 12-20) and eluted in 500 mM imidazole (lanes 21-23). Higher order species were 
observed in eluted protein fractions (lane 24) which could be removed or reduced to increase 
levels of monomeric NS2-3 by addition of 10 mM DTT (lane 25). 
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Figure 3.3: Optimisation of NS2-3 refolding reactions.  
A) J4 NS2-3 refolding reactions were performed in a range of buffer compositions (Refolding 
Buffer #1-#6, outlined in Section 2.3.1.6). Reactions were resolved by SDS-PAGE and analysed 
by western blot using αFLAG antibody. The 20 kDa NS3-FLAG autoproteolysis product was only 
observed in Buffer #5 and Buffer #6. B) Reactions in Buffer #5 and Buffer #6 were temperature 
optimised and analysed by western blot, with both producing the greatest NS3-FLAG at 27 °C. 
Reduced levels of NS3-FLAG were observed at 30 °C and no significant production of NS3-FLAG 
over 0 hour (0h) control at 37 °C. 
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To confirm that the observation of NS3-FLAG in refolding reactions was due to the catalytic 
activity of the NS2 autoprotease, the NS2-3 tertiary structure was disrupted by the addition of 
zinc chelators. Previous observations have demonstrated that the catalytic activity of NS2 is 
dependent on zinc, most likely as a structural element coordinated by C922 in NS2 and 
residues 1123, 1125 and 1171 in NS3 (Figure 1.8A). In line with this, these studies 
demonstrated that in vitro NS2 autoprotease activity could be abrogated by the addition of 
zinc chelators (Table 1.2). 
These observations were confirmed for the NS2-3 refolding reaction by addition of 10 mM 
EDTA or 10 mM 1,10-phenanthroline. Both zinc chelators completely abolished the production 
of detectable NS3-FLAG cleavage product after 16 hour refolding reactions, while untreated 
reactions produced NS3-FLAG (Figure 3.4). To demonstrate that this activity was through 
selective chelation of zinc atoms the treatment of refolding reactions with 10 mM EGTA, which 
selectively chelates calcium, did not have the same effect (Figure 3.4B). That the production of 
NS3-FLAG in refolding reactions can be inhibited by zinc chelators demonstrates that correctly 
folded NS2-3 is required and that the presence of NS3-FLAG represents catalytic activity of the 
NS2-3 pre-cursor. 
To explore the kinetics of NS2-3 autoproteolysis in the refolding reaction a timecourse was 
performed. NS2-3 refolding reactions were stopped by the addition of Laemmli SDS loading 
buffer every 30 minutes for 4 hours and additionally at 8, 16, 24 and 48 hours. Levels of NS3-
FLAG were quantified and compared to a 0 hour sample (Figure 3.5). NS3-FLAG significantly 
above background was observed after 2.5 hours. Levels of NS3-FLAG did not increase after 3.5 
hours, suggesting the reaction was complete by this timepoint. Total protein appeared 
reduced after 48 hours incubation, with decreased levels of NS3-FLAG and NS2-NS3-FLAG 
suggesting protein may not be stable over this length of time. 
Levels of NS3-FLAG up to 24 hours were plotted and a non-linear regression was fitted. These 
results demonstrate that the refolding reaction is complete by 3.5 hours (Figure 3.5B). As a 
consequence some further optimisation reactions were performed over a 4 hour refolding 
reaction. For consistency, all compound treatments were performed over a 16 hour timepoint. 
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Figure 3.4: Abrogation of autoprotease activity by zinc chelation.  
Refolding reactions were allowed to proceed for either 0 hours or 16 hours in the absence (-) or 
presence (+) of EDTA (10 mM), 1,10-phenanthroline (10 mM) or EGTA (10 mM). Reactions were 
resolved by SDS-PAGE and analysed by western blot. A) Production of NS3-FLAG from J4 NS2-3 
refolding reactions was prevented by addition of EDTA or 1,10-phenanthroline. B) NS3-FLAG 
autoproteolysis product was produced in the presence of EGTA. 
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Figure 3.5: NS2-3 refolding and autoproteolysis timecourse.  
A) JFH1 NS2-3 refolding reactions were allowed to proceed for indicated times before reactions 
were analysed by western blot. B) Levels of NS3-FLAG autoproteolysis product were quantified 
and plotted to fit non-linear regression. Autoproteolysis reactions were complete by 3.5 hours. 
  
  
0  0.5  1   1.5    2  2.5  3    3.5   4     8   16   24   48    0
Time (hours)
NS2-NS3-FLAG
NS3-FLAG
A
B
in  v it r o N S 2 -3  a u to p ro c e s s in g  t im e c o u r s e
T im e  (h )
N
S
3
-F
L
A
G
 i
n
te
n
s
it
y
2 4 6 8 1 0 1 2 1 4 1 6 1 8 2 0 2 2 2 4
-1 .01 0 5
0
1 .01 0 5
2 .01 0 5
3 .01 0 5
4 .01 0 5
Chapter 3 – Development and validation of screening assays for identification of NS2-targeting 
compounds 
 
 
90 
 
In order to test compounds against the NS2-3 refolding reaction, the assay was optimised for 
the effects of DMSO as a vector. A 16 hour refolding reaction was treated with concentrations 
of DMSO ranging from 0.25% to 50% (v/v) and compared to a 0 hour sample. NS3-FLAG was 
observed to similar levels when reactions were treated with 0.25% and 0.5% DMSO. NS3-FLAG 
was observed from 1% to 10% DMSO but appeared reduced (Figure 3.6A). To confirm these 
observations NS3-FLAG and NS2-NS3-FLAG were quantified (Figure 3.6B). DMSO levels below 
1% produced similar NS3-FLAG intensities as an untreated, 0% DMSO, reaction. At 1% DMSO 
and above the levels of NS3-FLAG produced in the refolding reaction were reduced and by 4% 
DMSO were not above background. Additionally, higher quantities of DMSO reduced detection 
of total protein, with intensity of NS2-NS3-FLAG also reduced. The refolding reaction can 
therefore tolerate a final DMSO concentration < 1% (v/v). All subsequent in vitro NS2-3 
refolding assays contain less than 1% final DMSO unless otherwise stated. 
Previous reports have linked NS2-3 derived from the genotype 1b J4 isolate with decreased 
homogeneity after purification due to the presence of a contaminant, most likely a truncation 
product, along with reduced levels of reconstituted autoprotease activity (Foster et al., 2009). 
Throughout the current study both J4 and JFH1 isolates of NS2-3 were associated with some 
contaminants when eluted with high imidazole after fewer washes, most notable of which was 
small amounts of the NS3-FLAG cleavage product used to monitor the refolding reaction. 
Optimisation of the purification protocol allowed for selection of the purest fractions by 
gradually increasing imidazole levels (Figure 3.2B), a process required for both isolates of the 
NS2-3 protein. By this method fractions were selected whereby only unprocessed NS2-NS3-
FLAG could be observed by Coomassie stain and anti-FLAG western blot analysis. 
Despite comparable purity, direct comparison of 16 hour refolding reactions for both JFH1 
NS2-3 and J4 NS2-3 confirmed that the JFH1 isolate was more efficient for reconstituting 
autoprotease activity in vitro. Refolded JFH1 NS2-3 produced significantly more NS3-FLAG than 
the J4 NS2-3 refolding reaction (Figure 3.7). Quantification of NS2-NS3-FLAG and NS3-FLAG 
from these reactions allowed calculation of the efficiency of the reconstituted autoproteolysis. 
The JFH1 NS2-3 autoprotease reaction was 37.6% efficient, in that 37.6% of the total protein 
quantified was present as NS3-FLAG. By contrast, the J4 NS2-3 refolding reaction was only 
6.4% efficient (Figure 3.7). Previous timecourse analysis suggests this efficiency is unlikely to 
improve with extended time (Figure 3.5). 
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Figure 3.6: In vitro NS2-3 autoproteolysis assay DMSO sensitivity.  
A) 16 hour NS2-3 refolding reactions were treated with indicated final DMSO concentration 
before analysis by western blot. NS3-FLAG autoproteolysis product was compared to a 0 hour 
control. B) Quantification of NS2-NS3-FLAG and NS3-FLAG bands from A.  
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Figure 3.7: Comparison of in vitro autoproteolysis between different genotypes.  
NS2-3 refolding reactions for the isolates JFH1 (gt 2a) and J4 (gt 1b) were compared at 0 hour  
(-) and 16 hour (+) timepoints by quantification of NS2-NS3-FLAG and NS3-FLAG following 
western blot analysis of reactions using αFLAG antibody. 
 
 
As a negative control, NS2-3 refolding reactions were treated with an available DAA, the NS5A 
inhibitor Daclatasvir (BMS-790052) (Gao et al., 2010). This DAA is proposed to act upon the 
NS5A protein and as such should have no effect on NS2-NS3 processing. Firstly, to confirm that 
Daclatasvir does not act upon NS2, both SGR-luc-JFH1 [NS3-5B] and SGR-luc-JFH1 [NS2-5B] 
transcripts were electroporated into Huh7.5 cells and treated with a range of concentrations 
of Daclatasvir for 48 hours. Inhibition profiles were similar regardless of the presence or 
absence of NS2 in the SGR and calculated EC50 values were similar; 2.5 pM and 1.8 pM for 
[NS3-5B] and [NS2-5B] SGRs respectively (Figure 3.8A), similar to reported EC50 against JFH1 
virus (28 ± 24 pM) (Gao et al., 2010). 
After confirming that Daclatasvir does not exert any additional anti-viral effect in SGRs which 
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same concentrations of Daclatasvir, ranging from 1 fM (10-3 pM)  to 10 nM (104 pM) (Figure 
3.8B). Quantification of NS3-FLAG from Daclatasvir treated samples confirmed no effect on 
levels of NS2-mediated autoproteolysis, even at active concentrations within the context of 
the SGR (Figure 3.8C). Thus active concentrations of the NS5A inhibitor Daclatasvir have no 
effect on the in vitro NS2-3 autoproteolysis assay and serve as a negative control. 
The use of a positive control for screening assays is more challenging. As previously stated, 
several groups have attempted to identify inhibitors of the NS2 autoprotease without success, 
both in cell based screens and in similar in vitro refolding or in vitro transcription reactions 
using the minimal NS2-NS3 subunit. Initially, such in vitro reactions were used to characterise 
the nature of the NS2 autoprotease through the use of protease inhibitors, none of which 
showed any activity against NS2-NS3 processing (Pallaoro et al., 2001, Pieroni et al., 1997, 
Tedbury and Harris, 2007, Thibeault et al., 2001). The only agents reported as capable of 
blocking NS2 maturation in vitro are zinc chelators and some thiol alkylating agents. The 
inhibition of the NS2 autoprotease by thiol alkylating agents, along with mutagenic analysis, 
helped to define the NS2 protease as a cysteine protease. 
As a positive control for the NS2-3 refolding reaction the halomethyl ketone thiol alkylating 
agent tosyl phenylalanine chloromethane ketone (TPCK) was used. NS2-3 refolding reactions 
were treated with TPCK at concentrations ranging from 1.7 µM to 300 µM alongside 0 hour 
and DMSO only controls. Western blot analysis confirmed the reduction or loss of NS3-FLAG in 
a dose-responsive manner above 9.5 µM TPCK (Figure 3.9A). NS3-FLAG was next quantified, 
normalised to DMSO controls and plotted to fit a non-linear regression, allowing the 
calculation of an EC50 of 15.3 µM (Figure 3.9B). These results confirm that the thiol alkylating 
agent TPCK blocks NS2-NS3 processing in vitro in a dose responsive manner. Furthermore, as a 
positive control TPCK demonstrates that quantification of NS3-FLAG from the NS2-3 refolding 
reaction allows the degree of NS2-mediated autoproteolysis to be accurately determined, to 
the extent that sensitivity of inhibition can be monitored through calculation of EC50. 
While useful as a positive control in vitro, toxicity analysis of TPCK in Huh7 cells revealed 
significant effects on cellular metabolism, with a CC50 of 3.3 µM (Figure 3.9C), not surprising 
considering the non-selective nature of this thiol alkylating agent. TPCK is therefore unlikely to 
be of any utility as a control in cell-based assays. Additional options for a positive control 
against NS2-dependent HCV replication in cell based assays are explored in Section 3.2.3.  
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Figure 3.8: Daclatasvir has no effect on the NS2 autoprotease.  
A) Luciferase reporter SGRs comprising NS3-5B or NS2-5B were electroporated into Huh7.5 cells 
and treated with a range of Daclatasvir concentrations from 1 fM to 10 nM for 48 hours. 
Luciferase activity was quantified and normalised to DMSO control (plotted as 10-4 pM). Non-
linear regression was fitted to calculate EC50 B) JFH1 NS2-3 refolding reactions were treated 
with the same concentrations of Daclatasvir for 16 hours before assessing levels of NS3-FLAG 
(arrowhead) relative to 0 hour and DMSO only controls by western blot analysis. C) 
Quantification of NS3-FLAG from B confirmed no effect of Daclatasvir on in vitro NS2-3 
autoproteolysis at active concentrations.  
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Figure 3.9: Thiol alkylating agents block in vitro NS2-3 autoproteolysis.  
A) JFH1 NS2-3 refolding reactions were treated with a range of concentrations of tosyl 
phenylalanine chloromethane ketone (TPCK) from 1.7 µM to 300 µM for 16 hours alongside a 
DMSO only control and 0 hour control. Refolding reactions were analysed for levels of NS3-
FLAG (arrowhead) by western blot using αFLAG antibody. B) Quantified NS3-FLAG from A was 
normalised to DMSO controls and plotted to fit a non-linear regression; EC50 = 15.3 µM. C) 
Huh7 cells were treated with a range of concentrations of TPCK from 0.1 µM to 100 µM for 48 
hours before monitoring cellular metabolism by MTT assay. Data was normalised to DMSO 
controls and plotted to fit a non-linear regression and calculate CC50 = 3.3 µM.  
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3.2.2 NS2-5B SGR stable cell lines as a measure of NS2-dependent genome replication. 
Previous work within this laboratory has utilised SGRs containing NS3-5B or NS2-5B with either 
a luciferase reporter in the first ORF (SGR-luc) for assays involving transient electroporation, or 
a NPT gene (SGR-neo) to allow selection of stable cell lines (Tedbury et al., 2011). More 
recently SGRs comprising NS3-5B derived from JFH1 and Con1 (BM4-5), a culture adapted 
genotype 1b SGR, were obtained as a kind gift from David Wyles, University of California. The 
first ORF of these SGRs encodes a ffLuc-NPT fusion protein. These constructs, termed SGR-feo, 
allow both analysis of SGR replication through luciferase activity and selection of stable cell 
lines (Wyles et al., 2009, Wyles et al., 2007). Due to elevated levels of luciferase achieved 
through constitutive SGR replication within stable cell lines and reduced variability usually 
introduced through the processes of preparing RNA transcripts and electroporation, these 
SGR-feo stable cell lines are more permissible to medium-high throughput screening. 
To allow a similar system to be utilised for studying inhibitors of the NS2 autoprotease, the 
relevant NS2 coding sequence was introduced into both SGR-feo-JFH1 [NS3-5B] and SGR-feo-
Con1 [NS3-5B] to produce SGR-feo-JFH1 [NS2-5B] and SGR-feo-Con1 [NS2-5B]. 
To produce SGR-feo-JFH1 [NS2-5B] a unique EcoRI site in the T7 promoter and a unique PmeI 
site at the start of the EMCV IRES were used to excise the HCV IRES and ffLuc-NPT fusion 
protein ‘feo cassette’ from SGR-feo-JFH1 [NS3-5B]. The same route was used to remove the 
NPT gene from SGR-neo-JFH1 [NS2-5B], allowing the NPT gene to be replaced by the feo 
cassette (Figure 3.10). 
SGR-feo-Con1 [NS2-5B] was produced using the same PmeI site at the start of the EMCV IRES 
and a unique XhoI site within the NS5A gene to excise the 5’ non-structural genes NS3-mid 
NS5A along with the EMCV IRES. The same fragment, containing NS2, was removed from SGR-
neo-FK5.1 [NS2-5B] and ligated into the backbone of the SGR-feo-Con1 [NS3-5B] (Figure 3.11). 
As this NS3-NS5A fragment contains all CAMs for both Con1 based SGRs (NS5A ∆S230 for BM4-
5 or NS3 E176G, NS3 I254T, NS5A N137D and NS5A S225P for FK5.1), the produced SGR-feo-
Con1 [NS2-5B] construct is essentially SGR-feo-FK5.1 [NS2-5B]. For simplicity SGR-feo-
Con1(BM4-5) [NS3-5B] and SGR-feo-Con1(FK5.1) [NS2-5B] will both be referred to as Con1. 
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Figure 3.10: SGR-feo-JFH1 [NS2-5B] cloning strategy.  
A unique EcoRI site at the start of the T7 promoter and a PmeI site unique to the start of the 
EMCV IRES were used to replace the neomycin phosphotransferase (NPT) gene of SGR-neo-JFH1 
[NS2-5B] (middle) with the firefly luciferase-neomycin phosphotransferase fusion protein gene 
(ffLuc-NPT) from SGR-feo-JFH1 [NS3-5B] (top).  
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Figure 3.11: SGR-feo-Con1 [NS2-5B] cloning strategy.  
A unique PmeI site at the start of the EMCV IRES and an XhoI site unique within the NS5A 
coding sequence were used to excise a fragment spanning the EMCV IRES – NS5A region and 
containing NS2 from SGR-neo-FK5.1 [NS2-5B] (top). This fragment was inserted in place of the 
corresponding EMCV IRES – NS5A region lacking NS2 of SGR-feo-Con1 [NS3-5B] (middle).     
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All SGR-feo [NS2-5B] constructs were confirmed by analytical digest and Sanger sequencing. 
Transcripts of SGR-feo-JFH1 [NS2-5B] and SGR-feo-Con1 [NS2-5B] were electroporated into 
Huh7.5 cells and subjected to selective pressure using G418. Separate plates were selected for 
either polyclonal or monoclonal stable cell lines, all of which produced detectable luciferase 
activity and could be cultured at up to 1 mg/ml G418. While luciferase activity was confirmed 
from monoclonal stable cell lines all future assays and the validation herein described for SGR-
feo were performed with a polyclonal stable cell line population. 
Once selection was complete and luciferase activity confirmed, stable cell lines were stored as 
frozen cell stocks as described in Section 2.2.3.3. Fresh stocks were thawed, cultured for at 
least two passages in the presence of G418 and seeded to the same cell density as after 
transient electroporation assays for analysis of luciferase signal and replication kinetics over 
various timepoints. In addition SGR-feo-JFH1 [NS3-5B] and SGR-feo-Con1 [NS3-5B] were 
analysed from frozen cell stocks in the same manner. SGR-feo [NS3-5B] stable cell lines were 
produced and selected by Yutaka Amako (University of Leeds) as polyclonal stable cell lines in 
Huh7.5 cells. 
Previous reports have demonstrated a replication impaired phenotype for SGRs comprising 
NS2-5B (Lohmann et al., 1999). Such an effect has been observed in this laboratory using SGR-
luc-JFH1 [NS3-5B] and SGR-luc-JFH1 [NS2-5B] in a transient luciferase reporter assay (Tedbury 
et al., 2011). Therefore if SGR-feo [NS2-5B] constructs rely on NS2-NS3 processing for genome 
replication, the same replication impaired phenotype should be apparent. In order to directly 
compare replication kinetics between SGR-luc and SGR-feo, SGR-feo-JFH1 [NS3-5B] or SGR-feo-
JFH1 [NS2-5B] RNA was electroporated into Huh7 cells and analysed transiently i.e. at up to 72 
hours post electroporation (h.p.e.) in the absence of G418. As a control for impaired 
replication when NS2 is present, transcripts of the previously reported SGR-luc-JFH1 [NS3-5B] 
and SGR-luc-JFH1 [NS2-5B] were also electroporated alongside a polymerase defective GND 
control (SGR-luc-JFH1 [NS3-5B] GND). 
As shown in Figure 3.12, when SGR-feo-JFH1 [NS3-5B] or SGR-feo-JFH1 [NS2-5B] RNA was 
electroporated into cells and analysed transiently they showed comparable replication kinetics 
to previously reported constructs; SGR-luc-JFH1 [NS3-5B] and SGR-luc-JFH1 [NS2-5B]. All 
constructs produced comparable 4 hour luciferase activity as a consequence of translation 
from the input RNA, irrespective of whether they contained luc or feo reporter genes. SGRs 
containing NS3-5B produced luciferase activity roughly 3 log10 higher than the GND SGR 
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negative control at 48-72 h.p.e. whether they contained luc or feo reporter genes. SGRs 
containing NS2-5B demonstrated a replication impaired phenotype, with luciferase activity 
over 1 log10 lower than the corresponding SGR spanning NS3-5B (Figure 3.12), in agreement 
with previously reported results (Lohmann et al., 1999, Tedbury et al., 2011). That the SGR-feo-
JFH1 [NS2-5B] displays this phenotype as a transient experiment suggests a dependency on 
NS2-NS3 processing for replication. 
However, following extensive selection with G418, cells stably-expressing the SGRs produced 
equivalent elevated levels of luciferase activity irrespective of the presence of NS2 in the 
polyprotein. Therefore, once selection was complete the phenotype of impaired replication 
due to NS2 appeared to be lost. As SGR replication is constitutive in these stable SGR cells, 
baseline luciferase activity is high at 4 hours post seeding (Figure 3.12). The subsequent 1 log10 
increase in luciferase activity by 48 and 72 hours most likely represents an increase in cell 
numbers. 
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Figure 3.12: SGR replication kinetics assayed via luciferase activity.  
Transcripts of indicated SGRs were either electroporated into Huh7 cells in the absence of 
selective pressure (transient) or electroporated into Huh7.5 cells and selected as polyclonal 
stable cell lines with G418. Stable cell lines (stable) were seeded alongside transient 
electroporations to directly compare replication kinetics. Luciferase activity at indicated 
timepoints post seeding is represented as relative luciferase units (RLU) on a logarithmic scale.  
Data represents the mean and standard deviation of one experiment seeded in triplicate. 
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Selection of SGR-feo [NS2-5B] as stable cell lines therefore appears to overcome the 
detrimental effect on replication imparted by the presence of NS2 in a ‘transient’ system. 
Providing that these stable cell lines are still dependent on NS2-NS3 processing for replication 
and have not acquired culture adapted mutations to improve replicative fitness (points that 
are addressed later in this chapter), the improved replication kinetics of a NS2-5B SGR as a 
stable cell line could be attributed to NS2-NS3 processing acting as a rate limiting step during 
the early establishment of HCV replication. As a transient experiment all non-structural 
proteins and RCs have to be produced de novo and as such replication may be more sensitive 
to slower polyprotein processing kinetics. 
Stable cells harbouring SGR-feo constructs provide an ideal platform to screen for inhibitors 
due to the high luciferase activity compared to transient systems, resulting in a better signal-
to-noise ratio. This effect is particularly pronounced with SGRs derived from genotype 1b. In a 
transient experiment both SGR-feo-Con1 [NS3-5B] and SGR-feo-Con1 [NS2-5B] produced no 
detectable luciferase activity over background, yet the selection of the same constructs as 
stable cell lines increased luciferase signal by over 3  log10 (Figure 3.12). The fact that the 
‘replication impaired’ phenotype of an NS2-containing SGR is not observed in these stable cell 
lines is also beneficial for screening against NS2, but requires confirmation that genome 
replication within these cell lines is still dependent on NS2-NS3 processing. To validate these 
SGR containing stable cell lines further, the presence of the NS2 coding sequence in 
autonomously replicating RNA was confirmed and the potential for additional culture adapted 
mutations within these SGRs was examined. Additionally, the presence of mature viral proteins 
was explored to demonstrate normal processing of the polyprotein, particularly at the NS2-
NS3 junction. Finally, the hypothesis that enhanced replication kinetics of SGR-feo [NS2-5B] 
was due to the selection of a sub-population of Huh7.5 cells more permissive to NS2-
dependent HCV replication was tested. 
Firstly, to confirm the presence of the NS2 coding region within the autonomously replicating 
RNA of SGR-feo [NS2-5B] stable cell lines, RNA was isolated by Trizol extraction following 
multiple passage of the cell population and used to perform an RT-PCR with NS2-specific 
primers. Available primer sets were used to amplify a 1280 base pair fragment for JFH1-based 
constructs and a  707 base pair fragment for Con1-based constructs. As a positive control for 
the fragments amplified with these primers a standard PCR was performed using the DNA 
template previously confirmed by Sanger sequencing. Amplified fragments of the correct size 
were observed for both positive control PCR reactions and RT-PCR reactions from total 
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extracted cellular RNA for SGR-feo-JFH1 [NS2-5B] and SGR-feo-Con1 [NS2-5B]. These products 
were not observed from identical reactions using SGR-feo-JFH1 [NS3-5B] or SGR-feo-Con1 
[NS3-5B], demonstrating both JFH1 and Con1 SGR-feo [NS2-5B] stable cell lines retained the 
NS2 coding region within the autonomously replicating SGR RNA after the process of selection 
and further passages (Figure 3.13). 
Improved replication kinetics of NS2-containing SGRs as stable cell lines could be attributed to 
culture-adapted mutations. To explore this possibility total cellular RNA from SGR-feo-JFH1 
[NS2-5B] was subjected to RT-PCR with primers designed to amplify the entire coding region in 
multiple overlapping fragments. Amplified fragments were confirmed by agarose gel 
electrophoresis and sequenced to confirm the presence of the entire NS2 coding region and 
identify any potential culture adapted mutations. Analysis revealed 100% nucleotide identity 
to the sequence of the DNA construct throughout the entire SGR, demonstrating that the 
improved replication kinetics of SGR-feo-JFH1 [NS2-5B] in the context of a stable cell line could 
not be attributed to culture adapted mutations. Similar sequencing analysis was performed for 
SGR-feo-Con1 [NS2-5B], revealing no amino acid changes within NS2 or the NS3 N-terminus. 
The cell lines were analysed for efficient processing at the NS2-NS3 boundary by probing 
cellular lysates for mature NS2. Replication kinetics of all four SGR-feo cell lines were directly 
compared in three independent experiments by seeding several timepoints in parallel before 
analysing luciferase activity, again confirming comparable kinetics. Lysates were analysed for 
the presence of post-cleaved NS2 and the endogenous marker GAPDH by western blot. As 
expected anti-NS2 antibody detected mature NS2 (23 kDa) from lysates of SGR-feo-JFH1 [NS2-
5B] and infectious JFH1 virus, with none detected from lysates of SGR-feo-JFH1 [NS3-5B] 
(Figure 3.14A). The antibody used was raised against JFH1 NS2 (Jirasko et al., 2008) and hence 
showed no reactivity to either SGR-feo Con1 [NS2-5B] or SGR-feo Con1 [NS3-5B] lysates. The 
detection of a previously reported 17 kDa NS2 truncation product tNS2 (Boson et al., 2011, 
Jirasko et al., 2008, Jirasko et al., 2010) was also noted in both SGR-feo-JFH1 [NS2-5B] lysates 
and from infectious JFH1 virus lysates. In addition lysates were analysed for the presence of 
other key proteins; feo (anti-NPT), NS3 and NS5A (Figure 3.14B). 
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Figure 3.13: NS2-dependent RT-PCR from SGR-feo cell lines.  
SGR-feo cell lines were passaged at least eight times before extraction of total cellular RNA 
followed by reverse transcription to cDNA using forward primers within the NS2 coding region 
(RT-PCR).  Conventional PCR amplification of initial DNA constructs with the same primers was 
used as a control (Control PCR). PCR reactions were analysed by gel electrophoresis. 
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Figure 3.14: Comparative analysis of SGR-feo cell lines.  
A) Luciferase activity from SGR-feo cell lines was analysed after indicated timepoints (N.D. – not 
determined). Data is the mean and standard deviation of three independent experiments. 
Below, lysates were analysed by western blot and probed with anti-JFH1 NS2 and anti-GAPDH 
antibody. 1) SGR-feo-JFH1 [NS3-5B], 2) SGR-feo-JFH1 [NS2-5B], 3) SGR-feo-Con1 [NS3-5B], 4) 
SGR-feo-Con1 [NS2-5B], 5) JFH1 HCVcc. B) Lysates probed with anti-NPT, anti-NS3 and anti-
NS5A antibody. 
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One final consideration to explain the enhanced replication kinetics of stable NS2-5B SGRs 
compared to transient NS2-5B SGRs could be the selection of a cell population more 
permissive to the replication of NS2-containing SGRs. To exclude this possibility the replicon 
was cleared from SGR-feo-Con1 [NS2-5B] cell lines by treatment with 1 µM Daclatasvir 
(approximately 140,000 x EC50) for 48 hours. Cells were maintained for a further 72 hours in 
the absence of Daclatasvir or G418 to remove the drug. Transcripts of SGR-luc-JFH1 [NS3-5B] 
and SGR-luc-JFH1 [NS2-5B] were then electroporated into the replicon-cleared cells and into 
both Huh7 and Huh7.5 cells for direct comparison. Similar to the data reported in Figure 3.12, 
SGRs containing NS2-5B had a severely impaired phenotype relative to SGRs containing NS3-
5B. However this phenotype was much less pronounced in Huh7.5 cells (Figure 3.15). Cells 
derived from cleared SGR-feo-Con1 [NS2-5B] showed no further enhancement in the 
replication kinetics of a SGR spanning NS2-5B, with a slight replication impaired phenotype still 
observed (Figure 3.15). Luciferase from mock electroporated cleared-SGR cells was within 
background variation confirming the initial SGR-feo-Con1 [NS2-5B] had been cleared from 
these cells. Taken together these results demonstrate that while Huh7.5 cells allow for a 
significant improvement in the replication kinetics of NS2-containing SGRs, no further 
enhancement is observed from the cell population present at the end of SGR-feo-Con1 [NS2-
5B] selection. Therefore a major influence on the replication kinetics of SGR-feo [NS2-5B] cell 
lines may be the use of Huh7.5 cells, though the process of constitutive autonomous 
replication may further elevate luciferase signals relative to transient electroporations. 
SGR-feo [NS2-5B] stable cell lines therefore offer a robust cell-based assay with which to test 
inhibitors of NS2-dependent genome replication. These cell lines undergo polyprotein 
processing as a requirement for genome replication in the absence of additional CAMs. 
Genome replication can be monitored through luciferase activity with a larger signal-to-noise 
ratio than obtained in ‘transient’ systems and in the absence of impaired replication kinetics 
due to the presence of NS2.  
Additional evidence that SGR-feo [NS2-5B] cell lines still require an active NS2 autoprotease for 
genome replication could be provided through the use of a positive control for selective 
inhibition of the NS2 autoprotease. As no specific small molecule inhibitor of the NS2 
autoprotease has been reported, the next Section (3.2.3) will explore the potential of 
antagonists of cellular chaperones implicated in the NS2 autoprotease activity to serve as such 
a control. 
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Figure 3.15: SGR replication kinetics in cleared SGR-feo cell populations.  
SGR-feo-Con1 [NS2-5B] was cleared with Daclatasvir and the resultant Huh7.5 derived cell 
population (Cleared SGR-feo (Huh7.5)) were subject to electroporation with SGR-luc-JFH1 [NS3-
5B] or SGR-luc-JFH1 [NS2-5B] or mock treated. The same constructs were electroporated into 
Huh7 cells and Huh7.5 cells for comparison. Luciferase activity was measured after indicated 
timepoints and represents the mean and standard deviation of one experiment seeded in 
triplicate. 
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3.2.3 Chaperone antagonists as a positive control against NS2-dependent replication 
Inhibitors of the cellular peptidyl-prolyl isomerase (PPI) cyclophilin A (CypA) are of interest as 
anti-viral agents targeting HCV replication, as described in Section 1.6.  
In 2009, it was reported that both infectious virus and SGRs containing NS2-5B displayed 
enhanced sensitivity to CypA antagonists compared to SGRs containing NS3-5B (Ciesek et al., 
2009). It was concluded that the isomerase activity of CypA played a role in the folding or 
activity of the NS2-NS3 auto-proteolysis event. If so, the differential sensitivity to CypA 
antagonsists observed between NS2-5B and NS3-5B replicons could serve as a useful positive 
control when screening compounds for specific inhibition of NS2-NS3 autoproteolysis. A 
control of this nature would benefit a screening programme aiming to identify a small 
molecule inhibitor of the NS2 autoprotease. 
3.2.3.1 Effects of NS2 on SGR sensitivity to cyclosporin A 
To explore previously reported effects of the CypA antagonist CsA on SGRs comprising NS3-5B 
and NS2-5B, SGR-luc-JFH1 [NS3-5B] and SGR-luc-JFH1 [NS2-5B] transcripts were electroporated 
into Huh7.5 cells. Electroporated cells were treated with CsA at a range of concentrations at 4 
h.p.e. until 48 h.p.e. before measuring luciferase activity. EC50 values were calculated and the 
obtained data agreed with that reported (Ciesek et al., 2009); a shift in sensitivity was 
observed when comparing the two SGRs. SGR-luc-JFH1 [NS3-5B] exhibited a CsA EC50 of 481.4 
nM, while the NS2-containing SGR gave an EC50 of 121.6 nM, a 4-fold increase in sensitivity 
(Figure 3.16A). 
CsA EC50 values were next determined for the SGR-feo cell lines described in Section 3.2.2. 
Cells were seeded and again treated with a range of concentrations of CsA for 48 hours. 
Toxicity analysis confirmed that any effects observed were a direct effect on genome 
replication, but the same shift in sensitivity was not observed. While SGR-feo-Con1 [NS2-5B] 
(CsA EC50 = 499.2 nM) did appear slightly more sensitive than SGR-feo-Con1 [NS3-5B] (CsA EC50 
= 686.3 nM) (Figure 3.16B), SGR-feo-JFH1 [NS2-5B] (CsA EC50 = 702.9 nM) was less sensitive to 
CsA inhibition than SGR-feo-JFH1 [NS3-5B] (CsA EC50 = 480.5 nM) (Figure 3.16C). These 
observations were confirmed by calculation of CsA EC50 values from three technical repeats 
(Table 3.1). SGR-feo-Con1 [NS2-5B] was 1.6 ± 0.3 fold more sensitive to CsA inhibition than 
SGR-feo-Con1 [NS3-5B], while SGR-feo-JFH1 [NS3-5B] was actually 1.3 ± 0.2 fold more sensitive 
than SGR-feo-JFH1 [NS2-5B] to CsA inhibition.  
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Figure 3.16: Cyclosporin A sensitivity in SGRs comprising NS3-5B or NS2-5B.  
A) SGR-luc-JFH1 [NS3-5B] and SGR-luc-JFH1 [NS2-5B] were electroporated into Huh7.5 cells and 
treated with a range of cyclosporine A (CsA) concentrations from 1 nM to 100 µM for 48 hours 
to calculate EC50. B) SGR-feo-JFH1 [NS3-5B] and SGR-feo-JFH1 [NS2-5B] stable cell lines treated 
with a range of cyclosporine A (CsA) concentrations from 10 nM to 5.6 µM for 48 hours to 
calculate EC50. Cell viability was analysed by MTT assay.  C) SGR-feo-Con1 [NS3-5B] and SGR-
feo-Con1 [NS2-5B] stable cell lines treated with a range of cyclosporine A (CsA) concentrations 
from 10 nM to 5.6 µM for 48 hours to calculate EC50. Cell viability was analysed by MTT assay. 
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Table 3.1: Sensitivity of SGR-feo cell lines to CsA.  
EC50 calculated from treatment with a range of CsA concentrations over 48 hours in indicated 
SGR-feo cell lines. Three technical repeats for each assay are reported. Example dose response 
curves used for the calculation of EC50 are shown for experiment #1 in Figure 3.16B and C. 
CsA sensitivity 
Experiment [NS3-5B] EC50 [NS2-5B] EC50 Fold change in 
NS2-5B 
sensitivity 
Average change 
in sensitivity 
SGR-feo-Con1 
#1 686.3 nM 499.2 nM x 1.4 
 
X 1.6 
#2 542.8 nM 355 nM x 1.5 
#3 412 nM 211.9 nM x 1.9 
SGR-feo-JFH1 
#1 480.5 nM 702.9 nM x 0.7 
 
X 0.8 
#2 515.2 nM 587.3 nM x 0.9 
#3 184.9 nM 234.1 nM x 0.7 
 
Therefore neither SGR-feo [NS2-5B] stable cell line displays increased CsA sensitivity such as 
that observed with transient SGR-luc-JFH1 [NS2-5B], despite the presence of the NS2 coding 
region (Figure 3.13) and the observation of NS2 in lysates from SGR-feo-JFH1 [NS2-5B] (Figure 
3.14). The shift in CsA sensitivity observed with transient replicons containing NS2-5B was 
therefore explored further to confirm a specific activity against NS2. 
One key difference between the transient SGR-luc and the SGR-feo stable cell lines is that 
selection of stable cell lines may have improved the replication kinetics of NS2-containing SGRs 
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(Figure 3.15). It was therefore considered that CsA sensitivity may be linked to the replicative 
ability of NS2-5B SGRs. CsA sensitivity of transient NS2-5B and NS3-5B SGRs was therefore 
examined in the context of different cell lines. Previous electroporation of transient SGR-luc 
for CsA treatment was performed in Huh7.5 cells, as was the selection of SGR-feo stable cell 
lines. As described in Section 1.7, this cell line is more permissive to HCV replication. To test 
any potential effect of replication kinetics on sensitivity to CsA-mediated inhibition, SGR-luc-
JFH1 [NS3-5B] and SGR-luc-JFH1 [NS2-5B] were transiently electroporated into the Huh7 cell 
line, where SGR replicative ability is reduced, an effect particularly pronounced in SGRs 
containing NS2-5B (Figure 3.12). 
To confirm any observations made in NS3-5B and NS2-5B SGR-luc, identical experiments were 
performed with the same two SGRs containing a CsA resistance mutation within NS5A; D316E 
(Yang et al., 2010). SGR-luc-JFH1 [NS3-5B] (D316E) was previously cloned by Douglas Ross-
Thriepland (University of Leeds). To produce SGR-luc-JFH1 [NS2-5B] (D316E), a fragment 
spanning NS3-NS5A was excised from SGR-luc-JFH1 [NS3-5B] (D316E) and ligated into SpeI and 
RsrII digested SGR-luc-JFH1 [NS2-5B]. The construct was confirmed by analytical digest and 
Sanger sequencing and in vitro transcribed and electroporated as before. This allowed analysis 
of the effect of NS2 on CsA sensitivity both within wt SGR-luc and in the context of a partially 
CsA resistant SGR-luc. 
To explore the replication kinetics of wt and D316E SGRs spanning NS3-5B and NS2-5B, 
transcripts were electroporated in parallel into Huh7 and Huh7.5 cells. To account for potential 
differences in input RNA, luciferase activity is normalised as fold increase from 4 h.p.e. (at 4 
h.p.e. no SGR replication is likely to have occurred and hence all luciferase present is a 
consequence of translation from the input RNA). 
 As shown in Figure 3.17, all SGRs produced detectable luciferase 48 h.p.e. significantly above 
GND negative control. SGR-luc-JFH1 [NS2-5B] (D316E) is replication competent with 
comparable replication kinetics in both cell lines to wt SGR-luc-JFH1 [NS2-5B]. 
The NS2 containing SGRs, both wt and D316E, had significantly impaired levels of replication 
48 h.p.e. in Huh7 cells relative to identical SGRs containing NS3-5B. All SGRs showed 
comparable increases in luciferase signal within the context of Huh7.5 cells (Figure 3.17). A 
similar profile for wt NS2-5B and NS3-5B SGRs was described in Figure 3.15. 
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After confirming that all constructs were replication competent, CsA EC50 values were 
calculated for all constructs in parallel in both Huh7 and Huh7.5 cells (Figure 3.18). 
 
 
 
Figure 3.17: Effect of cell context on SGR replication kinetics. 
 Indicated SGRs were electroporated into Huh7.5 cells (left panel) or Huh7 cells (right panel) 
and luciferase activity monitored after 48 hours. Luciferase activity as fold increase from signal 
4 hours post electroporation (h.p.e.) is plotted as the mean and standard deviation of each 
electroporation seeded in triplicate. Statistical significance was determined by unpaired 
Student’s t test (* p < 0.05). 
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Figure 3.18: Effect of cell context on the CsA sensitivity of NS3-5B and NS2-5B SGRs.  
A) wt SGR-luc-JFH1 [NS3-5B] and wt SGR-luc-JFH1 [NS2-5B] electroporated into Huh7.5 cells 
and treated with a range of cyclosporine A (CsA) concentrations from 1 nM to 100 µM for 48 
hours to calculate EC50. B) As in A with SGRs electroporated into Huh7 cells. C) As in A using 
SGRs containing the D316E CsA resistance mutation in NS5A. D) As in C with mutant SGRs 
electroporated into Huh7 cells. 
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 As previously observed in Huh7.5 cells (Figure 3.16A), CsA treatment of transient SGR-luc-JFH1 
[NS2-5B] produced a shift in sensitivity compared to the SGR-luc-JFH1 [NS3-5B] (Figure 3.18A). 
By contrast, when the same constructs were electroporated into Huh7 cells the sensitivity of 
SGR-luc-JFH1 [NS3-5B] and SGR-luc-JFH1 [NS2-5B] was much more similar (Figure 3.18B). 
Furthermore, a similar pattern was observed with SGRs containing the D316E CsA resistance 
mutation in NS5A. SGR-luc-JFH1 [NS2-5B] (D316E) was more sensitive to CsA inhibition than 
SGR-luc-JFH1 [NS3-5B] (D316E) when the experiment was performed in Huh7.5 cells (Figure 
3.18C), but both SGRs showed identical sensitivity to CsA when the experiment was performed 
in Huh7 cells (Figure 3.18D). It was also noted that the presence of the D316E mutation was 
sufficient to impart resistance to CsA in both NS3-5B and NS2-5B SGRs in all cell lines.  
As a mutation in NS5A is able to confer resistance to CsA regardless of the absence or presence 
of NS2, NS5A is likely to be directly involved in CsA-mediated inhibition. Furthermore, a shift in 
sensitivity to CsA-mediated inhibition between NS2-5B and NS3-5B SGRs is only observed in 
Huh7.5 cells and not Huh7 cells. This observation was made for both wildtype SGRs and 
partially CsA-resistant SGRs and implicates either an effect influenced by differential host 
factors between these two cell lines or an effect due to differences in SGR replication kinetics 
(Figure 3.17). 
To explore these possibilities, the same experiments were performed using genotype 1b SGRs. 
These constructs have significantly reduced replication kinetics in cell culture, with replicative 
ability remaining poor even in Huh7.5 cells. SGR-luc-FK5.1 [NS3-5B] and SGR-luc-FK5.1 [NS2-
5B] were electroporated into Huh7.5 cells and treated with a range of concentrations of CsA as 
before. Due to the reduced replicative ability of FK5.1 SGRs and the corresponding low 
luciferase signal, the experiments were performed over 72 hours for accurate calculation of 
EC50 values. Nonetheless as expected the sensitivity of SGR-luc-FK5.1 [NS2-5B] and SGR-luc-
FK5.1 [NS3-5B] to CsA were identical, despite being performed in Huh7.5 cells (Figure 3.19A).  
The shift in CsA sensitivity observed with NS2-containing SGRs (Ciesek et al., 2009) therefore 
appears to be an artefact of differences in replication efficiency specific to the strong levels of 
replication observed in JFH1-derived SGRs, and not a difference in host factor expression or 
activity. In agreement with this western blot analysis of lysates from Huh7 cells, Huh7.5 cells 
and from a range of SGR-feo constructs selected as stable cell lines did not show any 
significant differences in levels of endogenous CypA (Figure 3.19B). 
Chapter 3 – Development and validation of screening assays for identification of NS2-targeting 
compounds 
 
 
115 
 
 
Figure 3.19: CsA sensitivity is not directly linked to cell context.  
A) SGR-luc-FK5.1 [NS3-5B] and SGR-luc-FK5.1 [NS2-5B] electroporated into Huh7.5 cells and 
treated with a range of CsA concentrations from 3.16 nM to 10 µM for 72 hours to calculate 
EC50. B) Cellular abundance of CypA and GAPDH in cell lysates analysed by western blot. 
Quantification is plotted with the mean and standard deviation from Huh7 and Huh7.5 shown. 
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3.2.3.2 Effects of CypA on NS2 refolding and autoproteolysis in vitro 
Because antagonism with CsA is not directly affected by the NS2 protein, but appears to 
correlate with the replication kinetics of the SGR, this suggests that CypA plays no direct role in 
either the folding or autoprotease activity of NS2. To confirm this observation the effects of 
CypA were explored in the context of the in vitro NS2-3 refolding and autoprotease assay 
described in Section 3.2.1. 
Ciesek et al. briefly described that CsA or other CypA antagonists had no effect on NS2-NS3 
autoproteolysis in an assay based on in vitro translation of the minimal subunit required for 
NS2-NS3 processing in the presence of microsomal membranes (Ciesek et al., 2009).  The 
design of this assay is somewhat similar to the in vitro NS2-NS3 autoproteolysis assay 
described in Section 3.2.1. However, the assay in the current study uses purified bacterially 
expressed NS2-NS3 and hence lacks any eukaryotic cellular proteins such as CypA. The 
successful autoproteolysis of NS2-3 in this setting demonstrates that NS2 does not have an 
absolute requirement for CypA for correct folding, though the inefficiency of this in vitro 
reaction could be explained by a lack of important cellular factors such as chaperones. 
To examine whether a potential role of CypA in binding NS2-3 and aiding correct folding could 
be reconstituted in vitro, using autoprotease activity as a readout for the degree of correct 
NS2-3 folding, CypA was bacterially expressed as a GST fusion protein and purified by batch 
purification on Glutathione Sepharose 4B beads before being added to the in vitro NS2-3 
autoprotease assay. GST-CypA has been confirmed to enhance the ability of NS5A domain 2 to 
bind RNA in vitro, suggesting functional isomerase activity (Foster et al., 2011).  
Overexpression and purification of GST-CypA was performed both for wt CypA and a H126Q 
CypA mutant. This CypA mutation has been demonstrated to show less than 1% of wt PPIase 
activity (Chatterji et al., 2010) and thus served as a negative control to show whether observed 
effects were dependent on PPIase activity. Over-expression and purification by GST resin 
produced good yields of soluble protein; roughly 24 mg of protein from a 500 ml culture 
(Figure 3.20A). A series of dilutions for wt and H126Q mutants were analysed by western blot 
to confirm the purified protein was CypA (Figure 3.20B). 
Purified CypA (wt or H126Q) was added to a JFH1 NS2-3 refolding reaction at 5 x the NS2-3 
concentration (1 µM). After 16 hours the total amount of autoproteolysis was measured by 
quantifying the NS3-FLAG proteolysis product. Comparable levels of NS3-FLAG product were 
produced irrespective of the presence of GST-CypA (Figure 3.21A) suggesting that the addition 
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of 5x concentration of GST-CypA had no effect on the final amount of NS2-3 autoproteolysis 
within the context of the minimal NS2-3 subunit used in the assay. In addition, a timecourse 
was performed of the JFH1 NS2-3 refolding reaction in the absence or presence of 1 µM wt 
GST-CypA. Refolding reactions were terminated every 30 minutes by the addition of Laemmli 
SDS-PAGE running buffer before analysing by western blot for the levels of NS3-FLAG. Both 
refolding profiles appear similar with the control refolding reaction complete by 3 h and a 
reaction in the presence of 1 µM GST-CypA complete by 3 h (Figure 3.21B). 
These results demonstrate that in vitro and within the context of the JFH1 NS2 C-terminal 
domain and the NS3 N-terminal domain, bacterially expressed GST-CypA does not increase the 
total amount of refolding and auto-proteolysis or the rate of NS2-3 refolding. These results 
support the previous data using NS2-containing SGRs which suggest that NS2 is not directly a 
substrate for the cellular PPIase CypA and as such does not directly influence the anti-HCV 
activity of CsA. Therefore, antagonists of CypA do not represent a viable positive control for 
specific inhibition of NS2-dependent HCV replication. 
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Figure 3.20: Overexpression and purification of GST-CypA.  
A) Coomassie Brilliant Blue stained SDS-PAGE of fractions from wt and H126Q GST-CypA 
overexpression and purification. B) Western blot analysis of indicated amounts of GST-CypA 
from elution fractions. A Huh7 lysate control is confirmed by GAPDH and demonstrates 
reactivity of the antibody to endogenous CypA.  
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Figure 3.21: Effect of GST-CypA on NS2-3 refolding and auto-proteolysis in vitro.  
A) Addition of wt GST-CypA (1 µM) or H126Q GST-CypA (1 µM) to JFH1 NS2-3 (200 nM) had no 
effect on the levels of NS3-FLAG produced by auto-proteolysis following western blot analysis. 
B) Addition of wt GST-CypA (1 µM) did not increase the rate at which refolding and auto-
proteolysis occurs. Control (0.75% DMSO) refolding reaction complete by 3 h, GST-CypA treated 
refolding reaction complete by 3 h. Quantified NS3-FLAG is indicated by the arrowhead. 
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3.2.3.3 Analysis of NS2-dependent anti-HCV activity of Hsp90 inhibitors 
In addition to observations linking CypA to the folding of NS2, the cellular chaperone Heat-
shock protein 90 (Hsp90) has been implicated. An interaction of Hsp90 with NS2-3 in vitro has 
been demonstrated and the same system showed activity for the Hsp90 inhibitors 
geldanamycin and radicicol against NS2-NS3 processing in vitro. Subsequently these Hsp90 
inhibitors were reported to block NS2-mediated proteolysis in a cell-based system with EC50 
values in the nM range (Waxman et al., 2001). However, this system used NS2 proteolysis to 
stabilise a reporter in Jurkat cells, hence this system does not reveal whether Hsp90 is required 
for NS2 function in hepatoma cells or whether Hsp90 inhibitors display activity against NS2-
dependent HCV replication. 
To explore the potential for Hsp90 inhibitors to serve as a positive control for inhibition of NS2-
containing SGRs two Hsp90 inhibitors; radicicol and geldanamycin, were tested for anti-viral 
activity against SGR-feo-JFH1 [NS3-5B] and SGR-feo-JFH1 [NS2-5B] stable cell lines alongside 
toxicity analysis. As shown in Figure 3.22, both compounds showed significant cytotoxicity 
which matched luciferase activity. This toxicity precluded the observation of any anti-viral 
effect. A dose response treatment with radicicol yielded a CC50 of 695.4 nM, with similar EC50 
values calculated from luciferase activity demonstrating that the reduction of genome 
replication correlates with toxic effects on the cells (Figure 3.22A). A geldanamycin dose 
response curve produced a CC50 of roughly 74 nM, with the high degree of toxicity observed 
preventing accurate calculation of EC50 values from luciferase activity within this concentration 
range. Despite this the luciferase activity again appears to match the levels of cellular 
metabolism for all concentration points indicating effects are not anti-viral.  
The high degree of toxicity observed with Hsp90 inhibitors in Huh7.5 cells therefore does not 
allow any anti-viral effect to be examined and prevents their use as a positive control in SGR-
based assays. 
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Figure 3.22: Anti-viral effect of Hsp90 inhibitors.  
A) SGR-feo-JFH1 [NS3-5B] and SGR-feo-JFH1 [NS2-5B] were treated with a range of Radicicol 
concentrations before quantifying luciferase activity alongside toxicity analysis. Significant 
cytotoxicity was observed, with a CC50 of 695.4 nM, preventing the analysis of anti-viral effects 
specific for NS2. B) Identical experiment as in A) with Geldanamycin. Geldanamycin also shows 
significant toxicity to the extent that EC50 curves could not be accurately fitted within the tested 
concentration range. 
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3.3 Discussion 
3.3.1 NS2-3 in vitro refolding as an assay for NS2-mediated proteolysis 
Results in Section 3.2.1 describe the optimisation of a method of refolding a bacterially 
expressed, purified NS2-3 precursor for efficient processing at the NS2-NS3 boundary by the 
NS2 autoprotease. NS2-mediated autoproteolysis could be monitored through quantitative 
western blot analysis (Schutz-Geshwender, 2004) by detection of the NS3 proteolysis product 
via the FLAG tag. This refolding reaction as a measure of autoprotease activity can tolerate 
suitable levels of DMSO as a vector for the screening of compounds and can be performed 
over 4-16 hours. Positive controls for inhibition of autoproteolysis, as measured through 
prevention of NS3-FLAG production, are available by disruption of the NS2-NS3 protein fold 
with zinc chelators, through alkylation of thiol groups with TPCK and by comparison to 
refolding reactions terminated before refolding is allowed to occur (0h). HCV DAAs targeting 
the alternative non-structural protein NS5A serve as a negative control, with no effect on NS2 
autoproteolysis at concentrations active in cell culture models. An optimal signal to noise ratio 
from this assay is achieved with the JFH1 isolate of NS2-3, with sufficient signal to accurately fit 
a non-linear regression for the calculation of EC50 values demonstrated by a dose-response 
treatment with TPCK (Figure 3.9). The ability to fit EC50 models allows direct comparison of 
activity against the NS2 autoprotease for ranking of compounds during screening and for 
structure activity relationship (SAR) analysis of hit compounds. 
Due to the western blot readout of the assay, the NS2-3 refolding assay is not amenable to HTS 
and is technically demanding. It does however offer a sensitive assay for assessing activity 
directly against the NS2 autoprotease in an in vitro setting in the absence of potential off-
target effects. Additionally, the reasonably high tolerability for DMSO should allow screening 
of compounds at high concentrations.  
3.3.2 SGR-feo stable cell lines as an assay for NS2-dependent HCV replication amenable to 
HTS. 
The selection of SGR-feo [NS2-5B] produces stable cell lines with luciferase activity levels 
comparable to SGR-feo [NS3-5B] cell lines. The elevated luciferase from these stable cell lines 
can be at least partially attributed to the use of the more permissive Huh7.5 cell line, but may 
also be influenced by constitutive autonomous replication overcoming a more pronounced 
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rate-limiting effect of NS2-NS3 processing at early stages in the establishment of replication. 
SGR-feo [NS2-5B] cell lines produce mature NS2 and contain no culture adapted mutations 
following selection indicating a normal requirement for processing at the NS2-NS3 junction to 
allow replication. 
SGR-feo [NS2-5B] stable cell lines offer a robust, sensitive cell-based assay to screen for 
inhibitors of NS2-dependent replication. Moreover, the nature of the NS2 autoprotease offers 
a unique opportunity in terms of a selective cell-based screen. As replication only requires the 
NS2 autoprotease in the presence of an NS2-NS3 precursor in the polyprotein, SGRs spanning 
NS2-5B and NS3-5B are both replication-competent. Therefore SGR constructs that differ only 
by the presence or absence of NS2 provide one construct (SGR [NS2-5B]) dependent on the 
NS2 autoprotease for replication, and another (SGR [NS3-5B]) which can replicate 
independently of NS2 autoprotease activity. As such if a compound were to block the NS2 
autoprotease and exert an inhibitory effect, this effect should only be seen in the NS2-
containing SGR, and not in the corresponding SGR comprising NS3-5B. The NS3-5B SGR 
therefore provides a useful counter-screen with which to rule out false positives that are 
cytotoxic, that inhibit alternate viral functions required for replication and even that act 
against the luciferase reporter. Any compound reducing luciferase from the SGR [NS2-5B] but 
not the SGR [NS3-5B] would be expected to exert its action through the NS2 protein. The fact 
that as stable cell lines these SGRs have comparable luciferase signal should allow for reliable 
interpretation of results from screening against both in parallel. 
3.3.3 Effects of chaperone inhibitors on the NS2 autoprotease 
Unfortunately no suitable positive control could be identified to selectively inhibit a SGR 
comprising NS2-5B. Despite previous reports suggesting Hsp90 inhibitors could potently block 
NS2-NS3 processing in a cell-culture based system, in Huh7.5 cells the inhibitors geldanamycin 
and radicicol show potent cytotoxicity with no additional anti-viral effect. While the cell-based 
assay in Jurkat cells described by Waxman et al. did not describe any counter-measures for 
false positives due to cytotoxicity, it is possible that these compounds have considerably 
different toxicity profiles within Huh7.5 cells and Jurkat cells. 
An alternative option was to use the increased CsA sensitivity previously reported with NS2-
containing SGRs (Ciesek et al., 2009). However, while this effect could be reproduced in a 
transient system in Huh7.5 cells, the same shift in sensitivity was not observed between SGR-
feo [NS2-5B] and SGR-feo [NS3-5B] stable cell lines. Upon further analysis, the shift in CsA 
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sensitivity when the SGR includes NS2 appeared specific to transient electroporations in 
Huh7.5 cells and was not observed in Huh7 cells. In line with this all previous experiments 
reporting this effect have been performed in cleared SGR Huh7 cell lines similar to Huh7.5 cells 
(Ciesek et al., 2009, Kaul et al., 2009) (Lohmann,  pers  comm). 
Analysis of calculated EC50 values offers further insight into the cause of this effect. If the 
comparable CsA EC50 values in Huh7 cells for SGRs containing NS3-5B and NS2-5B is taken as 
the ‘normal’ CsA sensitivity, then in a Huh7.5 system, the EC50 of the NS3-5B SGR appears to 
have the greatest shift in sensitivity. While the CsA EC50 in Huh7 cells is 219.3 ± 8 nM (n=2; 
Figure 3.18B), the CsA EC50 of a SGR containing NS3-5B in Huh7.5 cells is 522.4 ± 58 nM (n=2; 
Figure 3.16A and Figure 3.18A), a 2.4-fold shift in sensitivity. 
This effect could be due to the rapid replication kinetics of a SGR derived from JFH1 that 
comprises NS3-5B. Such SGRs replicate very well in Huh7 cells. Replication kinetics by 
luciferase activity in Huh7.5 cells do not appear to be enhanced any further for these 
constructs (Figure 3.17), though it is possible these systems are saturated. SGR-JFH1 [NS3-5B] 
may be unique in that its replication cycle is limited only by the availability of essential cellular 
co-factors. As such when a proportion of HCV replication is inhibited by an antagonist, it may 
free essential host factors which can facilitate the formation of new RCs using additional NS 
proteins which would otherwise be redundant. A greater concentration of antagonist would 
therefore be required to exert an anti-viral effect. It is important to note that in the context of 
differential CsA sensitivity this ‘rate-limiting’ host factor is not proposed to be CypA but could 
be one of a number of other host factors known to be important for formation of the RC, such 
as the lipid kinase PI4K-α, endosomal Rab proteins or a member of the VAP family of proteins 
involved in vesicular trafficking, amongst others (Berger and Randall, 2009). 
In effect, NS3-5B SGRs derived from JFH1 may replicate better in Huh7.5 cells than Huh7 cells, 
but the saturation of a cellular host factor(s) may mask this effect in a 48 hour luciferase 
timepoint, as the SGR essentially already replicates to the maximal level permitted by the 
essential host co-factor(s). This effect is therefore only observed when replication is inhibited 
pharmacologically, wherein inhibiting replication only serves to free the co-factor(s) which can 
contribute to new RCs. As such a greater concentration of antagonist is required to block 
replication, and hence the SGR is less sensitive to inhibition. This effect is linked to replication 
kinetics, but only to the remarkable replication kinetics of a SGR comprising NS3-5B derived 
from JFH1. Replication kinetics of JFH1 replicons containing NS3-5B may be reduced in Huh7 
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cells relative to Huh7.5 cells (though the saturation of host factors limits replication in Huh7.5 
cells and masks this effect). As SGRs derived from genotype 1b isolates have reduced 
replication kinetics in Huh7.5 cells the rate-limiting factor for replication is virally-encoded 
instead of host-factor derived, hence no shift in CsA sensitivity is observed. 
Evidence for such an effect has recently been reported. Madan et al. recently demonstrated 
that an NS2-mediated shift in CsA sensitivity is not observed for SGRs derived from a genotype 
1b isolate, as observed in this study (Madan et al., 2014). They also reported observing no shift 
in CsA sensitivity between SGRs comprising NS3-5B and NS2-5B which contained mutations in 
NS4B impairing the fitness of the SGR, despite all these experiments being performed in 
cleared SGR-cell lines. This evidence led to the conclusion that SGRs dependent on NS2-NS3 
processing are more sensitive to CsA inhibition as the NS2 autoprotease reaction provides a 
rate-limiting step for replication of JFH1-derived SGRs (Madan et al., 2014). The data presented 
herein suggest a modified hypothesis, wherein a JFH1 SGR dependent on NS2-NS3 processing 
represents the ‘normal’ sensitivity to CsA. The effect observed is in fact a reduced sensitivity to 
CsA for SGRs lacking a virally encoded rate-limiting step (such as NS2-mediated processing or 
an alternative rate-limiting mutation) as in these cases replication is subject to a host-factor 
derived rate-limiting step. Assuming replication is only limited by the availability of host 
factors, in order to observe an actual reduction in replicative capacity an antagonist must first 
reduce the number of RCs to a point where host factor saturation does not occur. Such an 
effect would be observed through any pharmalogical inhibition of genome replication in this 
‘replication-saturated’ state. In agreement, Madan et al. reported a correlation between 
replication kinetics of SGRs and sensitivity to NS5A inhibitors and NI NS5B inhibitors. This 
effect may be easier to further study through the comparative use of Huh7 and Huh7.5 cells as 
in this study, though previous analysis of sensitivity to an NS5A inhibitor using SGR-luc-JFH1 
[NS2-5B] and SGR-luc-JFH1 [NS3-5B] in Huh7.5 cells suggested only a slight shift in sensitivity 
(Figure 3.8A). While Madan et al. suggested replication kinetics may be a useful determinant 
for the success of therapies with these compounds, the fact that the effect is specific to the 
JFH1 isolate, derived from a case of fulminant hepatitis, means that these findings may only be 
relevant in the rare cases of HCV causing fulminant hepatitis. 
An alternative theory involves an effect on the cellular immune response. While overwhelming 
evidence confirms that CypA antagonists do not exert their anti-viral effect through the 
immunosuppressive effect of mediating a CypA-CsA-calcineurin interaction (Paeshuyse et al., 
2006) (such an interaction blocks the phosphatase activity of calcineurin which would 
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otherwise mediate transcription of ISGs), recent evidence has linked CsA effects to immune 
responses in a different manner. CypA is now thought to form a double-stranded RNA (dsRNA) 
dependent interaction with protein kinase R (PKR) (Daito et al., 2014). Such a binding event 
leads to PKR phosphorylation, ultimately resulting in a block in translation of ISGs. CypA 
antagonists have been shown to prevent CypA-PKR interaction in the presence of dsRNA and 
as a consequence of alleviating a block on translation, upregulate the levels of ISG-encoded 
proteins (Daito et al., 2014). If CsA and other CypA antagonists can influence levels of ISG 
product translation, then altered levels of ISG transcription due to defective RIG-I in Huh7.5 
cells could further influence how CsA affects a host immune response.  How this effect might 
be mediated through the NS2 protein or the presence of the NS2 gene in the SGR RNA and 
why it is specific to the JFH1 isolate remains a mystery, and gaining a complete understanding 
of any potential effect would prove difficult due to the extensive feedback systems inherent in 
immune response pathways. 
In either case significant evidence now demonstrates that the mechanism of action of CsA is 
not directly linked to the NS2 autoprotease activity. In agreement with this, data presented in 
Section 3.2.3.2 demonstrated that bacterially purified GST-CypA has no effect on the folding of 
NS2-3 in vitro. Other groups have reported similar findings, with no interaction of NS2 and 
CypA observed in cell culture (Madan et al., 2014). The same group failed to identify resistance 
to CsA within the NS2 coding sequence and noted that the presence of NS2 did not affect the 
ability of an NS5A encoded resistance mutation to impart CsA resistance. Both findings were 
replicated within the course of this study. 
It therefore seems unlikely that CypA is required for correct folding of the NS2 autoprotease 
and hence CypA antagonists exert no specific anti-NS2 effect. 
Despite failing to identify a positive control for specific inhibition of NS2-dependent 
replication, the use of SGR-feo-[NS2-5B] and SGR-feo-[NS3-5B] stable cell lines in parallel 
should aid identification of a small molecule inhibitor of the NS2 autoprotease. This cell-based 
screening assay can be complemented with the in vitro NS2-3 refolding assay to directly assess 
effects of a compound against NS2-mediated proteolysis. 
 
 
Chapter 4 – Identification of small molecule inhibitors of the NS2 autoprotease 
 
 
127 
 
 
 
 
 
 
 
 
Chapter 4 - Identification of small 
molecule inhibitors of the NS2 
autoprotease 
  
Chapter 4 – Identification of small molecule inhibitors of the NS2 autoprotease 
 
 
128 
 
4.1 Introduction 
A common route to developing a protease inhibitor is the use of a mechanism-based inhibitor 
which produces a covalent interaction with the catalytic residues through a reactive 
electrophilic unit often referred to as a ‘chemical warhead’ (Powers et al., 2002). Such an 
approach was used in the development of NS3 protease inhibitors, with the inhibitory activity 
of proteolysis peptides enhanced by conjugating reactive α-ketoamides (Han et al., 2000). 
Similar methods have not proven as successful for the HCV NS2 autoprotease. While NS2 
mediated proteolysis can be inhibited in vitro by reactive halomethyl ketones, such as TPCK, 
less reactive mechanism-based protease inhibitors have not shown any activity (Table 1.2). An 
example of one such protease inhibitor is E64, a covalent cysteine protease inhibitor based 
around an epoxide warhead conjugated to a peptide derived backbone (Figure 4.1C). Despite 
relatively broad activity against cysteine proteases, E64 shows no activity against the NS2 
autoprotease (Figure 4.1) (Pieroni et al., 1997, Thibeault et al., 2001). Epoxysuccinyl peptides 
such as E64 are considered less reactive than more crude alkylating agents such as halomethyl 
ketones, as the rate limiting step of inhibition is the binding of the compound to the active site 
cavity in a non-covalent manner. A transient interaction is usually mediated by hydrogen bond 
interactions with S sites (each S site refers to a region of the active site occupied by the 
corresponding P residue of the substrate peptide sequence, as depicted in Figure 4.8). This 
transient interaction is required for correct orientation of the epoxide near the catalytic thiol 
before opening of the epoxide to form a covalent interaction, a process which, similar to 
peptide bond hydrolysis, is energetically favourable but kinetically slow (Bihovsky et al., 1993, 
Powers et al., 2002). This affords covalent inhibitors based around an epoxide warhead a 
higher degree of specificity, such that E64 is active against a wide range of cysteine proteases 
but inactive against all serine, aspartic- or metalloproteases.  
The key determinant of the interaction is the peptide-like backbone binding to S sites before 
any covalent complex is formed. As such, this peptide sequence can be further tailored to 
make epoxysuccinate peptide derivatives with enhanced specificity for certain cysteine 
proteases (Powers et al., 2002, Schiefer et al., 2013). A common starting point for design of 
mechanism-based inhibitors is therefore a suitable substrate peptide. However, a range of NS2 
substrate peptides exert little or no inhibition on the NS2 autoprotease (Table 1.2) (Pallaoro et 
al., 2001, Thibeault et al., 2001) and the conjugation of mechanism-based inhibitors to 
substrate peptides also failed to yield an inhibitor of the NS2 autoprotease (Pallaoro et al., 
2001). 
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The first section of this chapter (4.2.1) describes an examination of epoxide based warheads 
not conjugated to NS2 substrate peptides. Substrate peptide sequences seem unable to bind 
with high affinity into the NS2 active site, as evidenced by the lack of any potent inhibitory 
effect, so alternative backbone scaffolds were tested for their ability to allow an epoxide 
warhead to occupy the active site of NS2 and exert an inhibitory effect. A range of bis-amido 
epoxide compounds with functionalised aromatic groups were tested for the ability to block 
NS2-NS3 autoproteolysis in vitro. These compounds were designed and synthesised at the 
University of Leeds (Craig Avery, PhD Thesis) and show nM activity in vitro against an 
alternative cysteine containing system, factor XIIIa. Additionally, compounds from this series 
do not interact with free thiol agents in the form of up to 10 mM glutathione and exerted no 
activity up to 100 µM against an alternative cysteine protease Cathepsin S (Craig Avery, PhD 
Thesis). This selectivity against factox XIIIa suggests that selectivity to the NS2 autoprotease 
could be achieved.  
While the use of an epoxide as a less reactive electrophilic warhead amenable to a greater 
degree of selectivity overcomes many of the pitfalls associated with covalent inhibitors, the 
majority of drug discovery programmes still aim to identify non-covalent, reversible inhibitors 
of their target. Primarily this is due to safety concerns surrounding covalent inhibitors due to 
off-target effects made more likely by the inherent reactivity of the molecules (Singh et al., 
2011). Such a preference is evidenced by the progression of HCV NS3 protease inhibitors from 
reversible covalent inhibitors to non-covalent 2nd generation protease inhibitors. Identification 
of a more drug-like non-covalent inhibitor of the NS2 autoprotease requires screening of small 
molecule libraries. 
As described in Section 1.9, hit rates for screening programmes can be enriched through 
CADD. As structural information is available for the post-cleaved form of the NS2 
autoprotease, structure-guided CADD was applied to create an in silico enriched library for 
biological testing. Such an approach is particularly necessary for testing against the in vitro 
NS2-3 refolding assay described in Section 3.2.1 as this assay is not amenable to HTS, limiting 
the number of compounds that can be screened. Section 4.2.2 describes the application of 
structure-guided CADD and vHTS to a model of the NS2 protease using the aforementioned 
crystal structure so as to enrich a relatively small library with molecules predicted to be 
capable of forming favourable interactions with the NS2 active site. 
The use of a more manageable screening library allows compounds to be tested against both 
the in vitro NS2-3 refolding assay, to determine ability to block NS2-mediated proteolysis, and 
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the cell-based assay using stable SGR cell lines, to test for specific effects against HCV genome 
replication which is dependent on the activity of the NS2 autoprotease. Section 4.2.3 concerns 
the biological testing of the in silico enriched library described in 4.2.2 and the use of these 
two independent screening assays to eliminate false positives and identify a more lead-like 
small molecule inhibitor of the NS2 autoprotease. 
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4.2 Results 
4.2.1 Epoxide based inhibitors of the NS2 autoprotease 
As demonstrated in Section 3.2.1, the NS2 autoprotease can be inhibited in vitro by halomethyl 
ketone alkylating agents such as TPCK (Figure 3.9). However, such reactive alkylating agents 
offer little scope for specificity and consequently TPCK shows off-target effects in cell culture in 
the form of cytotoxicity (Figure 3.9C). By contrast, less reactive alkylating agents such as the 
epoxysuccinate cysteine protease inhibitor E64 exert no activity against the NS2 autoprotease 
(Figure 4.1) (Pieroni et al., 1997, Thibeault et al., 2001). However, E64 is based around a 
peptide-mimetic backbone. Previous observations have shown only weak or undetectable 
inhibitory activity of substrate peptides against NS2-mediated proteolysis, indicative that the 
NS2 autoprotease may not be sensitive to the binding of peptides in trans.  
 
 
 
Figure 4.1: The NS2 autoprotease is not sensitive to E64.  
A) JFH1 NS2-3 refolding reactions halted immediately or allowed to proceed in the absence or 
presence of E64 (300 µM). Reactions were analysed by western blot using αFLAG antibody. B) 
Quantification of NS2-3-FLAG and NS3-FLAG bands from refolding reactions allowed to proceed 
in A. C) Structure of E64. 
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To explore the use of an epoxide warhead conjugated to alternative scaffolds as a mechanism-
based inhibitor of the NS2 autoprotease, NS2-3 refolding reactions were treated with a range 
of concentrations of bis-amido epoxides conjugated to simple or functionalised aromatic rings. 
Reactions were treated with a range of concentrations of each epoxide based compound 
numbered 1-12 (Table 4.1) and analysed by western blot for levels of NS3-FLAG (Figure 4.2). 
Dose response curves were plotted to allow calculation of EC50 values (Table 4.1). Several of 
the epoxide based compounds appeared to show activity against NS2-NS3 autoproteolysis in 
vitro. Initial testing identified compound 1, which blocks production of the NS3-FLAG 
proteolysis product in a dose responsive manner (Figure 4.2, Figure 4.4A). Quantification of 
NS3-FLAG from two separate experiments yielded an EC50 of 91.6 ± 1.6 µM. To explore 
whether compound 1 exerted a pan-genotype effect against the NS2 autoprotease, identical 
concentrations were tested against the J4 NS2-3 refolding reaction. Again, compound 1 
showed a dose responsive effect with an EC50 of 79 µM (Figure 4.4B). Of interest, in the 
absence of the 3-chloro group of the benzene ring (2) activity was abolished up to 300 µM 
(Table 4.1, Figure 4.2) 
Along with removal of the 3-chloro substituent from the benzene (2), introduction of 3, 4-
dimethyl groups (5) reduced activity to below tested levels. The presence of a 4-bromo 
substituent reduced activity (3) as did a 3-chloro, 4-bromo substituted group (4).  
Compounds 7 and 8, with a 4-amino-phenyloxy or 4-nitro-phenyloxy substituent respectively, 
showed some activity but to a lesser extent to that shown by 1, though a 3-phenyloxy 
substituent did enhance activity (6). A larger substituent containing a N-Boc protected 
piperidinileoxy at the 4-position and a 3-chloro substituent (10) showed similar activity to that 
shown by 1. 
The most potent inhibitor was a 4-benzyloxy, 3-chloro substituted system (9) yielding an EC50 
of 55 µM. A bulky sulphonamide-based side chain at the para position (11) had reduced 
activity relative to 1, though in the absence of a 3-chloro substituent further SAR is required to 
determine the precise effect of this bulky sidechain. Integrity of all compounds in Table 4.1 
was confirmed by mass spectrometry (Appendix I). 
The observation that activity varies between the different epoxide based compounds 
suggested that features other than the epoxide warhead alone are required for activity against 
the NS2 autoprotease. Additional contacts formed between the R1 group of this range of 
compounds could facilitate binding to NS2-3 in a favourable conformation to allow opening of 
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the epoxide by the catalytic thiol to form a covalent interaction. In agreement with this the 
epoxide warhead alone (12) showed no activity against autoproteolysis when R1 was a primary 
alcohol (Table 4.1,Figure 4.2). It was also noted that the natural product cerulenin, based 
around a similar epoxide warhead with an extended hydrocarbon chain, showed no activity 
against NS2-3 autoproteolysis (Figure 4.5A). 
In addition to greater specificity than other alkylating agents such as TPCK, epoxide warhead 
based inhibitors have been shown to exhibit stability under physiological conditions and show 
little reactivity to free thiols, an observation previously made for the current range of 
compounds (Craig Avery, PhD Thesis). As such epoxide based protease inhibitors have more 
pharmaceutical applications than other mechanism-based inhibitors (Powers et al., 2002). 
In order to test whether epoxide based inhibitors of the NS2 autoprotease could mediate an 
effect against NS2-dependent HCV genome replication, it was first necessary to confirm they 
were not cytotoxic within the concentration ranges active in vitro. The most potent 
compounds had an EC50 < 100 µM against NS2-3 (1, 6, 7, 9 and 10). Compounds 1-12 were 
therefore analysed for toxicity up to 100 µM. Huh7 cells were treated with a range of 
concentrations from 1 nM to 100 µM and after 72 hours cellular metabolism was quantified by 
MTT assay (Figure 4.3) and data plotted to calculate CC50 (Table 4.1). Compounds 1-12 showed 
a range of toxicity profiles, with no correlation to in vitro activity against NS2-3. 
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Table 4.1: Activity and toxicity analysis of epoxide based inhibitors of the NS2 autoprotease. 
EC50 against JFH1 NS2-3 refolding reaction is calculated from data in Figure 4.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound # R1 NS2-3 refolding 
EC50 (µM) 
Huh7 CC50 
(µM) 
 
1 
 
 
93 
 
>100 
 
2 
 
 
>300 
 
>100 
 
3 
 
 
>200 
 
17 
 
4 
 
 
>200 
 
2 
 
5 
 
 
>300 
 
>100 
 
6 
 
 
70 
 
42 
 
7 
 
 
96 
 
>100 
 
8 
 
 
119 
 
62 
 
 
9 
 
 
 
55 
 
 
12.6 
 
10 
 
 
98.5 
 
>100 
 
 
11 
 
 
 
>200 
 
 
>100 
12  >300 >100 
cerulenin  >300 31.9 
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Figure 4.2: Activity of epoxide based compounds on in vitro NS2 autoprotease activity 
Refolding reactions treated with indicated concentrations of compounds 1-12 and analysed by 
western blot. Quantified NS3-FLAG is indicated by the arrowhead. Calculated EC50 values are 
reported in Table 4.1. 
 
0 1
.7
3 5
.4
9
.5
1
7
3
0
5
4
9
5
1
7
0
3
0
0
D
M
SO
0
 h
[1] µM
0 1
.7
3 5
.4
9
.5
1
7
3
0
5
4
9
5
1
7
0
3
0
0
D
M
SO
0
 h
[2] µM
0 1
.7
3 5
.4
9
.5
1
7
3
0
5
4
9
5
1
7
0
3
0
0
D
M
SO
0
 h
[3] µM
0 1
.7
3 5
.4
9
.5
1
7
3
0
5
4
9
5
1
7
0
3
0
0
D
M
SO
0
 h
[4] µM
0 1
.7
3 5
.4
9
.5
1
7
3
0
5
4
9
5
1
7
0
3
0
0
D
M
SO
0
 h
[5] µM
0 1
.7
3 5
.4
9
.5
1
7
3
0
5
4
9
5
1
7
0
3
0
0
D
M
SO
0
 h
[6] µM
0 1
.7
3 5
.4
9
.5
1
7
3
0
5
4
9
5
1
7
0
3
0
0
D
M
SO
0
 h
[7] µM
0 1
.7
3 5
.4
9
.5
1
7
3
0
5
4
9
5
1
7
0
3
0
0
D
M
SO
0
 h
[8] µM
0 1
.7
3 5
.4
9
.5
1
7
3
0
5
4
9
5
1
7
0
3
0
0
D
M
SO
0
 h
[9] µM
0 1
.7
3 5
.4
9
.5
1
7
3
0
5
4
9
5
1
7
0
3
0
0
D
M
SO
0
 h
[10] µM
0 1
.7
3 5
.4
9
.5
1
7
3
0
5
4
9
5
1
7
0
3
0
0
D
M
SO
0
 h
[12] µM
0 1
.7
3 5
.4
9
.5
1
7
3
0
5
4
9
5
1
7
0
3
0
0
D
M
SO
0
 h
[11] µM
Chapter 4 – Identification of small molecule inhibitors of the NS2 autoprotease 
 
 
136 
 
 
Figure 4.3: Cytotoxicity analysis of epoxide based compounds.  
Huh7 cells were treated with indicated concentrations of compounds 1-12 for 72 hours before 
monitoring cellular metabolism by MTT assay. Data is normalised to DMSO control (plotted as 
10-3.5 µM), n=2. Calculated CC50 values are reported in Table 4.1.  
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Figure 4.4: Pan-genotype activity of an epoxide warhead against the NS2 autoprotease.  
A) Top; JFH1 NS2-3 refolding reaction treated with indicated concentrations of an epoxide 
warhead (1) and analysed by western blot. Bottom; Quantification of NS3-FLAG (arrowhead) 
for calculation of EC50 = 92 µM. B) Identical experiment as in A) using J4 NS2-3, EC50 = 79 µM.  
 
 
 
Figure 4.5: Effect of cerulenin on the NS2 autoprotease and cytotoxicity analysis.  
A) Indicated concentrations of the natural product cerulenin tested in the JFH1 NS2-3 refolding 
assay and analysed by western blot. Quantified NS3-FLAG is indicated by the arrowhead. 
Calculated EC50 is reported in Table 4.1. B) Huh7 cells treated with indicated concentrations of 
cerulenin for 72 hours for toxicity analysis. Calculated CC50 is shown in Table 4.1. 
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Of the compounds showing activity in vitro only 1, 7 and 10 lacked significant toxic effects on 
Huh7 cells up to 100 µM. Of these, compound 1 showed the greatest activity in vitro. 
Additionally, the lack of toxicity observed with compound 2, which differs from 1 by a single 
atom, a 3-chloro group on the benzene ring, allowed for a comparative negative control as 2 
showed no activity against the NS2-3 refolding reaction. 
Compounds 1 and 2 were therefore tested against the SGR-feo-JFH1 [NS2-5B] cell line 
described in Section 3.2.2 at approximately the in vitro EC50; 90 µM. To explore whether any 
potential effects were mediated against NS2, compounds were tested in parallel against SGR-
feo-JFH1 [NS3-5B]. In all cases the luciferase signal after 48 hours was compared to analysis of 
cellular metabolism in the same cell lines. As a positive control, and to ensure similar 
sensitivity to DAA mediated inhibition between the two cell lines, both were treated with the 
NS3 protease inhibitor Telaprevir at an EC50 concentration; 150 nM. 
Addition of compound 1 (90 µM) to SGR-feo-JFH1 [NS2-5B] gave a significant decrease in 
luciferase activity to 48.1 ± 10.7% of DMSO control (Figure 4.6A), while analysis by MTT assay 
demonstrated no significant effect on levels of cellular metabolism (Figure 4.6B). In contrast, 
addition of compound 2 (90 µM), which lacks activity in vitro, had no effect on either luciferase 
activity from SGR-feo-JFH1 [NS2-5B] or the degree of cellular metabolism (Figure 4.6). 
Furthermore, the same treatment of SGR-feo-JFH1 [NS3-5B] did not significantly impact 
luciferase activity after treatment with compound 1 or compound 2. A slight decrease in the 
mean luciferase signal (which was not statistically significant) after treatment with compound 
1 correlates with a small reduction in levels of cellular metabolism (Figure 4.6). Addition of 
Telaprevir (150 nM) produced a similar effect in both cell lines. SGR-feo-JFH1 [NS2-5B] 
luciferase activity was reduced to 53.1 ± 3.6% of DMSO control and SGR-feo-JFH1 [NS3-5B] 
luciferase activity was reduced to 54.9 ± 5.7% of DMSO control. Cellular metabolism of both 
cell lines upon Telaprevir treatment was unaffected (Figure 4.6). 
Compound 1 therefore appears to block NS2-NS3 processing in vitro and inhibit NS2-
dependent genome replication in cell culture at similar concentrations. The reduced luciferase 
activity upon treatment of SGR-feo-JFH1 [NS2-5B] with 1 is not related to any effects on 
cellular metabolism and appears specific to a SGR where genome replication is dependent on 
the NS2 autoprotease, as no significant decrease in luciferase activity is observed upon 
treatment of SGR-feo-JFH1 [NS3-5B] with 1. Hence compound 1 appears inactive against a SGR 
that can replicate independently of NS2 autoprotease activity. Both SGR containing cell lines 
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show comparable sensitivity to Telaprevir suggesting this effect is not a consequence of 
different replication kinetics or response to DAA treatment. 
Furthermore, compound 2, which lacks only a 3-chloro group on the benzene ring, was inactive 
against NS2-mediated proteolysis in vitro up to 300 µM. A similar trend was observed in this 
cell based assay. Addition of compound 2 (90 µM) had no effect on the luciferase signal from 
either SGR-feo-JFH1 [NS2-5B] or SGR-feo-JFH1 [NS3-5B].  
 
 
Figure 4.6: Effect of epoxide based compounds 1 and 2 on HCV genome replication.  
A) Treatment of SGR-feo-JFH1 [NS2-5B] and SGR-feo-JFH1 [NS3-5B] with compound 1 (90 µM) 
and compound 2 (90 µM) for 48 hours. Luciferase activity is normalised to DMSO control. 
Values and error bars represent the mean and standard deviation of two independent 
experiments performed in triplicate.  Telaprevir (150 nM) was used as a control (one 
experiment, n=3). B) Toxicity analysis by MTT assay from the same experiments as in A. 
Statistical significance was determined by unpaired Student’s t test (*p < 0.02, **p < 0.0001). 
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In vitro analysis of the activity of compound 1 against the NS2 autoprotease indicated 
increased potency against genotype 1b (J4 NS2-3). To test for a similar trend against genome 
replication, compound 1 (90 µM) was added to both SGR-feo-JFH1 [NS2-5B] and a genotype 1b 
SGR cell line; SGR-feo-Con1 [NS2-5B], for 48 hours. The inactive compound 2 was included at 
the same concentration as a control. As previously observed (Figure 4.6), treatment with 
compound 1 reduced luciferase activity from SGR-feo-JFH1 [NS2-5B] to 52.2 ± 10.3% of DMSO 
control with a marginal effect on cellular metabolism. By contrast, addition of compound 1 to 
SGR-feo-Con1 [NS2-5B] reduced luciferase to 6.0 ± 1.0% of the signal from DMSO control. In 
both cases, the inactive compound 2 did not reduce luciferase signal. These findings suggest 
that, in line with in vitro observations, compound 1 appears more potent against NS2 
mediated proteolysis for genotype 1b than genotype 2a. Taken together these results indicate 
that a small molecule inhibitor of NS2 mediated proteolysis in vitro is capable of specifically 
blocking NS2-dependent HCV genome replication. 
 
 
Figure 4.7: Sensitivity of different genotypes to epoxide compounds 1 and 2.  
A) Treatment of SGR-feo-JFH1 [NS2-5B] and SGR-feo-Con1 [NS2-5B] with compound 1 (90 µM) 
for 48 hours. Luciferase activity is normalised to DMSO control. Values and error bars represent 
the mean and standard deviation of three independent experiments performed in triplicate.  
Compound 2 (90 µM) was used as a control (one experiment, n=3). B) Toxicity analysis by MTT 
assay from the same experiments as in A. Statistical significance was determined by unpaired 
Student’s t test (*p < 0.03, **p < 0.0001). 
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4.2.2 CADD to produce an in silico enriched screening library 
The observation that an epoxide-based compound which blocked NS2-mediated proteolysis in 
vitro inhibited NS2-dependent HCV genome replication suggested that the NS2 autoprotease 
represents a viable target for anti-virals. The screening assays described in Chapter 3 could 
therefore be applied to search for a more drug-like small molecule inhibitor of the NS2 
autoprotease. To attempt to enrich hit rates, structure-guided CADD was applied to the 
structural information available for the post-cleaved form of the NS2 protease C-terminal 
domain (NS2pro) (Lorenz et al., 2006). 
Structural coordinates for NS2pro were obtained from the protein data bank (PDB; 2HD0). 
Water molecules and buffer components such as detergents were removed manually using the 
Maestro interface (Schrodinger), as were additional subunits, leaving a single NS2pro 
homodimer. As described by Lorenz et al., the C-terminus of this structure represents the 
substrate sequence of the NS2 autoprotease, which is observed with P1 and P2 residues bound 
in the active site and postulated to exert an inhibitory effect. Therefore, to model an accessible 
active site, C-terminal residues were sequentially removed using the Maestro interface to yield 
the following NS2pro models; NS2proΔP1-P2, NS2proΔP1-P5 and NS2proΔP1-P10 (Figure 4.8A).  
Structure guided vHTS was performed on the above NS2pro models using the program eHITs 
with a structure file for residues P1 and P2 used to define the target cavity (S1 and S2). eHITs 
was performed using several virtual libraries, with optimal scoring obtained from the 
ChemBridge CORE virtual screening library. Therefore top-ranked compounds (as determined 
by eHITS) from the ChemBridge CORE collection were pooled as part of an in silico enriched 
library. 
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Figure 4.8: NS2pro models used for structure-guided vHTS.  
A) Structures of NS2pro models used for vHTS. Top left; NS2proΔP1-P2, Top right; NS2proΔP1-P5, 
Bottom left; NS2proΔP1-P10. Surface representation is shown with carbon atoms in green, 
oxygen atoms in red and nitrogen atoms in blue. Surface representation of removed substrate 
sequence residues are shown with yellow carbons. Bottom right; NS2proΔP1-P10 with S1, S2 and 
S’ sites indicated. B) SPROUT analysis of the S1 cavity of the NS2pro active site. Selected 
hydrogen bond donors are shown in red, selected hydrogen bond acceptors in blue and selected 
hydrophobic regions (HFOB) in green. 
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The in silico enriched library was also complemented with small molecules targeted to certain 
‘target sites’ using a combination of de novo design (SPROUT) and structural and chemical 
similarity searches (ROCS). Identification of key ‘target sites’ within the NS2pro active site 
focussed on the S1 site using the SPROUT program. The selected sites comprised two hydrogen 
bond donors; the backbone nitrogen of C184 and a H143 sidechain nitrogen. Both of these 
residues form part of the catalytic triad and comparison to other protease crystal structures 
suggested they occupy a physiologically relevant orientation in the NS2pro structure (Figure 
1.9), with the backbone nitrogen of C184 also postulated to contribute to the NS2 
autoprotease oxyanion hole. In addition, the C-terminal residue L217 of NS2pro is proposed to 
produce an inhibitory effect by sitting in the active site following proteolysis (Lorenz et al., 
2006). Within the NS2pro structure the carboxylate of L217 forms a hydrogen bond contact with 
the backbone nitrogen of C184 (Figure 1.8B). A hydrophobic pocket (HFOB) was also identified 
within the S1 site. In the NS2pro structure this site is occupied by the hydrophobic side chain of 
L217. Additionally, the backbone carboxylate of S194 was identified as a hydrogen bond 
acceptor. 
Appropriate ‘starting templates’ were docked to each target site using SPROUT before 
connecting with a variety of ‘spacer templates’ to produce numerous scaffolds. Relatively 
simple scaffolds making the required contacts were selected and the pose of these scaffolds 
were used as the input for a ROCS structural similarity search using a number of virtual 
libraries, to identify a pool of molecules predicted to be capable of forming some or all of the 
key contacts present in the initial scaffold. Optimal similarity scoring was also achieved with 
the ChemBridge CORE virtual library, unsurprising as this virtual library contains the highest 
number of molecules (> 5.2 x 105). 
Top ranked hits from the ChemBridge CORE screening library that scored well in either the 
eHITs vHTS, or in terms of structural similarity to SPROUT de novo designed molecule(s) (as 
determined by ROCS), were pooled into an in silico enriched library. This library was further 
pruned to remove molecules with unfavourable solubility characteristics (clogP > 5), to remove 
duplicates, to remove molecules with an unfavourable binding pose from vHTS docking and to 
maximise chemical diversity within the context of a library of around 200 molecules. The 
resulting in silico enriched library consisted of 213 compounds and was ordered as powder in 
96 well format from ChemBridge Corporation. Compounds were resuspended in DMSO solvent 
to a concentration of 40 mM for use in subsequent screening assays.  
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4.2.3 Screening for inhibitors of the NS2 autoprotease. 
The in silico enriched screening library described in Section 4.2.2 underwent biological testing 
against both in vitro NS2-NS3 processing and for the ability to specifically perturb NS2-
dependent HCV genome replication using the screening assays optimised in Chapter 3.  
Compounds were screened for the ability to block NS2-dependent HCV replication using the 
medium-high throughout cell based screening assay described in Section 3.2.2. This involved 
testing each compound in parallel against a SGR cell line dependent on the NS2 autoprotease 
(NS2-5B) and a negative control cell line capable of replication independent of NS2 
autoprotease activity and entirely lacking the NS2 coding region (NS3-5B). The epoxide based 
compounds described in Section 4.2.1 appear to inhibit the NS2 autoprotease with different 
genotypic sensitivity. Therefore, as the library of molecules to be screened had been enriched 
by vHTS against structural information of a genotype 1 isolate of the NS2 catalytic domain, the 
biological testing was performed against the genotype 1b SGR cell lines derived from the Con1 
isolate. To minimise the variability within the assay compounds were screened at 10 µM, 
allowing a final DMSO concentration of 0.025%. 
Most screening programmes produce a number of false positives. To strengthen the evidence 
in the event of identification of an inhibitor of the NS2 autoprotease, the in silico enriched 
library was also screened for the ability to block production of NS3-FLAG in the NS2-3 refolding 
assay. Due to the low throughput nature of the assay, each compound was tested at a single 
concentration. As this in vitro assay can tolerate reasonable levels of DMSO solvent, 
compounds could be screened at 100 µM (final DMSO 0.75%) in a 16 hour refolding reaction. 
Reactions were performed in batches of 12 compounds for comparative analysis by SDS-PAGE, 
with each batch of reactions including a 0 hour and DMSO only control.  Again, this screening 
was performed using a genotype 1b isolate to correlate both with the cell-based SGR assay and 
the crystal structure utilised for vHTS. 
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Figure 4.9: Screening of an in silico enriched library for inhibitors of the NS2 autoprotease. 
Representative data for compounds which had < 20% effect on luciferase signal from the 
control cell line (SGR-feo-Con1 [NS3-5B]). Luciferase activity from both cell lines is normalised 
to DMSO control (n=4). The normalised luciferase signal from both cell lines is plotted following 
a 72 hour treatment with each compound at 10 µM (n=1). Hits (*) were defined as exerting < 
10% effect against SGR-feo-Con1 [NS3-5B] while reducing SGR-feo-Con1 [NS2-5B] luciferase to 
< 85% of DMSO control (> 15% effect). Below, data for a 16 hour treatment of a J4 NS2-3 
refolding reaction with 100 µM of the same compound is shown. Reactions were resolved by 
SDS-PAGE and analysed by western blot using αFLAG antibody. Hits (*) were defined by a visual 
reduction or complete loss of NS3-FLAG (arrowhead).  
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Luciferase signal from SGR-feo-Con1 [NS2-5B] and SGR-feo-Con1 [NS3-5B] following parallel 
treatment with each compound was normalised to DMSO control for each plate, though 
luciferase signal was similar between the two cell lines. Average luciferase activity (± SD) from 
DMSO treated SGR-feo-Con1 [NS2-5B] was 8.35 x 105 ± 3.86 x 104 RLU, while luciferase activity 
from SGR-feo-Con1 [NS3-5B] was 8.31 x 105 ± 0.95 x 104. Compounds that reduced luciferase 
signal from the control SGR-feo-Con1 [NS3-5B] cell line to below 80% of DMSO control were 
excluded from analysis. A representative sample of data for the majority of the remaining 
compounds is shown in Figure 4.9. 
For analysis of cell based SGR screening data, a ‘hit’ was defined as any compound that did not 
reduce the SGR-feo-Con1 [NS3-5B] luciferase signal to < 90% of DMSO control but did reduce 
the SGR-feo-Con1 [NS2-5B] luciferase signal to < 85% of DMSO control (error within the DMSO 
control for the assay was 2.2 ± 2.0%). The in vitro NS2-3 autoproteolysis assay was monitored 
visually for loss or significant reduction of the NS3-FLAG proteolysis product band. Hits that 
meet the criteria for each assay are indicated in Figure 4.9 (*). 
Screening for specific effects against NS2-dependent HCV replication using the cell based SGR 
assay identified 17 hits that match the above criteria. 12 compounds were considered to have 
significantly affected NS2-mediated proteolysis in vitro. Of these compounds, 4 were identified 
as a hit in both the cell based SGR assay and the in vitro NS2 autoprotease assay; JS-64, JS-81, 
JS-90 and JS-160 (Figure 4.9). 
Compounds identified as a hit in the cell based SGR assay but not the in vitro assay most likely 
represent false positives. However, as the cell based assay will identify inhibitors of NS2-
dependent HCV genome replication, it was considered that these hits could inhibit NS2-
dependent replication without directly blocking the NS2 autoprotease. The most likely cause of 
this could be due to identification of an antagonist of a host factor essential for NS2-NS3 
proteolysis in cell culture. A subset of the best hits from the cell-based assay were therefore 
re-tested for a specific effect against NS2-dependent HCV replication. JS-43, JS-91 and JS-121 
were tested against both SGR-feo-Con1 [NS2-5B] and SGR-feo-Con1 [NS3-5B] for 72 hours at 
10 µM in duplicate (Figure 4.10A). These compounds failed to reproduce a specific reduction of 
luciferase from SGR-feo-Con1 [NS2-5B] and therefore most likely represent false positives. 
Similarly, hits from the in vitro NS2 autoprotease assay that do not impact on NS2-dependent 
replication could be false positives or could exert a true effect on the NS2 autoprotease but 
lack sufficient potency in cell culture at 10 µM. Inactivity in cell culture could include an 
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inability to cross the cell membrane or instability under cell culture conditions. Again, a subset 
of these molecules were re-tested against the J4 NS2-3 refolding assay at 100 µM, with JS-106 
and JS-137 most likely false positives due to subsequent inactivity (Figure 4.10B). 
Compounds identified as a hit in both screening assays were re-tested in the same manner. JS-
64, JS-81 and JS-90 all appeared inactive when re-tested against SGR-feo-Con1 [NS2-5B] and 
SGR-feo-Con1 [NS3-5B] in triplicate (10 µM). In contrast, a repeat of the SGR based assay with 
JS-160 in triplicate (10 µM) reproduced the initial cell-based screening data. JS-160 produced a 
significant decrease in luciferase activity from SGR-feo-Con1 [NS2-5B] to 67.6 ± 13.2% of DMSO 
control with no effect on SGR-feo-Con1 [NS3-5B] (98.8 ± 7.2% of DMSO control). 
Of the four compounds identified as a hit in both assays, JS-90 and JS-160 had the greatest 
effect on the in vitro NS2-3 refolding assay. J4 NS2-3 refolding reactions were treated with JS-
90 and JS-160 to validate these hits. Addition of JS-90 (100 µM) appeared to cause a slight 
reduction in levels of NS3-FLAG, though an additional repeat revealed no effect against NS2-
NS3 proteolysis. However, the activity of JS-160 against the in vitro NS2-3 autoprotease assay 
was reproducible. Addition of JS-160 (100 µM) to the J4 NS2-3 refolding reaction significantly 
reduced levels of NS3-FLAG from two technical repeats (Figure 4.10B).  
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Figure 4.10: Verification of screening ‘hits’.  
A) A subset of ‘hits’ from the cell based SGR screen from Figure 4.9 re-tested against SGR-feo-
Con1 [NS2-5B] and SGR-feo-Con1 [NS3-5B] for 72 hours at 10 µM. Luciferase activity is 
normalised to DMSO control. Statistical significance was determined by unpaired Student’s t 
test (* p < 0.006) B) A subset of ‘hits’ from the in vitro NS2-3 autoprotease assay shown in 
Figure 4.9 re-tested against a J4 NS2-3 refolding assay at 100 µM. Reactions were analysed by 
western blot, with NS3-FLAG indicated by the arrowhead. 
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Analysis of the combination of these two assays for the identification of inhibitors of the NS2 
autoprotease revealed that of the 213 compounds within the in silico enriched library, 63 
(29.6%) were ruled out due to a significant effect against SGR-feo-Con1 [NS3-5B] (most likely 
cellular toxicity). 4 of these molecules were defined as hits in the in vitro NS2-3 assay but were 
not pursued or validated. Data for a representative sample (containing all of the ‘hits’) of 127 
from the remaining 150 compounds is shown in Figure 4.9. The SGR based assay recorded 16 
false positives (7.5%). The NS2-3 refolding assay recorded 11 false positives (5.1%) within the 
context of compounds not affecting SGR-feo-Con1 [NS3-5B] luciferase activity. When 
combined, the two assays produced fewer false positives (1.4%). Validation experiments 
identified a single hit, JS-160, a hit rate of 0.47%. The chemical structure of JS-160 and 
physiochemical properties are shown in Figure 4.11.  
 
 
Figure 4.11: Structural and physiochemical properties of JS-160.  
Integrity of JS-160 was confirmed by mass spectrometry (Appendix I). 
  
JS-160
ChemBridge CORE # 38490315
(2R, 3R)-3-amino-1’-[(1-methylcyclohexyl) 
carbonyl]-2,3-dihydrospiro[indene-1.4’-piperidin]-
2-ol
C21H30N2O2
Mw 342
LogP 2.98
Racemic stereochemistry
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4.3 Discussion 
4.3.1 Epoxide warhead based compounds inhibit the NS2 autoprotease in vitro and block 
HCV genome replication 
To date no specific small molecule inhibitors of the NS2 autoprotease have been reported 
which are capable of blocking HCV genome replication by perturbing NS2-NS3 processing. Even 
inhibiting the NS2 autoprotease in vitro has proven difficult, with a wide variety of protease 
inhibitors and substrate peptides showing no activity or weak activity. Other than zinc 
chelators, the only small molecules identified as capable of blocking NS2-NS3 processing are 
highly reactive halomethyl ketones such as TPCK which are unlikely to exhibit much specificity. 
A common route for inhibition of proteases is conjugation of a reactive electrophilic warhead 
to a substrate-derived peptide to form a mechanism-based covalent inhibitor. Of the most 
common electrophilic warheads, epoxides arguably offer the greatest degree of selectivity 
based on the requirement of a non-covalent binding pose at the active site to allow opening of 
the epoxide. Due to the increased specificity and reduced reactivity of epoxide-derived 
mechanism-based inhibitors they have a greater range of pharmaceutical applications and as 
such an epoxide based inhibitor of the NS2 autoprotease is more likely to be capable of 
exerting an effect against NS2-dependent genome replication within a cell-based system. 
Mechanism-based inhibitors conjugated to NS2 substrate peptides have previously been 
reported to show no activity (Pallaoro et al., 2001), and a range of NS2 substrate peptides and 
different peptide-conjugated electrophilic warheads are also inactive. Within the context of 
the NS2-3 in vitro refolding assay similar observations were made, with the peptide-derived, 
epoxide warhead-based inhibitor E64 showing no inhibitory activity (Figure 4.1). Taken 
together these findings support that the NS2 autoprotease active site is not amenable to the 
binding of peptides in trans. This could be due to the size of such peptides (or their 
derivatives), an idea supported by the inactivity against the NS2 autoprotease of the epoxide-
based natural product cerulenin which contains an extended hydrocarbon chain. 
If substrate-derived peptides are unable to bind into the active site of NS2, alternative 
backbone scaffolds may be required to incorporate an electrophilic warhead as a mechanism-
based inhibitor. In this regard, a series of aromatic groups conjugated to an epoxide warhead 
show varying activity against the NS2 autoprotease in vitro. Variation of the backbone of this 
series alters activity against NS2-mediated proteolysis, supporting a contribution of the 
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backbone to a non-covalent binding pose before potential opening of the epoxide to form a 
covalent interaction. Additional evidence for this comes from the inactivity of the epoxide 
warhead alone. The SAR reported in Table 4.1 demonstrates that activity does not correlate 
with size of the backbone scaffold. Additional SAR around this series should be performed to 
refine the backbone scaffold for both activity against the NS2 autoprotease and for selectivity. 
The current range of epoxide based inhibitors offers the first evidence that a small molecule 
inhibitor of the NS2 autoprotease can exert effects against the virus lifecycle. The ability of 
compound 1 to reduce luciferase activity upon addition to SGR-feo-JFH1 [NS2-5B] with no 
significant effect on the levels of cellular metabolism is indicative of a block on genome 
replication. The proposed mode of action, through blocking essential NS2-mediated NS2-NS3 
processing, is supported by the observation that a similar activity is not observed upon 
treatment of SGR-feo-JFH1 [NS3-5B]. In this setting, where NS3 does not require release from 
NS2 and hence genome replication does not depend on the NS2 autoprotease, the epoxide 
based inhibitor did not significantly affect luciferase activity. This observation also confirms 
that compound 1 does not exert any inhibitory effect on the luciferase reporter. 
As further evidence that inhibitors that block the NS2 autoprotease in vitro can inhibit HCV 
genome replication via the NS2 autoprotease, observations made in the NS2-3 refolding assay 
were also made in the context of the SGR. Firstly, in vitro SAR analysis suggested compound 2 
exerted no activity against NS2, while toxicity analysis revealed a comparable toxicity profile to 
compound 1. Treatment of SGRs with compound 2 within this concentration range did not 
affect luciferase activity; hence compound 2 also appears inactive against NS2-dependent 
genome replication. Secondly, analysis of the activity of compound 1 in vitro demonstrated an 
enhanced inhibition of genotype 1b NS2 (J4 NS2-3). Again, a similar observation was made in 
the context of the SGR, where a stable cell line containing a SGR derived from a genotype 1b 
isolate (Con1) showed a greater reduction in luciferase activity upon treatment with 
compound 1. The correlation between in vitro activity against the NS2 autoprotease and 
activity against NS2-dependent genome replication supports a mode of action whereby 
genome replication is blocked by inhibiting the NS2 autoprotease. The fact that blocking the 
NS2 autoprotease can reduce reporter signal adds additional evidence that perturbing the 
action of the NS2 autoprotease with a small molecule inhibitor is a viable route to exert an 
anti-viral effect. 
Chapter 4 – Identification of small molecule inhibitors of the NS2 autoprotease 
 
 
153 
 
4.3.2 Identification of JS-160 as a lead-like small molecule inhibitor of the NS2 autoprotease 
by screening an in silico enriched library. 
To attempt to identify a novel, non-covalent small molecule inhibitor with improved ‘lead-like’ 
properties a library of compounds was screened for activity against the NS2 autoprotease. 
With the aim of improving hit rates, structure-guided CADD was applied to a series of models 
of the NS2 autoprotease derived from the post-cleaved NS2pro crystal structure (Lorenz et al., 
2006). These models lacked sequential residues from the C-terminus as these residues 
comprise the substrate sequence for the NS2 autoprotease and preclude the active site. 
Removal of these residues yielded a relatively shallow active site cavity with defined S1, S2 and 
S’ sites (Figure 4.8B). These sites were targeted by vHTS using eHITs, with top-ranked 
molecules pooled into an enriched libarary. Additionally the de novo design program SPROUT 
was implemented to identify good target sites within the active site and to build simple 
scaffolds predicted to be capable of forming contacts with these sites. Through chemical and 
structural similarity searches using ROCS, commercially available molecules were selected 
which were also predicted to form such contacts. 
Biological testing of this in silico enriched library identified a single confirmed hit. The validated 
hit, JS-160, was identified in both the cell-based and in vitro assays, validating each 
independently. However, the observation of several false positives from each of these assays 
demonstrated the effectiveness of the use of both assays in parallel to rapidly eliminate the 
majority of false positives. The true hit rate following completion of the assay was 0.47% 
(1/213), a fairly typical hit rate for a CADD screening programme and higher than the usual hit 
rate for HTS (Section 1.9).  
The NS2-3 refolding assay is clearly not amenable to a more high-throughput system in its 
current form. Due to the nature of the endpoint of the assay (western blot), compounds could 
only be analysed 12 at a time with each batch requiring controls and refolding assays having to 
be initiated manually. By contrast, the cell-based screening assay should be amenable to HTS 
as the readout requires addition of a luciferase reagent following treatment with compound so 
as to monitor luciferase activity from two cell lines in parallel. Indeed, the cell based screening 
assay has been reformatted to 384-well plate with automated addition of compounds before 
monitoring luciferase activity. This assay, which is amenable to HTS, is currently being 
employed to screen a library of > 10,000 compounds (Rachel Trowbridge, Richard Foster, 
University of Leeds). Such an assay may be of use for rapid identification of additional small 
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molecule inhibitors of the NS2 autoprotease which are capable of blocking NS2-dependent 
genome replication. 
While the hit from the initial assays, JS-160, was validated in both the in vitro refolding assay 
and the cell-based SGR assay, further analysis was performed to confirm anti-viral activity 
against HCV and support an NS2-mediated mode of action. Results of these experiments will 
be the subject of Chapter 5. 
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5.1 Introduction 
The NS2 autoprotease has been shown to be essential for HCV in both tissue culture models 
and in vivo (Jones et al., 2007, Kolykhalov et al., 2000) leading to the suggestion that 
pharmalogical inhibition of NS2-mediated polyprotein processing is a viable route to exert an 
anti-viral effect. Data presented in Chapter 4 supports the use of NS2 inhibitors to block 
genome replication by preventing proteolysis at the NS2-NS3 junction. The lead-like small 
molecule JS-160 identified from an in silico enriched library of compounds represents an 
attractive starting point for the development of an inhibitor targeting the NS2 autoprotease. 
While the identification of JS-160 as a ‘hit’ has been verified, the potency against the NS2 
autoprotease and against NS2-dependent genome replication remains to be determined. 
JS-160 causes only a partial reduction in luciferase activity against SGR-feo-Con1 [NS2-5B] at 10 
µM (Figure 4.10) indicating activity in the mid to high µM range against HCV genome 
replication. The potency of this range of NS2 autoprotease inhibitors would therefore most 
likely require significant improvement before consideration as a drug molecule. In order to 
improve activity through a SAR programme it is important first to gain an understanding of the 
features of JS-160 which are essential for or contribute to activity against the NS2 
autoprotease. The first section of this chapter (Section 5.2.1) focuses upon the determination 
of the potency of JS-160 against the NS2 autoprotease using the in vitro refolding assay. In 
addition an analysis of structurally similar small molecules is performed in vitro to begin to 
map the requirements for activity of JS-160. Structurally similar compounds were obtained 
both by the synthesis of novel molecules and as ‘SAR by inventory’ using commercially 
available compounds. 
Section 5.2.2 will explore the activity of JS-160 and its analogues against NS2-dependent 
genome replication. In particular the confirmation of a therapeutic window is required to 
confirm a concentration range that inhibits reporter signal from a SGR containing NS2-5B in 
the absence of cytotoxic effects.  
Subsequent experiments will explore the mode of action of JS-160. The NS2 autoprotease 
performs an essential proteolysis reaction during HCV polyprotein processing which if blocked 
is likely to negatively regulate the activity of the NS3 protease. As such a NS2 autoprotease 
inhibitor would be expected to act by a similar mode of action to the established NS3 protease 
inhibitors, albeit through an alternative molecular target. The profile of SGR inhibition upon 
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treatment with JS-160 should therefore be compared to the profile of an established NS3 
protease inhibitor. 
While SGR-based systems are well established for the identification and analysis of DAAs 
targeting HCV genome replication they do not represent the complete virus lifecycle. To 
confirm an anti-viral effect of inhibitors of the NS2 autoprotease, JS-160 was tested against 
infectious HCV in a cell culture model (HCVcc). These studies will be the subject of Section 
5.2.3, where the ability of NS2 autoprotease inhibitors to reduce the number of infectious HCV 
virions will be assessed. Furthermore, the use of HCVcc allows the effects of NS2 inhibitors on 
different stages of the virus lifecycle to be analysed.   
Chapter 5 – Analysis of NS2 autoprotease inhibitors 
 
 
158 
 
5.2 Results 
5.2.1 In vitro analysis of small molecule inhibitors of NS2 mediated proteolysis 
To examine the potency of JS-160 against NS2-3 autoprocessing, the compound was added to 
refolding reactions at a range of concentrations from 1.7 - 300 µM before quantification of the 
NS3-FLAG proteolysis product by western blot. All reactions contained standard levels of 
DMSO vector (0.75%), and DMSO only and 0 hour controls were included. In line with an 
inhibitory effect of JS-160 against the J4 NS2-3 refolding assay (Figure 4.10B), treatment with 
JS-160 reduced levels of NS3-FLAG proteolysis product in a dose responsive manner above 54 
µM, though inhibition was not complete at 300 µM (Figure 5.1). 
 
 
 
Figure 5.1: Activity of JS-160 against J4 NS2-3 refolding.  
A) J4 NS2-3 refolding reactions treated with indicated concentrations of JS-160 alongside 
controls before analysis by western blot. NS3-FLAG proteolysis product is indicated by the 
arrowhead. B) Quantification of NS3-FLAG from A. Proteolysis is reduced in a dose-responsive 
manner above 95 µM yielding an EC50 =   1̴23 µM. 
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Previous observations with the epoxide based inhibitors described in Section 4.2.1 suggested 
differing sensitivity between genotype 1b and genotype 2a isolates. Additionally, as the JFH1 
NS2-3 refolding reaction is more efficient it provides a more accurate assay to test the potency 
of different compounds. To test whether JS-160 was capable of inhibiting JFH1 NS2-NS3 
proteolysis, the same concentrations were added to JFH1 NS2-3 refolding reactions. As shown 
in Figure 5.2, JS-160 appears to be more potent against the JFH1 NS2 autoprotease. To confirm 
this observation, three technical repeats were performed. Each of these demonstrated a dose-
responsive reduction in NS3-FLAG, yielding an average EC50 of 44.6 ± 6.2 µM (Figure 5.2). In 
line with the epoxide-warhead based compound 1, JS-160 shows different sensitivity between 
genotype 1b and genotype 2a isolates. However, while compound 1 showed enhanced 
potency against genotype 1b, JS-160 appears more active against genotype 2a JFH1. 
To confirm the activity of JS-160, a synthetic route was devised and undertaken. Intermediates 
of this synthetic route were also tested for activity against the NS2 autoprotease to define the 
requirements for activity within JS-160 by SAR analysis. Additional SAR was performed using 
molecules structurally similar to JS-160 which were commercially available from the same 
source as JS-160. Compounds tested as part of a SAR analysis of JS-160 are shown in Table 5.1. 
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Figure 5.2: Activity of JS-160 against JFH1 NS2-3 autoprocessing.  
JFH1 NS2-3 refolding reactions treated with indicated concentrations of JS-160 and analysed by 
western blot. Three technical repeats are shown. NS3-FLAG (arrowhead) was quantified to 
calculate EC50 = 44.6 ± 6.2 µM (AVG ± SD, n=3).  
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Table 5.1: Structures tested for activity against the NS2 autoprotease as part of SAR analysis 
of JS-160. 
Compound Structure Source 
 
JS-160 
 
 
ChemBridge CORE 
 
JS-160-1 
 
 
In house synthesis 
 
JS-160-2 
 
 
In house synthesis 
 
JS-160-3 
 
 
ChemBridge CORE 
 
JS-160-4 
 
 
ChemBridge CORE 
 
JS-160-5 
 
 
ChemBridge CORE 
 
JS-160-6 
 
 
ChemBridge CORE 
 
JS-160-7 
 
 
ChemBridge CORE 
 
JS-160-8 
 
 
ChemBridge CORE 
 
JS-160-9 
 
 
ChemBridge CORE 
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Synthesis of JS-160 was performed by amide coupling of 1-methyl-1-cyclohexanecarboxylic 
acid (SM-2) and 4-spiroindene-piperidine hydrochloride (SM-1) to yield compound JS-160-1 
(for details of synthetic reactions see Appendix I). JS-160-1 was treated with meta-
chloroperbenzoic acid to yield the epoxide JS-160-1.2. However, this molecule proved 
insoluble in all tested solvents. Reaction of JS-160-1.2 with ammonia under heat and pressure 
did produce a small quantity of JS-160-1.3 but the low yield, most likely due to the majority of 
JS-160-1.2 remaining insoluble, prevented purification and complete analysis. Although the 
presence of JS-160-1.3 was confirmed by mass spectrometry (Appendix I), due to the insoluble 
nature of JS-160-1.2, synthesis of sufficient JS-160 for complete purification and analysis may 
require an alternative synthetic route. 
To explore the activity of JS-160-1, the same range of concentrations were added to JFH1 NS2-
3 refolding reactions. Interestingly, JS-160-1 also caused a dose-responsive reduction in levels 
of NS3-FLAG. Three technical repeats produced an average EC50 with no significant difference 
from JS-160 (Figure 5.4), suggesting the primary alcohol and amine groups of JS-160 are not 
essential for activity. The activity of JS-160-1 further indicates that the 1-methyl cyclohexane 
group of JS-160 may be important for activity. In order to further test the contributions of this 
group it was replaced by a cyclohexane group. Amide coupling of cyclohexane carboxylic acid 
to 4-spiroindene-piperidine hydrochloride (SM-1) yielded JS-160-2 (Figure 5.3). 
 
Figure 5.3: Chemical structures of synthetic products.  
For details of synthesis see Appendix I. 
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Figure 5.4: Activity of JS-160-1 against JFH1 NS2-3 autoprocessing.  
JFH1 NS2-3 refolding reactions treated with indicated concentrations of JS-160-1 and analysed 
by western blot. Three technical repeats are shown. NS3-FLAG (arrowhead) was quantified to 
calculate EC50 = 43.0 ± 0.5 µM (AVG ± SD, n=3). 
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Figure 5.5: Activity of JS-160-2 against JFH1 NS2-3 autoprocessing.  
JFH1 NS2-3 refolding reactions treated with indicated concentrations of JS-160-2 and analysed 
by western blot. Three technical repeats are shown. NS3-FLAG (arrowhead) was quantified to 
calculate EC50 = 68.4 ± 5.6 µM (AVG ± SD, n=3).  
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As evidenced by three technical repeats, while JS-160-2 did retain activity, it appeared less 
potent against JFH1 NS2-mediated proteolysis with an average EC50 of 68.4 ± 5.6 µM (Figure 
5.5). Therefore, while the cyclohexane group of JS-160 is sufficient for activity against the NS2 
autoprotease, the 1-methyl group also contributes to activity. 
Treatment of JFH1 NS2-3 refolding reactions with the starting materials 4-spiroindene-
piperidine hydrochloride (SM-1) or  1-methyl-1-cyclohexanecarboxylic acid (SM-2)  confirmed 
that while the 1-methyl-cyclohexane is required for activity (Figure 5.6B), it is not sufficient for 
activity (Figure 5.6A). In addition, the NS2-3 refolding reaction could be treated simultaneously 
with up to 300 µM SM-1 and 300 µM SM-2 without affecting levels of proteolysis (Figure 5.6C). 
Yet when these two molecules were coupled together they produce activity with an average 
EC50 of 43 µM (JS-160-1). 
To further explore the chemical features of JS-160 important for activity a range of structurally 
similar compounds were tested. These molecules (JS-160-3 to JS-160-9) are commercially 
available from the same source as JS-160. Compounds were again tested at a range of 
concentrations to allow calculation of EC50 against the JFH1 NS2-3 refolding reaction. However, 
none of the tested compounds showed any activity up to 300 µM (Figure 5.7, Figure 5.8). 
Variation of the 1-methyl cyclohexane group from JS-160, as in JS-160-3 to JS-160-7, abolished 
all activity. More significant changes (JS-160-8 and JS-160-9) to the structure also showed no 
activity against the NS2 autoprotease. This SAR analysis adds additional evidence that the 1-
methyl cyclohexane moiety is essential for the activity of JS-160. As similar compounds from 
commercial sources have proven inactive, further SAR will likely rely on the synthesis of novel 
molecules.  
 
Table 5.2 shows SAR analysis of the current series of compounds for activity against the JFH1 
NS2 autoprotease in vitro, summarising the data from Figure 5.2, Figure 5.4, Figure 5.5, Figure 
5.6, Figure 5.7 and Figure 5.8. 
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Figure 5.6: Activity of JS-160-1 fragments against JFH1 NS2-3 autoprocessing.  
A) Chemical structure of JS-160-1 fragment SM-1. JFH1 NS2-3 refolding reactions treated with 
indicated concentrations of SM-1 alongside controls were analysed by western blot. Quantified 
NS3-FLAG (arrowhead) is plotted normalised to DMSO control. B) The same experiment as in A 
with JS-160-1 fragment SM-2. C) JFH1 NS2-3 refolding reactions treated with indicated 
concentrations of both SM-1 and SM-2 and analysed by western blot. Quantified NS3-FLAG is 
normalised to DMSO (1.5%) control.  
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Figure 5.7: Activity of molecules structurally similar to JS-160 on JFH1 NS2-3 autoprocessing. 
A) JFH1 NS2-3 refolding reactions treated with indicated concentrations of JS-160 structural 
analogue JS-160-3 alongside controls. Quantified NS3-FLAG (arrowhead) is plotted below 
normalised to DMSO control. B) The same experiment as in A with compound JS-160-4. C) The 
same experiment with JS-160-5. D) The same experiment with JS-160-6. 
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Figure 5.8: Activity of additional molecules structurally similar to JS-160 on JFH1 NS2-3 
autoprocessing. 
A) JFH1 NS2-3 refolding reactions treated with indicated concentrations of JS-160 structural 
analogue JS-160-7 alongside controls. Quantified NS3-FLAG (arrowhead) is plotted below 
normalised to DMSO control. B) The same experiment as in A with compound JS-160-8. C) The 
same experiment with JS-160-9.  
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Table 5.2: Summary of in vitro SAR of JS160. *Average of three technical repeats ± SD. 
Compound Structure JFH1 NS2-3 EC50 (µM) 
 
JS-160 
 
 
44.6 ± 6.2 * 
 
JS-160-1 
 
 
43.0 ± 0.5 * 
 
JS-160-2 
 
 
68.4 ± 5.6 * 
 
JS-160-3 
 
 
>300 
 
JS-160-4 
 
 
>300 
 
JS-160-5 
 
 
>300 
 
JS-160-6 
 
 
>300 
 
JS-160-7 
 
 
>300 
 
JS-160-8 
 
 
>300 
 
JS-160-9 
 
 
>300 
 
SM-1 
 
 
>300 
 
SM-2 
 
 
>300 
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To explore the kinetic profile of NS2 inhibition in vitro, JFH1 NS2-3 refolding reactions were 
treated with an intermediate concentration of JS-160-1 (100 µM) or with DMSO alone and 
reactions halted every 30 minutes for 4.5 hours. Quantified NS3-FLAG is plotted without 
normalisation (raw NS3-FLAG intensity), demonstrating reduced levels of the NS3-FLAG 
proteolysis product. However, JS-160-1 does not appear to have any dramatic effect on the 
rate of NS2-mediated proteolysis. Both untreated reactions and reactions in the presence of 
the inhibitor were complete by 3 h (Figure 5.9A). 
As an additional control to demonstrate that addition of JS-160-1 blocks NS2-mediated 
proteolysis rather than affecting detection of the NS3-FLAG product, a range of refolding 
reactions were allowed to proceed untreated for 16 hours. JS-160-1 was then added to these 
reactions at a range of concentrations and incubated for 30 minutes before quantifying NS3-
FLAG by western blot. In this setting, where NS2-mediated processing of NS2-3 has already 
reached completion, the addition of JS-160-1 up to 300 µM had no effect on levels of the NS3- 
FLAG proteolysis product (Figure 5.9B). 
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Figure 5.9: Effects of JS-160-1 on the NS2-3 refolding reaction.  
A) JFH1 NS2-3 refolding reactions halted at indicated timepoints in the presence or absence of 
100 µM JS-160-1 before analysis by western blot. Quantified NS3-FLAG (arrowhead) intensity is 
plotted. B) JFH1 NS2-3 refolding reactions were allowed to proceed untreated for 16 hours then 
treated with indicated concentrations of JS-160-1 for a further 30 minutes before quantifying 
NS3-FLAG by western blot analysis. 
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5.2.2 Effects of NS2 autoprotease inhibitors against NS2-dependent genome replication 
As described in Section 4.3, JS-160 was also identified as a hit in a cell based screening assay. 
10 µM JS-160 appeared to have a reproducible effect against luciferase activity from SGR-feo-
Con1 [NS2-5B] without affecting the luciferase activity from SGR-feo-Con1 [NS3-5B]. 
As JS-160 appeared more potent against the JFH1 NS2 autoprotease in vitro, effects on the 
SGR were further evaluated using JFH1 isolates. Such an approach was also necessary as only 
JFH1 derived genotype 2a isolates can sufficiently reproduce the entire HCV lifecycle in cell 
culture, hence the effect of JS-160 against infectious virus can only be examined for JFH1. 
Before analysing compounds for effects against the SGR, the toxicity profile of key compounds 
was determined. Huh7.5 cells were treated with a range of concentrations of JS-160 and the 
inactive derivatives JS-160-3, JS-160-4, JS-160-5, JS-160-6 and JS-160-7. After 48 hours levels of 
cellular metabolism were monitored by MTT assay. JS-160 showed some effects on cellular 
metabolism at concentrations greater than 100 µM. A similar profile was observed with the 
inactive derivative JS-160-3. By contrast, JS-160-4, JS-160-5, JS-160-6 and JS-160-7 showed no 
significant toxic effects up to 300 µM (Figure 5.10). 
These findings suggest that a hydrophobic group in position of the 1-methyl-cyclohexane of JS-
160 is associated with some toxic effects in cell culture. However, while the hydrophobic di-
methyl groups at this position in JS-160-3 produce a similar toxicity profile, these groups are 
not sufficient for any activity against the NS2 autoprotease in vitro (Table 5.2). As such JS-160-
3 may prove useful as a negative control as an inactive compound with a comparable toxicity 
profile to JS-160 in Huh7.5 cells. 
To explore the activity of these compounds against the SGR, a range of concentrations were 
added to SGR-feo-JFH1 [NS2-5B] for 48 hours before measuring luciferase activity. In parallel, 
cells were analysed for cytotoxic effects. 
Treatment of SGR-feo-JFH1 [NS2-5B] with JS-160 produced a dose-responsive reduction in 
luciferase activity with an EC50 of 43.4 µM (Figure 5.11A). As toxic effects were not apparent at 
lower concentrations (CC50 = > 100 µM) reduced luciferase activity in this range most likely 
represent activity against genome replication. In contrast, reduced luciferase activity at higher 
concentrations upon addition of JS-160-3 correlated with toxicity analysis (ffLuc EC50 = >100 
µM, CC50 = >100 µM) (Figure 5.11C). This data supports the use of JS-160-3 as a negative 
control wherein a similar toxicity profile is observed to that of JS-160, but no additional effect 
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on replication (as measured by luciferase activity) is apparent, in line with the inactivity of JS-
160-3 against the NS2 autoprotease in vitro. As additional evidence that the SAR reported in 
Table 5.2 is observed in the context of HCV replication, treatment of SGR-feo-JFH1 [NS2-5B] 
with JS-160-4, which exerts no toxic effects below 300 µM, had no effect on luciferase activity 
(Figure 5.11E). 
 
 
 
Figure 5.10: Toxicity profiles of JS-160 and inactive structural analogues. 
Huh7.5 cells were treated with a range of concentrations of indicated compounds for 48 hours 
before monitoring cellular metabolism by MTT assay. Data normalised to DMSO control 
(plotted as 10-0.25 µM). 
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Figure 5.11: Activity of JS-160 and analogues against NS2-containing replicons. 
A) SGR-feo-JFH1 [NS2-5B] was treated with a range of concentrations of JS-160 from 1 µM to 
300 µM for 48 hours before quantifying luciferase (ffLuc). Cell viability was analysed in parallel. 
Data normalised to DMSO control. B) SGR-luc-JFH1 [NS2-5B] was electroporated into Huh7.5 
cells and treated with the same concentrations of JS-160 at 4 h.p.e. for 48 hours. Cell viability 
was analysed in parallel. C) The same experiment as in A treated with JS-160-3 D) The same 
experiment as in B treated with JS-160-3 E) The same experiment as in A treated with JS-160-4. 
F) The same experiment as in B treated with JS-160-4. 
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To confirm the effect of JS-160 against NS2-dependent genome replication, the same 
experiments were repeated in the context of a transient electroporation into Huh7.5 cells. A 
transcript of SGR-luc-JFH1 [NS2-5B] was electroporated into Huh7.5 cells and treated with the 
same range of compound concentrations at 4 h.p.e.. The observed data showed a similar 
effect as in SGR-feo-JFH1 [NS2-5B]. JS-160 produced a dose-responsive reduction in luciferase 
activity in concentration ranges that exhibited no effect on cellular metabolism; EC50 = 20.2 
µM, CC50 = > 100 µM (Figure 5.11B). Treatment with JS-160 in a transient SGR assay appeared 
to produce a lower EC50. This effect could be due to enhanced sensitivity to inhibition of the 
NS2 autoprotease over 48 hours when all NS proteins and RCs have to be established de novo 
in a transient system, an effect previously observed for other classes of HCV DAAs (Lee et al., 
2011). 
Treatment of SGR-luc-JFH1 [NS2-5B] with JS-160-3 and JS-160-4 produced similar results as 
experiments in SGR-feo-JFH1 [NS2-5B] stable cell lines. Loss of luciferase activity upon 
treatment with JS-160-3 above 100 µM correlated with reduced cellular metabolism while 
addition of JS-160-4 had no effect on luciferase activity or cellular metabolism up to 300 µM 
(Figure 5.11F). 
As the loss of luciferase activity upon addition of JS-160-3 correlates with reduced cellular 
metabolism, the MTT assay (as a measure of cell viability) and luciferase activity (as a measure 
of genome replication) appear to show similar sensitivity, supporting a direct effect of JS-160 
against genome replication at concentrations which are not cytotoxic. To further validate this 
effect, an additional readout of cell viability was employed. Cell viability in the experiment in 
Figure 5.11A was analysed using the ATPLite assay to quantify levels of ATP. This system has 
the advantage of quantifying the number of healthy cells using a luciferase based assay and 
hence should show comparable assay sensitivity to the luciferase based readout of genome 
replication. However, because this assay uses luciferase activity as a measure of healthy cells, 
and SGR containing cells produce luciferase, ATPLite analysis was performed in parallel in naïve 
Huh7.5 cells. The toxicity profile of JS-160 in Huh7.5 cells using the ATPLite assay (Figure 5.11A) 
was comparable to the toxicity profile in Huh7.5 cells by MTT assay (Figure 5.10A) and to the 
toxicity profile in SGR containing cells using the MTT assay (Figure 5.11B). These data 
demonstrate an accurate measure of cytotoxicity caused by JS-160 and support an additional 
effect against the NS2-containing SGRs at concentrations below 100 µM. 
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5.2.3 Mode of action studies of NS2 autoprotease inhibitors 
To explore the mode of action by which JS-160 inhibits HCV replication, the kinetics of 
inhibition at an intermediate concentration were investigated. Inhibitors of the NS2 
autoprotease should act by perturbing polyprotein processing in a similar manner to NS3 
protease inhibitors. The profile of JS-160 mediated inhibition was therefore compared to that 
of the NS3 protease inhibitor Telaprevir. SGR-luc-JFH1 [NS2-5B] was electroporated into 
Huh7.5 cells and at 4 h.p.e. an EC50 concentration of JS-160 (25 µM) or Telaprevir (100 nM) was 
added. Luciferase activity was assayed every 4 hours for the next 48 hours (52 h.p.e.). As an 
additional control, SGR-luc-JFH1 [NS3-5B] GND was electroporated and analysed in parallel.  
As shown in Figure 5.12A, Huh7.5 cells electroporated with SGR-luc-JFH1 [NS2-5B] and treated 
with a DMSO control gave a gradual increase in luciferase activity over time, while the GND 
polymerase defective control produced no significant luciferase signal. Addition of Telaprevir 
(100 nM) led to a reduction in luciferase activity at later timepoints and a lag in detectable 
luciferase activity. Treatment with JS-160 (25 µM) produced a similar effect, reducing the 
luciferase signal and again delaying the onset of detectable luciferase activity (Figure 5.12A), 
indicative of a similar mechanism of action. 
Based on the dose response curves shown in Figure 5.11 this concentration of JS-160 should 
not exert any cytotoxic effects. To confirm this within the context of the current experiment, 
cellular lysates at various hours post electroporation were analysed for the presence of the 
endogenous cellular protein GAPDH by western blot. To allow comparison of the total number 
of cells protein levels were not normalised. GAPDH could be detected from all tested lysates 
from DMSO treated-, JS-160 treated- or Telaprevir treated-cells, and in all cases levels of 
GAPDH increased over time (Figure 5.12B). Previous calculation of EC50 and CC50 for Telaprevir 
in SGR containing Huh7.5 cells had confirmed no toxic effects with up to 10 µM Telaprevir, 
while the CC50 of Telaprevir in hepatoma cell lines has been reported as greater than 10 µM 
(Kwong et al., 2011). As such treatment with 100 nM Telaprevir can be considered a similar 
control to DMSO only. 
The observation of GAPDH in lysates confirmed the presence of significant cell numbers up to 
48 h.p.e. in the presence of JS-160. In addition, to confirm that the addition of JS-160 has no 
effect on cell proliferation, GAPDH was quantified and plotted as a relative fold increase in 
intensity over 4 h.p.e.. A similar increase in GAPDH intensity over time to that of the DMSO 
control was observed in the presence of JS-160 (25 µM) or Telaprevir (100 nM) (Figure 5.12C). 
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Furthermore, a lack of cytotoxic effects in the presence of JS-160 at 25 µM was confirmed 
using the ATPLite assay in Huh7.5 cells. The average of three technical repeats revealed no 
effect on the levels of ATP as a measure of living cells upon treatment with JS-160 (Figure 
5.13A). To confirm that inhibition of genome replication occurred in the absence of cytotoxic 
effects cellular lysates (at 52 h.p.e. from the experiment shown in Figure 5.12) were analysed 
by western blot for both GAPDH and NS5A. Both JS-160 (25 µM) and Telaprevir (100 nM) 
treated cells had reduced levels of NS5A relative to DMSO control, correlating with luciferase 
activity from Figure 5.11A (Figure 5.12B). 
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Figure 5.12: JS-160 inhibition kinetics.  
A) SGR-luc-JFH1 [NS2-5B] was electroporated into Huh7.5 cells and treated at 4 h.p.e. with 
either JS-160 (25 µM), Telaprevir (100 nM) or DMSO control. As a negative control SGR-luc-
JFH1 [NS3-5B] GND was also electroporated into Huh7.5 cells and remained untreated. 
Luciferase was monitored at indicated timepoints (n=3). B) Indicated timepoints from A 
analysed for levels of endogenous GAPDH by western blot. C) Quantified GAPDH from B 
normalised to 4 h.p.e. (n=1).  
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Figure 5.13: Activity of JS-160 in cell based assays.  
A) JS-160 (25 µM) was added to Huh7.5 cells for 48 hours before analysing cell viability by 
quantifying ATP in a luciferase based system using the ATPLite assay. Luciferase activity is 
normalised to DMSO control. Data represents the average of three technical repeats, each in 
triplicate. B) SGR-luc-JFH1 [NS2-5B] was electroporated into Huh7.5 cells which were then 
treated with DMSO control, JS-160 (25 µM), or Telaprevir (100 nM). SGR-luc-JFH1 [NS3-5B] 
GND was also electroporated into Huh7.5 cells. After 48 hours lysates were analysed for NS5A 
and GAPDH by western blot. 
 
Having confirmed that JS-160 exerts an inhibitory effect on NS2-dependent HCV replication in 
the absence of cytotoxicity, the same concentration (25 µM) was used to treat both SGR-feo-
JFH1 [NS2-5B] and the SGR-feo-JFH1 [NS3-5B] cell line. Similarly, the anti-viral effects of JS-160 
were assessed following electroporation of a Jc1-NLuc transcript of infectious HCVcc into 
Huh7.5 cells. In a similar manner to a transient SGR experiment, electroporation of a Jc1-Nluc 
transcript allows sensitive quantification of the degree of genome replication by quantifying 
Nanoluciferase (Nluc) activity from cellular lysates. However, Jc1 encodes a complete HCV 
genome along with the reporter (Figure 1.7) and is therefore capable of the assembly and 
release of infectious virions and the subsequent re-infection of naïve cells (Pietschmann et al., 
2006). Therefore, Nluc activity is representative of genome replication in the context of the 
entire HCV lifecycle. 
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While neither JS-160 (25 µM) nor JS-160-3 (25 µM) had any significant effect on the luciferase 
activity from SGR-feo-JFH1 [NS3-5B], JS-160 did produce a 58.4 ± 7.2% reduction in luciferase 
activity from SGR-feo-JFH1 [NS2-5B] (Figure 5.14A). This data supports the observation from 
the cell-based screening that the inhibitory effect of JS-160 is only apparent when replication is 
dependent on the NS2 autoprotease, as with SGRs comprising NS2-5B. JS-160 produced a 
similar effect on Nluc activity in the context of Jc1 infectious virus, reducing signal to 38.5 ± 
7.8% of DMSO control (Figure 5.14A). Comparative MTT assays performed in parallel again 
confirmed no significant effects on cellular metabolism upon addition of JS-160 (25 µM) 
(Figure 5.14B).  
 
 
 
Figure 5.14: Activity of JS-160 against SGRs and infectious virus.  
A) SGR-feo-JFH1 [NS3-5B] was treated with JS-160 (25µM) or JS-160-3 (25 µM) for 48 hours. 
Luciferase activity is normalised to DMSO control for each experiment (one technical repeat, 
n=3). The experiment was performed in parallel against SGR-feo-JFH1 [NS2-5B]. Jc1-NLuc was 
electroporated into Huh7.5 cells and treated at 4 h.p.e. with JS-160 (25 µM) or JS-160-3 (25 
µM) for 48 hours alongside DMSO control. Statistical significance was determined using an 
unpaired Student’s t test (* p < 0.005) B) Analysis of cellular metabolism by MTT assay from 
experiments in A. 
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To explore the sensitivity to JS-160 in the context of infectious HCV, a Jc1-NLuc transcript was 
electroporated into Huh7.5 cells and treated with a range of concentrations of either JS-160 or 
JS-160-3. After 48 hours, NLuc activity was quantified. The data obtained was similar to that 
observed in the context of SGRs (Figure 5.11). JS-160 had an inhibitory effect on NLuc activity 
with an EC50 of 49.4 µM, while cytotoxic effects were observed at higher concentrations, with 
CC50 = > 100 µM (Figure 5.15A). JS-160-3 exhibited a similar toxicity profile with a closer 
correlation between loss of NLuc activity and loss of viable cells such that both EC50 and CC50 
were above 100 µM (Figure 5.15B). Toxicity analysis for this assay was performed in the same 
Huh7.5 cells electroporated with Jc1-NLuc transcript, hence these toxicity profiles are in the 
context of infectious virus.  
 
 
 
Figure 5.15: Activity of JS-160 and analogues against Jc1.  
Jc1-NLuc was electroporated into Huh7.5 cells and treated with a range of concentrations of JS-
160 from 1 µM – 300 µM at 4 h.p.e. for 48 hours. Quantified Nanoluciferase (NLuc) activity is 
normalised to untreated control. Identical JS-160 treated, Jc1 harbouring Huh7.5 cells were 
analysed for cellular metabolism by MTT assay normalised to untreated. B) Identical 
experiment as in A treated with a range of concentrations of JS-160-3. 
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As described in Section 1.5.4, NS2 is known to play a role in virus assembly. While this activity 
is thought to be independent of the NS2 protease activity, it may still require mature NS2 and 
hence be dependent on NS2-mediated processing at the NS2-NS3 junction. 
JS-160 was therefore tested for additional effects against alternative stages of the HCV 
lifecycle. Huh7.5 cells were electroporated with Jc1-NLuc and treated with a range of inhibitor 
concentrations. At 48 h.p.e., virus-containing supernatant was harvested and cells lysed for 
NLuc quantification, indicative of genome replication. Virus was titrated onto naïve Huh7.5 
cells, which were lysed 16 hours post infection to reduce the degree of re-infection and cell-to-
cell transmission. NLuc activity of these lysates was measured and reflects the initial infectious 
titre of the treated producer cells. 
NLuc activity from the producer cells was reduced in a dose-responsive manner by JS-160 
(Figure 5.16B) to a similar degree as previously observed in Figure 5.15, while a comparable 
profile was observed upon treatment with JS-160-3 where NLuc activity was reduced at higher 
concentrations (Figure 5.16C). Previous results have demonstrated this effect to be due to 
cytotoxicity. Typical sensitivity to Telaprevir was also observed, with an EC50 of 121.4 nM 
(Figure 5.16D). 
Analysis of infected cells following 16 hour incubation with virus-containing supernatant 
revealed significant NLuc activity, demonstrating infection of Huh7.5 cells with Jc1-NLuc. The 
infection experiment produced a strong NLuc signal approximately 1 log10 lower than the signal 
from producer cells 48 h.p.e. (Figure 5.16A). To simplify comparison between the two stages of 
the experiment, NLuc activity from both producer cells and infected cells was normalised to 
the relative DMSO control shown in Figure 5.16A.  
NLuc activity from infected cells was reduced when replication was reduced (as monitored by 
producer cells NLuc activity), demonstrating that decreased genome replication over 48 hours 
leads to a reduction in the number of infectious virions released. As such the first conclusion 
drawn was that JS-160 mediated inhibition of HCV replication (at concentrations previously 
shown not to exert cytotoxic effects) manifests as a reduction into the number of infectious 
virions released and hence a decrease in infectious titre. This finding demonstrates an anti-
viral effect of JS-160 and supports the use of NS2 autoprotease inhibitors as a viable class of 
DAA. 
An additional observation was that NLuc activity from infected cells was more sensitive to 
inhibition by JS-160 than genome replication (producer cells NLuc activity) (Figure 5.16B). The 
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same effect was apparent to some degree with Telaprevir treatment (Figure 5.16D), though 
the effect was most pronounced for JS-160, where concentrations appearing to exert no effect 
against replication 48 h.p.e. reduced NLuc activity in the subsequent infection assay. This 
indicates that despite these concentrations of JS-160 having no effect on HCV replication, they 
reduce the number of infectious virions released, implicating an effect on virus assembly or 
release. 
The design of this experiment is such that NLuc activity from infected cells may not directly 
correlate with the number of infectious virions in the media; for example there may have been 
compound carried over in the media which could further inhibit virus replication in the 
infected cells. This possibility and other limiting factors to these conclusions are discussed in 
Section 5.3.3. However, it is encouraging that this effect is not observed upon treatment with 
JS-160-3. NLuc activity from producer cells and infected cells correlates well in the presence of 
a range of JS-160-3 concentrations (Figure 5.16C), indicating no additional effect on virus 
release and that virus release is only reduced as a consequence of reduced genome 
replication. This reduction in genome replication upon JS-160-3 treatment has been previously 
shown to be due to cytotoxic effects. As this is not a specific anti-viral effect, no additional 
effect on virus release would be expected. Therefore JS-160, which inhibits the NS2 
autoprotease in vitro and inhibits NS2-dependent genome replication in SGRs, appears to exert 
an additional effect on the release of infectious virus, while JS-160-3, which is inactive against 
the NS2 autoprotease in vitro and does not inhibit NS2-dependent genome replication in SGRs 
other than as a product of cytotoxicity, causes no additional effect on the release of infectious 
virus. 
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Figure 5.16: Effect of NS2 inhibitors on different stages of the virus lifecycle.  
A) Nanoluciferase (NLuc) activity from Huh7.5 cells 48 h.p.e. of Jc1-NLuc RNA (producer cells) 
and NLuc activity from Huh7.5 cells following 16 hour incubation in virus containing 
supernatant (infected cells). Data the mean and standard deviation represented on a 
logarithmic scale of one experiment (n=6). B) Jc1-NLuc was electroporated into Huh7.5 cells 
and treated with a range of concentrations of JS-160 from 1 µM to 300 µM at 4 h.p.e. until 48 
h.p.e.. At 48 h.p.e. NLuc was quantified (producer cells). Virus containing supernatant was 
titrated onto naïve Huh7.5 cells in the absence of inhibitor. NLuc activity was quantified 16 
hours later (infected cells). NLuc activity from producer cells and infected cells was normalised 
to the relevant DMSO control in A. C) Identical experiment as in B treated with a range of 
concentrations of JS-160-3. D) Identical experiment as in A treated with a range of 
concentrations of Telaprevir from 316 pM to 31.6 µM. 
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5.2.4 Modelling NS2 autoprotease inhibitors 
To model an interaction of this series of compounds with the NS2 autoprotease, compound 
structures were built using the Maestro interface (Schrodinger) and underwent energy 
minimisation. JS-160 was modelled against NS2pro∆P1-P2 using Autodock, with a single binding 
pose produce (Figure 5.17A). JS-160 was predicted to sit in the S1 pocket at the active site of 
the NS2 autoprotease. An identical binding pose was produced using the alternative software 
Glide. In addition, this JS-160 binding pose was reproduced using the NS2pro∆P1-P5 and 
NS2pro∆P1-P10 models. To explore whether features of this model matched experimental 
evidence, JS-160-1, JS-160-2 and JS-160-3 were modelled in the same manner. While JS-160-1 
was able to reproduce this binding pose, JS-160-2 had a slightly altered pose, as did JS-160-3 
(Figure 5.17A).  
While these models matched the experimentally observed SAR to some degree, they could not 
explain all the observations made. The primary amine of JS-160 is proposed to form hydrogen 
bond contacts with backbone carboxylates from A179 and A182 (Figure 5.17A).  JS-160-1 is 
predicted to bind in a similar manner, but lacks this amine group and hence cannot form these 
hydrogen bonds. This is reflected in a less favourable docking score for JS-160-1 relative to JS-
160. However, in vitro SAR suggests JS-160-1 had comparable activity to JS-160 against NS2-
mediated proteolysis. Hence the experimental evidence suggests this amine group does not 
contribute to JS-160 activity. 
Further experimental evidence derived from SAR analysis revealed the cyclohexane of JS-160 
to be essential for activity, yet the model binding pose of JS-160 predicts this region to be 
relatively solvent exposed with little obvious contribution to the ligand interaction. However, 
the models for both JS-160 and JS-160-1 (which showed comparable activity in vitro) place the 
1-methyl cyclohexane group in an identical orientation. JS-160-2, which showed a slight 
reduction in activity in the absence of the 1-methyl group, is modelled with a modified 
cyclohexane position despite the ‘core’ of the compound docking in a similar manner to JS-160 
and JS-160-1 (Figure 5.17A). Furthermore, JS-160-3, which was inactive in vitro, produced a 
pose that varied more significantly at this position (Figure 5.17A). Hence variability in the 
position of the cyclohexane group (or alternative groups in this position) from modelling 
ligand-protein interactions correlates with reduced or abolished activity observed 
experimentally. As the contribution of this cyclohexane region of the series is not apparent 
from the current models, its importance may be mediated through an alternative element of 
the NS2-3 precursor, perhaps through a region encoded within the NS3 N-terminal domain 
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which forms an interaction near the NS2 active site or within a cavity formed at such an 
interface. Structural data for the NS2-NS3 pre-cursor would help to further validate and refine 
the model for the current series of NS2 autoprotease inhibitors. 
Residues of NS2 contributing to the S1 cavity where JS-160 is predicted to bind are highlighted 
in Figure 5.17A (amino acids within 4Å of the JS-160 docked pose). These residues appear 
highly conserved across all HCV genotypes (Figure 5.17B). Observations made against the NS2 
autoprotease in vitro suggested enhanced potency against genotype 2a (JFH1) compared to 
genotype 1b (J4), yet the residues surrounding the NS2 active site differ by only a single 
substitution between these two isolates (D180E), while across a subset of other genotypes 
only residue 201 is not conserved. Such conservation is indicative of a strong selective pressure 
on residues contributing to the active site of NS2 and suggests that should inhibitors of the 
NS2 autoprotease bind at the active site they may exhibit a high barrier to resistance. 
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Figure 5.17: Model of JS-160 – NS2pro interaction. 
A) Top left, predicted binding pose of JS-160 (blue carbons) docked to various models of NS2pro 
(NS2∆P1-P10 shown). The NS2 catalytic triad are highlighted with orange carbons. Residues 
within 4Å are shown. Top right, binding poses of active molecules JS-160 (blue carbons), JS-160-
1 (pink carbons) and JS-160-2 (yellow carbons) and the inactive derivative JS-160-3 (grey 
carbons). Bottom left, space fill model of JS-160 in the S1 pocket of the NS2 active site. Bottom 
right, 2D ligand interaction diagram created using the Maestro interface highlighting 
interactions and residues within 4Å of the JS-160 binding pose. B) Sequence alignment of the 
NS2pro C-terminal catalytic domain from the crystal structure (2HD0) and selected HCV 
genotype 1-6 isolates. Residues forming the catalytic triad are highlighted in green. Residues 
within 4Å of the S1 site are highlighted in yellow. Alignment performed using EMBL-EBI (Clustal 
W2). 
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5.3 Discussion 
5.3.1 JS-160 is a small molecule inhibitor of NS2 mediated proteolysis in vitro 
Results reported in Section 5.2.1 confirmed the identification of JS-160 as a small molecule 
capable of blocking NS2-mediated proteolysis in vitro. While the activity against J4 NS2-3 
described in Chapter 4 was reproduced in a dose-responsive manner, JS-160 appears more 
potent against the JFH1 isolate of NS2. The enhanced potency against JFH1, and the greater 
signal to noise from refolding reactions using JFH1 NS2-3, allowed the calculation of the EC50 
for blocking production of the NS3-FLAG cleavage product, which is produced as a measure of 
NS2 autoprotease activity. As such in this in vitro system JS-160 is active in the µM range with 
an EC50 of 44.6 ± 6.2 µM. 
The activity of JS-160 described throughout Section 5.2 was verified for three separate batches 
of JS-160 from its original commercial source, while the structure shown is consistent with m/z 
peaks identified during mass spectrometry analysis (Appendix I). Synthesis of this molecule 
was attempted to confirm that the structure reported for JS-160 is responsible for inhibitory 
activity against the NS2 autoprotease. Amide coupling of commercially available starting 
materials (SM-1 and SM-2) yielded JS-160-1. Treatment of this product with an epoxidisation 
agent converted the alkene to an epoxide which could subsequently be opened with ammonia 
to yield a form of JS-160 without chiral selectivity (JS-160-1.3). However, as the epoxide 
intermediate JS-160-1.2 was insoluble in all tested solvents, poor yields were obtained for the 
final target molecule JS-160-1.3 preventing adequate purification or complete analysis. While 
the synthesis of some JS-160-1.3 was confirmed by mass spectrometry, an alternative 
synthetic route may be required to produce greater quantities of pure JS-160 (or derivatives 
thereof). 
A degree of SAR surrounding this series has been performed in vitro. The observation of 
inhibition of the NS2 autoprotease upon treatment with JS-160-1, with no significant 
difference in potency from JS-160, reveals that the primary alcohol and amine groups at the 
chiral centres of the indene do not directly contribute to activity in vitro. While these chiral 
centres are not racemic in JS-160, the fact that NS2 inhibitors do not require these 
heteroatoms in an R, R conformation should simplify future synthesis exploring this series. 
While JS-160-1 does not meet the criteria for lead-likeness as it only contains one hydrogen 
bond acceptor, impacting on cLogP, it retains features of JS-160, most notably an interesting 
non-planar shape. Such distinctive three-dimensional shapes are a favourable property of lead-
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likeness (Nadin et al., 2012). The reduced activity of JS-160-2 revealed that the 1-methyl group 
at the cyclohexane of JS-160 contributes to, but is not required for, activity. These findings, 
along with the inactivity of both of the aforementioned starting materials (SM-1 and SM-2) 
indicate that the cyclohexane moiety makes a significant contribution to the activity of JS-160. 
Further SAR of this portion of JS-160 was performed using commercially available molecules 
JS-160-3 to JS-160-7. Replacing the 1-methyl cyclohexane portion of JS-160 with any of an 
isobutyl (JS-160-3), a hydroxyl-methyl (JS-160-4), a 3-pyridile (JS-160-5), a 2-hydroxy phenyl 
(JS-160-6) or a methyl-pyrrolidine-2-one (JS-160-7) all abolished activity below 300 µM, further 
confirming the contribution of the cyclohexane portion of JS-160. Compounds with greater 
structural diversity from JS-160 with a spiro-indolone in place of the spiro-indene core (JS-160-
8 and JS-160-9) also lacked any activity against the NS2 autoprotease, though as both of these 
molecules also lack the cyclohexane moiety the precise effects of changes to the indene 
cannot be determined. 
Current SAR, while failing to improve the activity of JS-160, has begun to map the molecular 
features that are required for and that contribute to activity. A particular structure consisting 
of a spiro-indene-piperidine core linked to a cyclohexane appears important for activity, 
further suggesting that the shape of this non-planar scaffold is paramount.  
In agreement with this, the NS2-3 refolding reaction could tolerate 300 µM SM-1 and 300 µM 
SM-2 without affecting the levels of NS2-mediated proteolysis. These two starting materials 
each represent a slightly modified ‘half’ of the active molecule JS-160-1. Hence both ‘halves’ of 
JS-160-1 added individually do not block the NS2 autoprotease, yet when these two 
components are coupled to form a similar structure to JS-160 (JS-160-1), the resulting product 
acts as an inhibitor of the NS2 autoprotease. At an intermediate concentration, JS-160-1 has 
little detectable effect on the rate of NS2-mediated proteolysis but reduces the amount of 
NS2-mediated processing for the duration of the assay (Figure 5.9A). 
The current series contains three compounds active against the NS2 autoprotease in vitro. 
5.3.2 Effects of NS2 autoprotease inhibitors on HCV genome replication  
While activity in the µM range in an in vitro system is unlikely to translate into remarkable 
activity against HCV in cell-based systems it is important to determine that this series displays 
anti-viral activity at an early stage. Unfortunately, JS-160 showed a degree of cytotoxicity at 
higher concentrations. The observation of reduced cellular metabolism in the presence of ≥ 
100 µM JS-160 complicated analysis of anti-viral effects. Therefore significant efforts were 
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made to establish a therapeutic window between cytotoxic effects and anti-viral effects. The 
structural analogue JS-160-3 was used to help define this window. JS-160-3 was inactive 
against the NS2 autoprotease in vitro but showed a comparable toxicity profile to JS-160 in 
Huh7.5 cells. All other inactive analogues of JS-160 tested did not affect cellular metabolism 
below 300 µM. This suggests that the presence of a hydrophobic group in position of the 
cyclohexane of JS-160 is associated with cytotoxic effects, though only a cyclohexane group at 
this position confers activity against the NS2 autoprotease. JS-160-3 was therefore used as a 
comparative tool in cell-based assays to add additional evidence for an effect against genome 
replication greater than that inferred solely due to cytotoxic effects. 
JS-160 caused a reproducible reduction in luciferase activity from SGR-feo-Con1 [NS2-5B] in 
Chapter 4 (Figure 4.10). Upon addition of a range of concentrations to SGR-feo-JFH1 [NS2-5B], 
JS-160 caused a dose-responsive reduction in luciferase activity, with an EC50 of 43.4 µM. 
Comparative analysis of cytotoxic effects through two independent assays demonstrated 
reduced luciferase activity at concentrations which did not affect cell viability, most notably 
upon addition of 54 µM, 30 µM, 17 µM and 9.5 µM JS-160 (Figure 5.11A). An identical 
experiment treated with JS-160-3 only reduced luciferase activity at higher concentrations 
such that an EC50 could not be accurately fitted, with a correlation between cell viability and 
luciferase activity apparent. Upon treatment with JS-160-3 both the EC50 for effect against the 
luciferase reporter and the CC50 were greater than 100 µM (Figure 5.11C). 
Data reported in Figure 5.11 demonstrates that JS-160, which inhibits the NS2 autoprotease in 
vitro, has an inhibitory effect against NS2-dependent genome replication  (at concentrations 
lower than those determined as cytotoxic) while JS-160-3, which lacks activity against the NS2 
autoprotease in vitro, does not affect genome replication other than as a consequence of 
cytotoxicity. Hence SAR observed in vitro is also apparent in SGR based assays. As further 
evidence of a correlation between in vitro activity and reduced luciferase activity in cell-based 
SGR assays, a JS-160 analogue lacking activity in vitro and devoid of cytotoxicity (JS-160-4) had 
no effect on luciferase activity up to 300 µM (Figure 5.11E). 
The data obtained using SGR-feo-JFH1 [NS2-5B] was replicated in a transient SGR system using 
a previously reported construct (SGR-luc-JFH1 [NS2-5B]) (Figure 5.13B, D and E). However it 
was noted that JS-160 appeared more potent in this transient system with an EC50 of 20.2 µM. 
Such a shift in sensitivity might be due to the different SGR systems. As a stable cell line 
harbouring constitutive genome replication, SGR-feo-JFH1 [NS2-5B] contains numerous active 
RCs at the time of addition of the compound. In contrast, the transient assay requires all RCs to 
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be produced de novo, with fewer RCs established within these cells at the time of adding 
compound. Hence a transient system may be more sensitive to inhibition as it is more reliant 
on the production of new RCs. Such a phenomenon has been previously reported for other 
classes of DAA (Lee et al., 2011), thus further supporting an inhibitory action of JS-160 against 
genome replication. 
The mode of action of JS-160 is proposed to be a block of polyprotein processing, a very similar 
mode of action to NS3 protease inhibitors such as Telaprevir. In support of this JS-160 has a 
similar inhibition profile to Telaprevir at an intermediate concentration (Figure 5.12A). This 
effect is apparent at a concentration of JS-160 that does not exert any cytotoxicity by MTT 
assay in Huh7.5 cells or SGR containing Huh7.5 cells (Figure 5.10, Figure 5.11), by ATPLite assay 
in Huh7.5 cells (Figure 5.11A, Figure 5.13A) or through detection of endogenous GAPDH 
(Figure 5.12B, C). Furthermore, the reduction in luciferase activity upon addition of this dose of 
JS-160 correlates with reduced levels of HCV NS5A by western blot analysis (Figure 5.13B). 
As previously observed for Con1 derived SGRs in the cell based screening assay in Section 
4.2.3, the reduction of luciferase activity from SGR-feo-JFH1 [NS2-5B] upon treatment with a 
non-cytotoxic dose of JS-160 was not observed upon treatment of SGR-feo-JFH1 [NS3-5B], 
indicating an effect against replication mediated through the NS2 protein. The current data 
therefore supports an inhibitory effect of JS-160 against genome replication mediated through 
the NS2 protein with a similar mode of action to an NS3 protease inhibitor which blocks 
polyprotein processing. 
 
5.3.3 Anti-viral effects of NS2 autoprotease inhibitors on the HCV lifecycle 
In addition to blocking NS2-dependent genome replication in a SGR system, JS-160 reduces 
reporter activity as a measure of viral replication in the context of infectious HCV. Jc1-Nluc is a 
chimeric HCV genome containing a Nanoluciferase reporter which is capable of numerous 
rounds of infection in cell culture (Pietschmann et al., 2006). Addition of JS-160 following 
electroporation of Jc1-Nluc into Huh7.5 cells reduced reporter activity in a similar manner to 
that observed with SGRs that contain NS2-5B (Figure 5.14), indicating a similar block on 
genome replication within the context of infectious virus. This observation was confirmed at 
several doses of JS-160 where, as in SGR based experiments, luciferase activity was reduced in 
a dose responsive manner, with cytotoxicity only observed at higher concentrations. Similarly, 
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the profile of the inactive analogue JS-160-3 was comparable to experiments using SGRs, 
indicating this analogue has no anti-viral effect. 
Data presented in Figure 5.16 demonstrates that this effect on HCV replication leads to a 
reduction or loss of infectious HCV particles secreted into the media. JS-160, within a range of 
concentrations previously shown not to exert cytotoxicity, affected not only the activity of the 
reporter in producer cells over the first 48 hours following electroporation (a measure of 
genome replication following artificial introduction of the HCV genome) but also reporter 
signal from naive cells subjected to virus containing supernatant. 
Huh7.5 cells with significant Nluc activity within this re-infection assay, such as when 
untreated (Figure 5.16A) represent infection by Jc1 virus particles which were released into the 
media within the first 48 hours following electroporation. Cells not infected with Jc1-Nluc virus 
particles would not otherwise contain the Nluc reporter. As would be expected, where 
genome replication is reduced or abolished in producer cells, the effect on replication 
manifests as a reduction in the number of released infectious virions. Hence upon addition of 
this media to naïve Huh7.5 cells the Nluc activity (as a measure of infection) is reduced relative 
to DMSO control, demonstrating a reduction in infectious titre. 
This demonstrates that addition of non-cytotoxic concentrations of JS-160 (e.g. 54 µM and 30 
µM) inhibits genome replication and reduces the degree of Nluc activity as a measure of 
infected cells. JS-160 therefore reduces the infectious titre of HCV, most likely by diminishing 
the number of infectious virions released as a consequence of blocking genome replication. 
This data therefore supports the use of inhibitors of the NS2 autoprotease to exert an anti-viral 
effect. 
This assay also offers insights into the effect of NS2 autoprotease inhibitors on different stages 
of the virus lifecycle. NLuc activity from infected cells appears more sensitive to inhibition by 
JS-160 than NLuc from producer cells, hence the effect of JS-160 on infectious titre is greater 
than the effect on genome replication. Not only was the calculated EC50 from infected cells 
lower than the calculated EC50 for producer cells, but concentrations of JS-160 that did not 
affect genome replication reduced Nluc activity in the subsequent infection assay. This could 
suggest an additional effect of JS-160 on other stages of the HCV lifecycle. Significant evidence 
links NS2 with a role in release, possibly at an early stage of virion assembly through 
interactions with other HCV proteins, most notably p7, E2 and NS3. JS-160 may exert an 
inhibitory effect on the process of virus assembly and release through the NS2 protein at doses 
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that do not significantly perturb genome replication. Further studies will be required to 
confirm such an effect as the current assay contains a number of caveats. 
Firstly, the virus containing supernatant added to infected cells will still contain compound. 
Given the enhanced potency of JS-160 in a transient SGR assay compared to a stable SGR 
assay, JS-160 may exhibit greater potency still in the context of an infection, as the cell is 
subjected to much less infectious genome than in the artificial situation of electroporation. The 
presence of compound with the virus before infection also allows for the possibility of an 
additional effect on HCV entry. Given that NS2 is not thought to be present in the virion or to 
play any role in entry this seems unlikely. 
Secondly, Nluc activity only serves as an indirect measure of the number of infectious particles. 
This reporter quantifies the amount Nluc that is present in the cell as a consequence of 
infection and translation from the genome and is amplified further by replication within the 
infected cells over 16 hours. With numerous variables the Nluc activity may not correlate 
directly with the number of infectious virions (i.e. a 50% reduction in the number of released 
infectious particles may not necessarily correlate with a 50% reduction in Nluc signal from the 
infected cells). However, such differences in sensitivity are unlikely to explain why treatment 
of producer cells with a concentration of JS-160 that does not affect replication (9.5 µM) leads 
to a 50% reduction in Nluc activity in infected cells. 
Controls included in this experiment support an additional effect of JS-160 against virus 
release. Firstly, a shift in sensitivity of Nluc activity between replication and infection assays is 
not observed to the same degree with JS-160-3. This molecule is inactive against the NS2 
autoprotease and the reduced Nluc activity at higher concentrations has been shown to be a 
consequence of cytotoxicity. Both the degree of Jc1 replication and the number of infectious 
Jc1 virions released (as monitored by NLuc activity in infected cells) correlate well, suggesting 
both are a consequence of the loss of viable cells. 
In addition, inhibitors of the NS3 protease have recently been reported to exert effects on HCV 
release. A kinetic analysis of a range of DAAs revealed reductions in virus release at early 
timepoints before a later effect on genome replication, an effect observed for both NS5A 
inhibitors and the 1st generation NS3 protease inhibitor Boceprevir (McGivern et al., 2014). The 
NS3 protease inhibitor Telaprevir appeared to exert additional effects on release as measured 
by NLuc activity from infected cells in a similar manner to JS-160. This data supports an 
additional effect of the NS3 protease inhibitor Telaprevir on virus release and suggests that 
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inhibitors of the NS2 autoprotease may exert a similar effect. As previously reported, the 
effect of JS-160 on virus release should be tested at earlier timepoints, before a significant 
effect on replication has occurred.  
While both NS2 and NS3 are documented to play roles in HCV assembly and release, an 
intriguing hypothesis might be that release is tightly linked to polyprotein processing. Given 
the important roles for several non-structural proteins in this process, most notably NS5A, the 
process of HCV release may be more sensitive to a block of polyprotein processing than the 
process of genome replication. It certainly seems feasible that perturbing polyprotein 
processing, either through an NS3 protease inhibitor or an NS2 autoprotease inhibitor, would 
negatively impact both replication and release. 
While further studies will be required to explore the effects of these compounds on different 
stages of the virus lifecycle, the data presented in this chapter demonstrates an inhibitory 
effect of JS-160 against HCV genome replication where polyprotein processing relies on the 
NS2 autoprotease, and that this activity produces an anti-viral effect capable of reducing the 
number of infectious virions released from HCV infected cells. 
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Prior to this study NS2 represented the only HCV-encoded enzyme activity that had not been 
targeted with small molecule inhibitors, despite extensive evidence that the NS2 autoprotease 
activity is essential in the virus lifecycle. This study set out both to test the hypothesis that a 
small molecule inhibitor of the NS2 autoprotease could exert an anti-viral effect and to identify 
a lead-like compound as a suitable starting point for the development of a DAA targeting NS2. 
Following the observation that chaperone antagonists, which were previously reported to 
perturb NS2-NS3 proteolysis, do not mediate an effect against NS2-dependent genome 
replication, it was apparent that the ability to block HCV replication by pharmalogical inhibition 
of NS2 had yet to be demonstrated. The observation that an epoxide-based small molecule 
which blocks NS2-mediated proteolysis in vitro is able to reduce reporter signal from a SGR 
that requires NS2-NS3 processing for replication offered the first evidence that an anti-viral 
effect could be exerted through an inhibitor of the NS2 autoprotease. 
Subsequently, the combination of two assays which measure NS2 autoprotease function 
allowed for the identification of a lead-like small molecule inhibitor of the NS2 autoprotease; 
JS-160. This compound blocks NS2-mediated processing at the NS2-NS3 junction in vitro and 
exerts a specific effect on SGRs that require NS2 autoprotease function for constitutive 
replication. Furthermore, JS-160 blocks replication in the context of infectious virus in cell 
culture, which manifests as a reduction in the number of infectious virions released from a cell 
population. Hence inhibitors of the NS2 autoprotease are able to exert an anti-viral effect. 
These findings suggest NS2 autoprotease inhibitors could represent an additional class of DAA 
to complement combination therapies for the treatment of HCV. Inhibitors of the NS2 
autoprotease have the advantage of targeting an entirely novel molecular target yet acting 
through a somewhat established mode of action, in that perturbing HCV polyprotein 
processing has already been shown to produce a beneficial effect in the clinic through 
inhibitors of the NS3 protease. 
A degree of SAR analysis has been performed for the current series, beginning to map the 
requirements for activity. An obvious next step would be a more extensive SAR programme to 
attempt to improve activity. Ideally such a programme would benefit from further CADD, 
though current models of an interaction at the NS2 active site may need further refinement 
and ideally, experimental evidence, as at present they do not correlate with all the 
experimental observations. Indeed the precise impact of using structure-guided CADD prior to 
screening for an NS2 autoprotease inhibitor is hard to gauge. While circumstantial evidence 
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suggests a hit-rate higher than would be expected from unbiased HTS, no direct evidence 
exists as yet that JS-160 interacts with NS2 as modelled in silico. A more feasible route for 
future SAR may be to focus on assays amenable to more high-throughput systems. This is 
unlikely to be achieved using the in vitro NS2-3 refolding assay, but could be performed in the 
cell-based SGR screen, as evidenced by re-formatting of this assay and its application to screen 
a library of > 10,000 compounds. 
The current series should undergo further study to confirm that inhibition of genome 
replication is a consequence of a block on polyprotein processing. While these compounds 
have been shown to block NS2-mediated proteolysis in vitro and show comparable inhibition 
kinetics to an NS3 protease inhibitor against replicons, a build-up of unprocessed polyprotein 
would be difficult to observe in the current systems. Where polyprotein processing is blocked, 
the inhibition of replication (due to the absence of mature viral proteins to form RCs) prevents 
sufficient protein accumulating for detection (and may be further influenced by the rapid 
degradation of unprocessed NS2-NS3). Detection of unprocessed polyprotein in the presence 
of JS-160 would require the use of expression constructs or constitutive expression through a 
vaccinia system, systems previously used to explore inhibitor mode-of-action for other classes 
of HCV DAAs (Targett-Adams et al., 2011). 
Experiments using the current series should also further explore effects on different stages of 
the virus lifecycle. Additional effects on the assembly and release of virus are beginning to 
become apparent for several DAA classes including NS5A inhibitors and NS3 protease 
inhibitors (McGivern et al., 2014), with obvious advantages for progression to the clinic. 
Confirming effects of NS2 autoprotease inhibitors on multiple stages of the virus lifecycle 
would support their progression as a DAA. 
The ability of HCV to establish resistance to an NS2 autoprotease inhibitor should be 
examined, and the identification of resistance mutations encoded within the NS2 protein 
would further validate the molecular target. While this experiment is challenging at present 
due to the narrow therapeutic window of JS-160 in cell culture, the high degree of 
conservation at the NS2 active site across all HCV genotypes suggests a strong selective 
pressure and indicates that inhibitors which bind at the NS2 active site may exhibit a high 
barrier to resistance. As with many of the investigations described above, the identification of 
resistant variants would benefit from a more potent inhibitor of the NS2 autoprotease. 
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It will also be important to investigate the selectivity of this series with regards to other 
viruses, other proteases and in particular, to the NS2 proteins of related viruses which encode 
a protease. For example, the catalytic domain of the NS2 protein from the Pestivirus BVDV 
shows considerable homology to HCV NS2, and has been shown to act as a stand-alone 
cysteine protease (Lackner et al., 2004). While HCV NS2 protease activity is enhanced by the 
zinc binding domain of NS3 (Schregel et al., 2009), NS2 of BVDV encodes a series of additional 
residues proposed to coordinate zinc and replace the contribution of NS3 to NS2-NS3 
processing required in HCV (Lackner et al., 2004). It would therefore be intriguing to test the 
current series for activity against BVDV or other members of the Pestivirus genera. In contrast, 
for members of the Flavivirus genera (e.g. YFV), the NS3 protease performs all the non-
structural proteolysis events with NS2A-2B acting as a co-factor (Chambers et al., 1991, 
Chambers et al., 1990). Given that JS-160 appears inactive against the HCV NS3 protease (as it 
does not affect a SGR containing NS3-5B), this series would be expected to show no activity 
against members of the Flavivirus genus. 
More broadly, to the best of our knowledge this series represents the first small molecule 
inhibitors of a viral autoprotease. Other viral autoproteases have been postulated as attractive 
therapeutic targets, such as the HIV-1 autoprotease activity encoded within the Gag-Pol 
precursor (PR) (Huang, 2013). As an aspartyl autoprotease formed from a homo-dimer this 
HIV-encoded target could benefit from identification of inhibitors of the HCV NS2 
autoprotease, at the least as evidence that a viral autoprotease can be blocked with a small 
molecule inhibitor. Other virally encoded autoproteases that may be of interest for this series 
include the Npro protein of BVDV, a cysteine autoprotease for which structural information has 
recently become available (Gottipati et al., 2013). 
Finally, regardless of its viability as a DAA, JS-160 and other inhibitors of the NS2 autoprotease 
may be of use for further study of the HCV NS2-NS3 precursor. The enhancing role of the NS3 
N-terminus on the NS2 autoprotease remains poorly understood.  Given the evidence for a 
regulatory role of NS2-NS3 processing on both viral replication and the pathogenicity of BVDV 
(Lackner et al., 2004), processing at the HCV NS2-NS3 junction may have important 
implications for the mechanism by which HCV self-regulates its lifecycle, with direct 
implications for the disease state and ability of HCV to establish a persistent, chronic infection. 
The use of an NS2 autoprotease inhibitor may aid structural studies on the pre-processed form 
of NS2-3 which would further inform on the molecular basis by which the NS2 autoprotease 
functions. 
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Synthetic procedures 
 
1-[(1-Methylcyclohexyl)carbonyl]-spiro[indene-1,4’-piperidine]  
(JS-160-1) 
 
1-Hydroxybenzotriazole (457.1 mg, 3.383 mmol) and 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide (648.5 mg, 3.383 mmol) were added to a stirred solution of 1-methyl-1-
cyclohexanecarboxylic acid (352.8 mg, 2.481 mmol) in DMF (12.5 ml), and the resulting 
solution was stirred at room temperature for 1 hour. 4-Spiroindene-piperidine hydrochloride 
(0.5 g, 2.255 mmol) and TEA (376 µl, 2.706 mmol) were then ad ded and stirred at room 
temperature for 16 hours. Following evaporation of the solvent the resulting residue was 
partitioned between EtOAc (20 ml) and water (2 x 20 ml) followed by brine (2 x 20ml) and the 
organic extracts were dried (MgSO4) before the solvents were removed under reduced 
pressure. The resulting solid was purified via column chromatography to yield the title 
compound (294 mg, 0.950 mmol, 42%) as a colourless powder; m.p 116-118 °C ; Rf 0.88 (10% 
MeOH/DCM); δH (500 MHz, CDCl3); 7.30 (m, 4H), 6.86 (dd, (J = 24.1, 5.7, 2H), 4.54 (d, J = 14.3, 
2H), 3.20 (d, J = 13.0, 2H), 2.20-1.89 (m, 4H), 1.59 (m, 5H), 1.52-1.12 (m, 10H); δC (75 MHz, 
CDCl3); 176.07 (CO), 151.37 (12-C), 142.79 (11-C), 140.47 (5-C), 130.41 (6-C), 127.13 (8-C), 
125.46 (9-C), 121.66 and 121.55 (10-C and 7-C), 52.35 (4-C), 44.25 (2-C), 42.74 (1’-C), 37.22 (2’-
C), 33.95 (3-C), 29.71 (4’-C), 25.99 (5’-C), 23.18 (3’-C); m/z (ES); (found MH+ 310.224; C21H27NO 
requires MH 310.21); LC-MS (RT= 2.15 min, m/z found MH+ 310.2). 
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1’-[(Cyclohexyl)carbonyl]-spiro[indene-1,4’-piperidine]  
(JS-160-2) 
 
1-Hydroxybenzotriazole (182.8 mg, 1.353 mmol) and 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide (259.4 mg, 1.353 mmol) were added to a stirred solution of cyclohexane 
carboxylic acid (123 µl, 0.992 mmol) in DMF (5 ml). The solution was stirred at room 
temperature for 15 minutes. 4-Spiroindene-piperidine hydrochloride (200 mg, 0.902 mmol) 
and TEA (150 µl, 1.082 mmol) were then added and the resulting solution was stirred at room 
temperature for 16 hours. Following evaporation of the solvent the resulting residue was 
partitioned between EtOAc (20 ml) and water (2 x 20 ml) followed by brine (2 x 20ml) and the 
organic extracts were dried (MgSO4) before the solvents were removed under reduced 
pressure. The resulting solid was purified via column chromatography to yield the title 
compound (148.8 mg, 0.504 mmol, 56%) as a colourless powder; m.p 134-135 °C ; Rf 0.80 (10% 
MeOH/DCM); δH (500 MHz, CDCl3); 7.36-7.18 (m, 4H), 6.84 (dd, (J = 27.0, 5.7 , 2H), 4.70 (d, J = 
13.7, 1H), 4.04 (d, J = 13.3, 1H), 3.40 (t, J = 12.3, 1H), 3.00 (t, J = 12.2, 1H), 2.56 (t, J = 11.5, 1H), 
2.05-1.92 (m, 2H), 1.81 (m, 4H), 1.72 (s, 1H), 1.68-1.36 (m, 5H), 1.29 (m, 3H); δC (75 MHz, 
CDCl3); 174.85 (CO), 151.30 (12-C), 142.76 (11-C), 140.12 (5-C), 130.59 (6-C), 127.17 (8-C), 
125.49 (9-C), 121.68 and 121.58 (10-C and 7-C), 52.27 (4-C), 44.35 (2-C), 40.64 (1’-C), 34.58 (2’-
C), 33.33 (3-C), 29.67 (4’-C), 25.94 (3’-C); m/z (ES); (found MH+ 296.192; C20H25NO requires MH 
296.2); LC-MS (RT= 2.20 min, m/z found MH+ 296.2). 
 
  
Chapter 8 – Appendix 
 
 
219 
 
1’-[(1-Methylcyclohexyl)carbonyl]-spiro[indeno[2,3-b]oxirene-1,4’-piperidine] 
JS-160-1.2 
 
Sodium bicarbonate (162.8 mg, 1.938 mmol) and meta-chloroperbenzoic acid (77%, 202.8 mg, 
1.175 mmol) were added to 1-[(1-methylcyclohexyl)carbonyl]-2,3-dihydrospiro[indene]-1,4’-
piperidine] (JS-160-1) (200 mg, 0.646 mmol) in DCM (7 ml) and the resulting mixture was 
stirred for 10 minutes at 0 °C. The solution was allowed to warm to room temperature and 
then stirred for 16 hours. Following evaporation of the solvent the resulting residue was 
partitioned between DCM (20 ml) and sodium sulphate solution (10% (w/v), 20 ml) and the 
solvents were removed under reduced pressure. The resulting brown residue (70.6 mg) proved 
insoluble in all tested solvents preventing spectroscopic analysis. Title compound was 
identified by mass spectrometry; LC-MS (RT= 2.05 min, m/z found MH+ 326.2, C21H27NO2 
requires MH 326.21). 
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1’-[(1-Methylcyclohexyl)carbonyl]-2,3-dihydrospiro[indene-1,4’-piperidine]-2-ol, 3-amine 
JS-160-1.3 
 
Lithium perchlorate (22.9 mg, 0.215 mmol) and aqueous ammonia (35%) (2 ml) were added to 
a solution of 1’-[(1-methylcyclohexyl)carbonyl]-spiro[indeno[2,3-b]oxirene-1,4’-piperidine] (JS-
160-1.2) (70 mg, 0.215 mmol) in THF (2 ml) and the resulting solution was stirred at 125 °C at 
220 psi for 45 minutes. Following evaporation of the solvent the resulting residue was 
partitioned between DCM (20 ml) and water (2 x 20 ml) followed by brine (2 x 20 ml) and the 
organic extracts were dried (MgSO4) before the solvents were removed under reduced 
pressure. The resulting yellow-green powder proved insufficient for further purification or 
spectroscopic analysis (6 mg, 0.018 mmol, 8%). Title compound was identified by mass 
spectrometry; m/z (ES); (found MH+ 344.222; C21H30N2O2 requires MH 343.23); LC-MS (RT= 
1.60 min, m/z found MH+ 343.2). 
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(2R, 3R)-3-amino-1’-[(1-methylcyclohexyl) carbonyl]-2,3-dihydrospiro[indene-1.4’-piperidin]-
2-ol 
(JS-160) 
 
Title compound was from Chembridge ‘screening library’ as a white film; m/z (ES); (found MH+ 
343.239; C21H30N2O2 requires MH 343.23) 
 
 
 
(2R, 3R)-3-amino-1’-(3-methylbutanoyl)-2,3-dihydrospiro[indene-1,4’-piperidin]-2-ol 
(JS-160-3) 
 
Title compound was from Chembridge ‘screening library’ as a white-yellow film; m/z (ES); 
(found MH+ 303.207; C18H26N2O2 requires MH 303.2) 
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 (2R, 3R)-3-amino-1’-glycoloyl-2,3-dihydrospiro[indene-1,4’-piperidin]-2-ol 
(JS-160-4) 
 
Title compound was from Chembridge ‘screening library’ as a white film; m/z (ES); (found MH+ 
277.156; C15H20N2O3 requires MH 277.15) 
 
 
 
 
(2R,3R)-3-amino-1’-(3-pyridinylcarbonyl)-2,3-dihydrospiro[indene-1,4’-piperidin]-2-ol 
(JS-160-5) 
 
Title compound was from Chembridge ‘screening library’ as a white-yellow film; m/z (ES); 
(found MH+ 324.171; C19H21N3O2 requires MH 324.17) 
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(2R,3R)-3-amino-1’-(2-hydroxybenzoyl)-2,3-dihydropsiro[indene-1,4’-piperidin]-2-ol 
(JS-160-6) 
 
Title compound was from Chembridge ‘screening library’ as a white-yellow film; m/z (ES); 
(found MH+ 339.166; C20H22N2O3 requires MH 339.17) 
 
 
 
 
1-{2-[(2R,3R)-3-amino-2-hydroxy-2,3-dihydro-1’H-spiro[indene-1,4’-piperidin]-1’-yl]-2-
oxoethyl}-2-pyrrolidinone 
(JS-160-7) 
 
Title compound was from Chembridge ‘screening library’ as a yellow film; m/z (ES); (found 
MH+ 344.196; C19H25N3O3 requires MH 344.19) 
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1-methyl-1’-(tetrahydro-2H-pyran-4-yl)spiro[indole-3,4’-piperidin]-2(1H)-one 
(JS-160-8) 
 
Title compound was from Chembridge ‘screening library’ as a white film; m/z (ES); (found MH+ 
301.192; C18H24N2O2 requires MH 301.19) 
 
 
 
 
1’-(2-hydroxyethyl)-1-methylspiro[indole-3,4’-piperidin]-2(1H)-one 
(JS-160-9) 
 
 
Title compound was from Chembridge ‘screening library’ as a yellow film; m/z (ES); (found 
MH+ 261.159; C15H20N2O2 requires MH 261.16) 
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Compound 1 
(2S*,3R*)-N2-(3-Chlorophenyl)oxirane-2,3-dicarboxamide 
 
Title compound was synthesised in Leeds by Craig Avery (CA424, 6.26, Craig Avery PhD Thesis, 
University of Leeds); m/z (ES); (found MNa 263.019; C10H9ClN2O3 requires MNa 263.02). 
 
Compound 2 
(2S*,3R*)-N2-Phenyloxirane-2,3-dicarboxamide 
 
Title compound was synthesised in Leeds by Craig Avery (CA441, Craig Avery PhD Thesis, 
University of Leeds); m/z (ES); (found MNa 229.059; C10H10N2O3 requires MNa 229.06). 
 
Compound 3 
(2S*,3R*)-N2-(4-Bromophenyl)oxirane-2,3-dicarboxamide 
 
Title compound was synthesised in Leeds by Craig Avery (CA445, Craig Avery PhD Thesis, 
University of Leeds); m/z (ES); (found MNa 306.969; C10H9BrN2O3 requires MNa 306.97). 
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Compound 4 
(2S*,3R*)-N2-(4-Bromo-3-chlorophenyl)oxirane-2,3-dicarboxamide 
 
Title compound was synthesised in Leeds by Craig Avery (CA446, Craig Avery PhD Thesis, 
University of Leeds); m/z (ES); (found MNa 340.930; C10H8BrClN2O3 requires MNa 340.93). 
 
Compound 5 
(2S*,3R*)-N2-(3,4-Dimethylphenyl)oxirane-2,3-dicarboxamide 
 
Title compound was synthesised in Leeds by Craig Avery (CA447, Craig Avery PhD Thesis, 
University of Leeds); m/z (ES); (found MNa 257.090; C12H14N2O3 requires MNa 257.09). 
 
Compound 6 
(2S*,3R*)-N2-(3-Phenoxyphenyl)oxirane-2,3-dicarboxamide 
 
Title compound was synthesised in Leeds by Craig Avery (CA432, Craig Avery PhD Thesis, 
University of Leeds); m/z (ES); (found MNa 321.085; C16H14N2O4 requires MNa 321.09). 
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Compound 7 
(2S*,3R*)-N2-(4-(4-Aminophenoxy)phenyl)oxirane-2,3-dicarboxamide 
 
Title compound was synthesised in Leeds by Craig Avery (CA451, Craig Avery PhD Thesis, 
University of Leeds); m/z (ES); (found MNa 336.096; C16H15N3O4 requires MNa 336.10). 
 
Compound 8 
(2S*,3R*)-N2-(4-(4-Nitrophenoxy)phenyl)oxirane-2,3-dicarboxamide 
 
Title compound was synthesised in Leeds by Craig Avery (CA450, Craig Avery PhD Thesis, 
University of Leeds); m/z (ES); (found MNa 366.070; C16H13N3O6 requires MNa 366.07). 
 
Compound 9 
(2S*,3R*)-N2-(3-Chloro-4-(2-ethoxyphenyl)phenyl)oxirane-2,3-dicarboxamide 
 
Title compound was synthesised in Leeds by Craig Avery (CA462, Craig Avery PhD Thesis, 
University of Leeds); m/z (ES); (found MNa 369.062; C17H15ClN2O4 requires MNa 369.06). 
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Compound 10 
(2S*,3R*)-N2-(3-Chloro-4-(4-(tert-Butoxycarbonyl)piperidin-1-methoxy)phenyl)oxirane-2,3-
dicarboxamide 
 
 
Title compound was synthesised in Leeds by Craig Avery (CA465, Craig Avery PhD Thesis, 
University of Leeds); m/z (ES); (found MNa 462.140; C20H26ClN3O6 requires MNa 462.14). 
 
Compound 11 
(2S*,3R*)-N2-(4-(2-(2-Nitrophenylsulphonamido)ethyl)phenyl)oxirane-2,3-dicarboxamide 
 
Title compound was synthesised in Leeds by Craig Avery (CA434, Craig Avery PhD Thesis, 
University of Leeds); m/z (ES); (found MNa 457.079; C18H18ClN4O7S requires MNa 457.08). 
 
 
 
 
 
 
